CURRICULUM VITAE
Date Prepared:
keb 07-07-2011
Name:
Bruce D. Walker, M.D.
Office Address:
149 13th Street, Room 5212D, Charlestown, MA 02129
Home Address:
7 Valley Road, Nahant, MA 01908
Work Phone:
617-724-8332
Work Email:
bwalker@partners.org
Work FAX:
617-726-4691
Place of Birth:
Champaign, Illinois
Education
1976
1980
B.A.
M.D.
Chemistry
University of Colorado, Boulder, CO
Case Western Reserve University, Cleveland, OH
Postdoctoral Training
1980-1981
1981-1983
1983-1984
1984-1987
1985-1987
Intern
Resident
Resident
Clinical Fellow
Research Fellow
Medicine
Medicine
Pathology
Infectious Disease
Infectious Disease
Massachusetts General Hospital, Boston, MA
Massachusetts General Hospital, Boston, MA
Massachusetts General Hospital, Boston, MA
Massachusetts General Hospital, Boston, MA
Massachusetts General Hospital, Boston, MA,
Harvard Medical School, Boston, MA
Faculty Academic Appointments
July 1988 - June 1989
July 1989 - June 1992
July 1992 - June 1999
July 1999 - present
Instructor
Assistant Professor
Associate Professor
Professor
Medicine
Medicine
Medicine
Medicine
Harvard Medical School, Boston MA
Harvard Medical School, Boston MA
Harvard Medical School, Boston MA
Harvard Medical School, Boston MA
Appointments at Hospitals/Affiliated Institutions
Past
1988-1989
1989-1992
1992-1996
1996-2001
Clinical Assistant
Assistant
Assistant Physician
Assistant Physician
Medicine
Medicine
Medicine
Medicine
Massachusetts General Hospital, Boston MA
Massachusetts General Hospital, Boston MA
Massachusetts General Hospital, Boston MA
Massachusetts General Hospital, Boston MA
Physician
Senior Physician
Investigator
Medicine
Medicine
Medicine
Massachusetts General Hospital, Boston, MA
Brigham & Women’s Hospital, Boston, MA
Howard Hughes Medical Institute, Chevy Chase,
MD
Present
2001-present
2002-present
2002-present
1
Other Professional Positions
1997-2005
1998-present
1998
1998
1999-2001
2000-present
2000-present
2001-present
Scientific Advisory Board
Scientific Advisory Board
Scientific Advisory Board
Scientific Advisory Committee
Scientific Advisory Board
Scientific Steering Committee
Scientific Advisory Board
External Advisory Board
2001-2006
2008-present
Scientific Advisory Board
Scientific Advisory Board
Elizabeth Glaser Pediatric AIDS Foundation
Partners/Genzyme Scientific Advisory Board
Dana Farber Cancer Institute
University of Alabama Scientific Advisory Board
Women & Infant’s Transmission Study
HIV Vaccine Trials Network
Objectif Recherche Vaccin Sida (ORVACS)
Albert Einstein College of Medicine Center for
AIDS Research
University of Colorado Center for AIDS Research
Centre for the AIDS Programme of Research in
South Africa
Major Administrative Leadership Positions
Local
1988-present
1988-present
Member, AIDS Clinical Trials Group
Attending Physician, ID Consult
Service
Acting Director, Clinical Virology
Laboratory
Assistant Director, Advanced Basic
Science Course on AIDS
Pathogenesis
Director, Partners AIDS Research
Center
Co-Director, AIDS Postgraduate
Course
Co-Director, “AIDS Medicine: An
Intensive Course”
Director, Division of AIDS
Director, Harvard University Center
for AIDS Research
Director
Massachusetts General Hospital, Boston, MA
Massachusetts General Hospital, Boston, MA
2002-present
Visiting Professor
2006-2009
Visiting Professor
Nelson Mandela School of Medicine, University
of KwaZulu-Natal, Durban, South Africa
University of Oxford, Oxford, England
1989-1990
1992-1994
1995-2008
1995-2003
1996-2003
2001-2005
2006-present
2008-present
Massachusetts General Hospital, Boston, MA
Harvard Medical School, Boston, MA
Massachusetts General Hospital, Boston, MA
Massachusetts General Hospital, Boston, MA
Harvard Medical School, Boston, MA
Harvard Medical School, Boston, MA
Harvard University, Cambridge, MA
Ragon Institute of MGH, MIT and Harvard
International
Committee Service
Local
1989-present
1989
Member, Committee on Research
Member, International Program
Committee
Massachusetts General Hospital
6th International Conference on AIDS
2
1989-1990
1990
1990
1990-present
1991
1991
1995-present
1997
1998-present
1998-present
1998-present
1999-present
2009-present
2010-present
2010-present
2010-present
Chairperson, Workshop on CellMediated Immunity
Member, International Program
Committee
Member, AIDS Curriculum Planning
Project
Member, Ad Hoc Committee on
AIDS Policy
NCI/Frederik Member, NIH Site
Visit
Member, Basic Science Program
Member, Executive Committee
Training Program
Member, AIDS Vaccine Research
Member, Academic Council
Member, Awards Committee
Member, Research Operations
Improvement
Member, Faculty Development
Committee
Associate Member
Member, Executive Committee on
Research
Co-Chair, AIDS Vaccine 2012
Co-Chair, Science, Medicine and
Public Health, AIDS@30 Conference
2nd and 3rd Annual National Cooperative
Vaccine Development Group Meeting
7th International Conference on AIDS
Harvard Medical School
Massachusetts General Hospital
Cancer Research and Development Center
8th International Conference on AIDS
Massachusetts General Hospital/ Brigham &
Women’s Hospital
Massachusetts Institute of Technology
Massachusetts General Hospital
Massachusetts General Hospital
Massachusetts General Hospital
Massachusetts General Hospital
Broad Institute of MIT and Harvard
Massachusetts General Hospital
Global HIV Vaccine Enterprise
Harvard University
National
1989
1991
1991
1991
1992-1997
1992-1993
1993
1994-1999
Consultant, AIDS Study Section
Invited Participant, U.S. - Japan
Hepatitis Panel
Invited Participant, Roundtable
Against AIDS
Chairperson, Immunology Working
Group
PAF Elizabeth Glaser Scientist
Award Think Tank
1992
1996
1997
AIDS Clinical Trials Group
1992
1993
Steering Committee Member,
Project Immune Restoration
AIDS ARRA Study Section
1994-1998
3
National Institutes of Health
US Department of State
Institute of Medicine Development of Drugs and
Vaccines
National Cooperative Vaccine Development
Group
Pediatric AIDS Foundation
Invited Participant
Member
Member
National Institutes of Health.
Co-Chair, ACTG Trial 209
Co-Chair, ACTG Trial 214
Project Inform
National Institutes of Health
Member
1995
1996
1996
1997
1998
1999-2000
1998-1999
Panel Member, Office of AIDS
Research Review
Member, Immune Restoration
Think Tank
Member, Panel to Define Principals
of Therapy of HIV Infection
Clinical Scientist Award, Chair
Member, Uganda Vaccine Lab
Subgroup
Member, NIAID Program Review
Chair
National Institutes of Health
Project Inform
National Institutes of Health
Doris Duke Charitable Foundation
National Institutes of Health
National Institutes of Health
Professional Societies
1989-Present
American Association of Immunologists
1992-Present
Infectious Diseases Society of America
2000-Present
Association of American Physicians
2006-Present
Infectious Diseases Society of America
2009-Present
Institute of Medicine, National Academy of Sciences
2010-Present
American Academy of Arts and Sciences
Member
Member
Member
Member/Fellow
Member
Member
Editorial Activities
Nature, Science, Nature Medicine, Nature Immunology, Immunity, Journal of Virology, Journal of
Immunology, AIDS, Journal of Experimental Medicine, New England Journal of Medicine
Other Editorial Roles
1990-Present
Associate Editor
1992-Present
Associate Editor
1993-1998
Associate Editor
1995-Present
Editor
1996-1998
Section Editor
2003-Present
Editorial Board
2009-Present
Board of Reviewing Editors
AIDS Research and Human Retroviruses
AIDS
Journal of Immunology
Immunology Section, Los Alamos HIV Data Base
Journal of Immunology
Journal of Virology
Science
Honors and Prizes
1975
1976
1980
1980
1986
1988
1988
Phi Beta Kappa
Jacob Van Ek Award for Academic
Excellence
Alpha Omega Alpha
Lubrizol Foundation Award for
Excellence in Patient Care
Physician Research Training Fellowship
Maxwell Finland Young Investigator
Award
Young Investigator Award in Virology
University of Colorado
University of Colorado
Case Western Reserve University
Case Western Reserve University
American Cancer Society
Infectious Disease Society of Massachusetts
Infectious Disease Society of America/Burroughs
4
1993
1994
1994
1999
2002
Selected Member
NIH Merit Award
Linda Laubenstin Memorial Lecture,
Honors Program Lecture
John T. Carey Memorial Lecture
B. Frank Polk Memorial Lecture
Endowed Chair for AIDS Research
Gill Lectureship Award
Distinguished Clinical Research Scientist
Award
Jonathan Lax Memorial Lecture
Fellow
2003
2008
Honorary Member
Honorary Degree
2009
Selected Member
2010
Selected Member
1998
1998
1999
1999
1999
Welcome
American Society for Clinical Investigation
National Institutes of Health
New York University
Case Western Reserve University
Johns Hopkins University,
AIDS Research Amsterdam
University of Colorado
Doris Duke Charitable Foundation
The Wistar Institute
American Association for the Advancement of
Science
Ludwig Heilmeyer Society
Nelson Mandela School of Medicine, University of
KwaZulu-Natal, South Africa
Institute of Medicine, National Academy of
Sciences
American Academy of Arts and Sciences
Report of Funded and Unfunded Projects
Funding Information
Current
11/01/02-08/31/12
07/01/04-07/31/14
02/01/06-01/31/11
01/01/07-06/30/11 NCE
AIDS Research
Howard Hughes Medical Institute
P.I. ($5,199,062 + P.I.'s annual salary; YR5 amount TBD)
The specific focus of the HHMI grant is to develop new strategies for
immune reconstitution in HIV and HCV infected persons, with funding to
support preclinical and clinical development.
Harvard Medical School Center for AIDS Research
NIH P30 AI60354-04
P.I. ($20,459,814 07/01/04-07/31/11)
To consolidate and expand existing collaborations of two existing, highly
successful HMS-affiliated CFARs and to promote new interactions and
research initiatives capable of more effectively addressing key AIDS
research questions.
Pathogenesis of Clade C HIV Infection
NIH RO1 AI067073-05
P.I. ($2,366,488)
Proposal to build on solid preliminary data and outstanding functional
collaborations to establish a longitudinal cohort of untreated HIV clade C
infected persons with acute and chronic infection to define epitope specific
immune responses associated with controlled and uncontrolled infection.
Capacitating Clinical Research in Africa
DDCF/Demitra Mentoring Award
P.I./Mentor ($200,000)
5
09/01/07-08/31/12
09/26/08-08/31/12
09/22/08-08/31/13
01/01/09-12/31/10
01/01/09-12/31/10
02/01/09-01/31/14
Building on the initial successes of the DDMRI to help create the next
generation of leaders in translational clinical research in Africa, using a focus
on key research questions related to the AIDS and TB epidemics.
HIV Controllers: Implications for Immunogen Design
Bill & Melinda Gates Foundation
P.I. ($19,099,923)
To use population based studies of immune responses, viral evolution and
host genetics to achieve effective immunogen design for a global HIV
vaccine.
Acute HIV Infection: Implications for vaccine design
5 PO1 AI074415-03
Project 2 Leader ($455,517)
The aims of this Program Project are to expand and maintain an Acute HIV-1
infection cohort, to study innate and adaptive immunology, antigenprocessing, viral evolution and the impact of viral sequence evolution on
mDC function.
PD-1 expression and HIV specific T cell dysfunction
5 PO1 AI080192-03
P.I. ($2,315,365)
The goal of this program is to elucidate the mechanisms of PD-1 function,
signaling, and expression in healthy and HIV-infected individuals and in
model systems.
HIV inhibition: development of a novel high throughput single cell array to
define correlates of antiviral cytotoxic T-lymphocyte (CTL) function
Ragon Institute of MGH, MIT, and Harvard
Co P.I. ($123,000)
Aim of this proposal is to develop a single cell CTL killing assay combined
with phenotyping and genetic analyses that will allow us for the first time to
define immunologic and genetic correlates of effective antiviral CD8+ T cellmediated immunity
Ragon Institute Adaptive Immunity Program
Ragon Institute of MGH, MIT, and Harvard
P.I. $910,000
The aim of this program is to identify areas of focused research to define the
role of adaptive cellular immune responses in HIV control, including the
basis for the protective role of HLA B57 on disease outcome, the basis for
the association between specific epitope targeting and lower viral load, and
the investigation of tissue specific adaptive immune responses; and to expand
a cohort of HIV controllers and engage other MIT and Harvard faculty in
investigating the basis for durable control.
Inhibition of HIV1 Replication by Cytotoxic Lymphocytes
NIH/NIAID ROI AI30914-15
P.I. ($1,240,000)
Continuation of this study to determine the ability of CTL to inhibit HIV
replication, and the mechanisms by which this occurs. It focuses on persons
with chronic HIV-1 infection. Specifically, we propose to use established
cellular assays to characterize CTL from infected persons in order to
determine the importance of epitope specificity and restricting HLA class I
6
08/02/10-08/01/11
Past
03/01/93-02/28/98
01/01/94-12/31/97
07/01/94-06/30/98
09/01/94-05/31/98
02/01/95-01/31/96
09/30/96-07/31/01
01/01/97-12/31/01
05/01/97-04/30/98
07/01/97-06/30/02
alleles on their ability to inhibit HIV-1 replication.
ARRA Administrative Supplement: Identification of “good” CTL epitopes
for vaccine design
NIH/NIAID 3 PO1 AI074415-02S1
Project 2 Leader ($100,000)
This project serves to identify key targets for vaccine design across HIV by
characterizing the impact of specific mutations in the virus on the ability of
HIV to replicate.
Evolution of HIV ENV antigens & Immune Response
NIH
The goal of this project was to define cellular immune responses to HIV
envelope proteins
CD and T cells and maternal-fetal transmission
Pediatric AIDS Foundation
The goal of this project was to define the potential role of CTL in limiting
HIV transmission from mother to child
Correlates of immune protection in AIDS vaccine recipients
Northwestern Univ.
Sub
This was a multi-site consortium to examine cellular and humoral immune
responses in AIDS vaccine recipients
CD4 cell therapy in HIV-1 infection
NIH
The goal of this project was to define the role of CD4 T cells in HIV
pathogenesis
Immune responses to live attenuated retroviruses vaccine
Harvard Medical
Sub
The goal of this project was to define immune responses induced by a live
attenuated AIDS virus vaccine in monkeys
Immunobiology of HHV8 in Kaposi’s Sarcoma
NIH R01 CA73580
Co-P.I.
The goal of this project was to define cellular immune responses to HHV-8
Countermeasures to Biologic Pathogens and Myelotoxins Agency (DARPA)
Defense Advanced Research Projects
Co-P.I.
The goal of this project was to develop universal antiviral T cell responses
Immune reconstitution in AIDS virus infections
NIH
The goal of this project was to define mechanisms to augment HIV-specific
immunity in the setting of chronic infection
Immunologic and Virologic Features of Early HIV Infection
NIH U01 AI41531
P.I. (Sub)
The goal of this project was to define the impact of early treatment of acute
7
09/30/97-08/31/01
07/15/99-06/30/05
12/01/99-03/14/07
06/01/00-05/31/03
05/09/01-11/30/06
06/15/01-04/30/06
02/01/02-07/31/07
03/01/02-02/29/04
03/15/02-03/14/04
03/15/02-04/14/07
HIV infection on the evolution of immune responses to HIV
HIV-1-specific CD4 Cells in Disease Pathogenesis
NIH R01 AI40873
The goal of this project was to define the role of CD4 T cells in AIDS virus
pathogenesis
Immune Control of HIV Replication
NIH R01 AI44656
The goal of this project was to define the effector mechanisms in CD8 T cells
that limit HIV replication
Immune Reconstitution in HIV Infection
Doris Duke Charitable Foundation 201433
P.I.
Focused on HIV-1 immunotherapy, and the use of dendritic cells to boost
CD4/CD8 responses to HIV/ HCV.
HIV Vaccine Trial Clinical Unit
NIH U01 AI48023
P.I. (Sub)
The goal of this sub was to assess immune responses in AIDS vaccine
recipients
HLA Typing and Epitope Mapping to Guide IV Vaccine Design – No Cost
Extension
NIH/NIAID N01 AI15442
P.I.
Contract to determine epitopes and restricting alleles for CTL in persons
infected with non-B clade viruses and non-Caucasian individuals infected
with B clade viruses.
Cell Mediated Immunity in Hepatitis C Virus Infection
NIH 1R01 AI31563
The goal of this project was to define the cellular immune responses in HCV
infected humans, both in liver and in peripheral blood
Inhibition of HIV-1 Replication by Cytotoxic Lymphocytes
NIH R01 AI30914
The goal of this project we to define the mechanisms of anviral function of
CD8 T cells in persons with chronic HIV infection
In Vivo Induction of HIV Specific CTL by Dendritic Cells
NIH R01 AI44628
Sub
The goal of this project was to develop techniquest to induce HIV-specific
CTL using peptide-pulsed dendritic cells
Center for Research at the Nelson R. Mandela School of Medicine
Doris Duke Charitable Foundation 20011033
P.I.
Established Phase 1 of a custom designed research institute in KwazuluNatal, South Africa.
HIV Pathogenesis Program Charitable Foundation
Doris Duke Charitable Foundation 20011032
UKZN, S. Africa, PARC-MGH/Harvard Medical School collaboration for a
multidisciplinary HIV pathogenesis research initiative: immunology
8
07/01/02-06/30/08
09/30/02-08/31/04
07/01/03-06/30/05
08/01/03-07/31/08
04/01/04-03/31/09
08/17/05-07/31/10
09/01/06-08/31/07
01/01/07-12/31/08
program; a training program and research center infrastructure in Africa.
Pathogenesis and treatment of acute HIV infection
NIH/NAIAD U01 AI52403-05
Boston & Sydney collaboration demonstrating acute infection is associated
with a clinical syndrome; linking severity of acute infection symptoms to
long-term progression of infection; demonstrating early treatment enhances
critical CD4 cellular immune responses; early intervention can enhance
immune control; and immune selection pressure influences viral evolution
and cohort studies.
Development of a Microarray for CTL Detection
NIH R21 AI53911
P.I.
The goal of this project was to develop a microarray based mechanism for
CTL detection
Development of Affordable HIV Diagnostics Using Microchips
Doris Duke Charitable Foundation
Co-Invest.
The goal of this project was to use nanotechnology and microfluidics to
develop a point of care diagnostic platform for use in resource constrained
settings
HLA Typing and Epitope Mapping to Guide HIV Vaccine Design
NIH/NIAID N01 AI30024
P.I.
Study addresses CTL and Th cell responses and the role of neutralizing
antibody immune responses to HIV-1 infection. Subjects in Peru, Thailand
and China are HLA typed at hhg resolution and tested with overlapping
peptide sets for cellular immune responses to locally circulating virus.
HIV-Specific T cell clones
NIH/NAIAD 5R01 AI028568-17
P.I.
This is a study of HIV-1-specific CTL in terms of epitope specificity and
HLA restriction, as well as T cell receptor usage in chronically infected
persons.
Immune Control and Immune Evasion during Acute HCV Infection.
Relinquished 12/14/07
NIH U19 AI066345
The goal of this project was to define the mechanisms and pathways to
immune escape from CTL responses in acute HCV infection
Planning Grant for Immune Regulation of HIV Infection
IAVI
Goal was to develp a research program to address an issue of critical
importance for vaccine design, namely definition of functional immune
responses that exhibit antiviral efficacy, focusing on conditions of
spontaneous immune control
Immune Regulation of HIV: Providing insights for Improved AIDS Vaccine
Design
IAVI
P.I.
9
05/01/07-04/30/08
Goal is to address an issue of critical importance for vaccine design, namely
definition of functional immune responses that exhibit antiviral efficacy,
focusing on conditions of spontaneous immune control.
Restoring Function in HIV-Specific T-Cells
Emory U/CPFA sub
The goal of this project was to define immunoregulatory networks in HIV
infected persons in an attempt to utilize these to augment immunity
Report of Local Teaching and Training
Teaching of Students in Courses
1989-1993
HST040, Mechanisms of Microbial Pathogenesis
2nd year HST students/30 attendees
1990
AIDS Pathogenesis
2nd year medical students/30 attendees
1990-1992
Mechanisms of Infection, Medicine 513M.J
2nd year medical students/40 attendees
Advanced Basic Science (ABS) Course
“Pathogenesis of AIDS”
1992-1994
4th year students/8 attendees
Harvard Medical School
3 hours of preparation per year
Harvard Medical School
3 hours of preparation
Harvard Medical School
3 hours of preparation per year
Harvard Medical School
15 hours of preparation per year
Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)
1990
Infectious Disease Seminar Series
Boston City Hospital
Faculty and Students/40 attendees
2 hours of preparation
1991, 1995
Pathology Seminar Series
Massachusetts General Hospital
Pathology Residents, Fellows and
2 hours of preparation
Staff/30 attendees
1992
Immunology Seminar Series
University of Massachusetts
Graduate Students/50 attendees
2 hours of preparation
1992
AIDS Provider Group
Beth Israel Hospital
Physicians/80 attendees
2 hours of preparation
1992
Allergy & Immunology Seminar
Massachusetts General Hospital
Faculty, Residents and Medical
2 hours of preparation
Students/30 attendees
1993, 1995, 1997 Immunology Seminar
Boston University
Graduate students and physicians/40
2 hours of preparation
attendees
1993
AIDS Pathogenesis
New England Deaconess Hospital
Physicians/50 attendees
2 hours of preparation
1995-1998
“Contemporary Topics in
Harvard Medical School
Immunology”, Immunology 200
Immunology graduate students/20
3 hours of preparation per year
attendees
1997
Immunology Seminar
Massachusetts General Hospital
Faculty and Fellows/25 attendees
4 hours of preparation
1997
Arthur Ashe Program in AIDS Care
Harvard AIDS Institute
Seminar Series
All levels of medical students/30
2 hours of preparation
attendees
10
1998
1999
2005
2008
2008
2008
2008
2009
2009
HST-175: Cellular and Molecular
Immunology
Immunology graduate students/20
attendees
Immunology Seminar Series
Faculty and Students/100 attendees
Cellular and Molecular Immunology
AIDS Lecture
Harvard Medical School Students
Harvard-MGH Infectious Diseases of
Adults Post-Graduate
Ph.D supplementary training
Global Health Course
Medical students/30 attendees
HIV Immunology Lecture
Medical students/30 attendees
Center for Population & Development
Studies
Medical students/30 attendees
Introduction to Global Medicine
Graduate students /40 attendees
Chemical and Biological
Thermodynamics
Graduate Students/40 attendees
Harvard Medical School
3 hours of preparation
Harvard Medical School
4 hours of preparation
Massachusetts General Hospital
4 hours of preparation
Massachusetts General Hospital
8 hours of preparation
Harvard Medical School
2 hours of preparation
Harvard Medical School
2 hours of preparation
Harvard University School of Public Health
2 hours of preparation
Harvard-MIT Health Sciences and
Technology
2 hours of preparation
Massachusetts Institute of Technology
2 hours of preparation
Clinical Supervisory and Training Responsibilities
1988-present
Attending Physician, Infectious Disease
Service / Massachusetts General
Hospital
4 Fellows per year
1 month per year @ 6 hrs/day
Laboratory and Other Research Supervisory and Training Responsibilities
Formally Supervised Trainees
1987-1991
V. Johnson, Associate Professor, University of Alabama
Research Training Fellowship Mentor
1989-1992
R. P. Johnson, Associate Professor, Harvard Medical School
Research Training Fellowship Mentor
1990-1996
M. Koziel, Staff Scientist, Vertex
Research Training Fellowship Mentor
1990-1995
C. Jassoy, Professor, University of Wurzburg, Germany
Research Training Fellowship Mentor
1991-1994
S. Kalams, Associate Professor, Vanderbilt University
Research Training Fellowship Mentor
1991-1994
T. Harrer, Professor, University of Erlangen, Germany
Research Training Fellowship Mentor
11
1991-1994
1992-1995
1993-1999
1994-1997
1994-1997
1994-1998
1994-1999
1995-1999
1995-1997
1996
1996-2000
1996
1996-1999
1996-1999
1997-2000
1997-2000
1997-1999
1997-1998
1997-1998
1997-1999
1997-2001
1998-1999
1998
1998-2002
T. Curiel, Associate Professor, Tulane University
Research Training Fellowship Mentor
C. Wilson, Associate Professor, University of Colorado
Research Training Fellowship Mentor
O. Yang, Associate Professor, UCLA
Research Training Fellowship Mentor
N. Sipsas, Assistant Professor, Athens
Research Training Fellowship Mentor
S. Threlkeld, Physician, University of Tennessee
Research Training Fellowship Mentor
C. Brander, Professor, Barcelona
Research Training Fellowship Mentor
D. Wong, McMaster University Medical Centre, Canada
Research Training Fellowship Mentor
H. Cao, Scientist, California Department of Health Services
Research Training Fellowship Mentor
J. Walter, Assistant Professor, Gesellschaft fur Molekulare Medizin, Germany
Research Training Fellowship Mentor
Jean-Louis Sankale, Harvard School of Public Health, Boston, MA
Thesis Reviewer
Fidencio Saldana, Harvard Medical School, Boston, MA
Faculty Advisor
Efi Kokkotou, Harvard School of Public Health, Boston, MA
Thesis Reviewer
M. C. Hay, Assistant Professor, Columbia University
Research Training Fellowship Mentor
E. Rosenberg, Associate Professor, Harvard Medical School
Research Training Fellowship Mentor
Glenda Callendar, Harvard Medical School, Boston, MA
Faculty Advisor
Fatema Aziz, Harvard Medical School, Boston, MA
Thesis Advisor
P. Goulder, Professor, Oxford University
Research Training Fellowship Mentor
R. Klein, Assistant Professor, Washington University School of Medicine
Research Training Fellowship Mentor
M. Severino, Scientist, Merck Research Laboratories
Research Training Fellowship Mentor
J. Mukherjee, Medical Director, Partners in Health
Research Training Fellowship Mentor
R. Geiben, Biotechnology
Research Training Fellowship Mentor
Mischo Kursar, Freie Universitat Berlin
Thesis Advisor
Linda Tremblay, Tufts University
Thesis Reviewer
G. Lauer, Associate Professor, Harvard Medical School
Research Training Fellowship Mentor
12
1999-2000
1999-2000
1999-2001
1999-2003
1999-2003
1999-2003
1999-2003
2000-2003
2001-2002
2001-2002
2001-2003
2001-2003
2001-present
2002-2003
2002-2004
2002-Present
2002-Present
2002-Present
2002-Present
2003-2004
2003-Present
2003-2006
2003-Present
2004-2005
F. Lee, Staff Physician, MGH
Research Training Fellowship Mentor
M. Altfeld, Associate Professor, Harvard Medical School
Research Training Fellowship Mentor
G. Cohen, Instructor, New England Regional Primate Research Center
Research Training Fellowship Mentor
P. Norris, Senior Scientist, Blood Systems Research Institute
Research Training Fellowship Mentor
M. Addo, Instructor, Harvard Medical School
Research Training Fellowship Mentor
M. Feeney, Associate Professor, University of California San Francisco
Research Training Fellowship Mentor
C. Day, Assistant Professor, Emory
Research Training Fellowship Mentor
W. Rodriguez, Instructor, Harvard Medical School
Research Training Fellowship Mentor
T. Allen, Associate Professor, Harvard Medical School
Research Training Fellowship Mentor
A. Kim, Assistant Professor, Harvard Medical School
Research Training Fellowship Mentor
R. Draenert, Physician, Ludwig-Maximilians-Universitaet, Germany
Research Training Fellowship Mentor
X. Yu, Associate Professor, Harvard Medical School
Research Training Fellowship Mentor
Y. Tang, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
S. Le Gall, Assistant Professor, Harvard Medical School
Research Training Fellowship Mentor
J. Timm, Physician, Ruhr-University Bocheim, Germany
Research Training Fellowship Mentor
M. Brockman Associate Professor, Simon Frasier University
Research Training Fellowship Mentor
K. Dong, Lecturer, Harvard Medical School
Research Training Fellowship Mentor
M. Lichterfeld Instructor, Harvard Medical School
Research Training Fellowship Mentor
J. Wiesch, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
G. Tanzi, Consultant, Private Industry
Research Training Fellowship Mentor
G. Alter, Assistant Professor, Harvard Medical School
Research Training Fellowship Mentor
T. Koibuchi, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
B. Ojikutu, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
N. Lin, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
13
2004-Present
2004-Present
2005-Present
2006-Present
2007-Present
2007-Present
2008-Present
2009-Present
2009-Present
2010-Present
2010-Present
F. Pereyra, Assistant Professor, Harvard Medical School
Research Training Fellowship Mentor
T. Miura, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
H. Chen, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
Z. Brumme, Associate Professor, Simon Frasier University
Research Training Fellowship Mentor
D. Kwon, Instructor, Harvard Medical School
Research Training Fellowship Mentor
B. Juelg, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
G. Gaiha, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
Z. Ndhlovu, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
M. Leshwedi, Research Fellow, University of KwaZulu-Natal
Research Training Fellowship Mentor
D. Shasha, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
N. Holt, Research Fellow, Harvard Medical School
Research Training Fellowship Mentor
Formal Teaching of Peers (e.g., CME and other continuing education courses)
"No presentations below were sponsored by outside entities"
1989-2003
Infectious Disease Postgraduate Course
Harvard Medical School
1990-1995
Lecture on AIDS
Anesthesia Postgraduate Course, Harvard Medical School
1995
Pulmonary Postgraduate Course
Harvard Medical School
1994
Aids Pathogenesis
Postgraduate Course, Boston University
1998
Aids Pathogenesis
Harvard Retrovirology Dinner Club, Harvard Medical School
1998
Virology Seminar Series
Harvard Medical School
1998-2000
AIDS Postgraduate Course
Harvard Medical School
2009
Computational Immunology Symposium
Massachusetts Institute of Technology
Lecture
Boston, MA
Lecture
Boston, MA
Lecture
Boston, MA
Lecture
Boston, MA
Lecture
Boston, MA
Lecture
Boston, MA
Lecture
Boston, MA
Lecture
Cambridge, MA
Local Invited Presentations
1989, 1992
Gastroenterology Grand Rounds, Massachusetts General Hospital, Boston, MA
1990
Hematology Grand Rounds, Massachusetts General Hospital, Boston, MA
1994
Pathology Department Grand Rounds, Massachusetts General Hospital, Boston, MA
14
1995, 1998
1996
1998
2000
2000
2000
2000
2001
2001
2001
2001
2001
2001
2001
2001
2002
2002
2002
2002
2003
2003
2003
2003
2004
2004
2004
2004
2005
2005
2005
Medical Grand Rounds, Massachusetts General Hospital, Boston, MA
Medical Grand Rounds, Brigham & Women’s Hospital, Boston, MA
Harvard AIDS Institute Think Tank, Harvard Medical School, Dedham, MA
Partners Physician’s Day, Massachusetts General Hospital, Boston, MA
Partners Health Care Senior Management Retreat, Massachusetts General Hospital,
Boston, MA
Harvard Medical School Scientific Symposium, Harvard Medical School, Boston, MA
Harvard Medical Service Alumni Reunion, Harvard Medical School, Boston, MA
Transfusion Medicine Grand Rounds, Brigham & Women’s Hospital, Boston, MA
Infectious Diseases of Adults - 2001, MGH Infectious Disease Division, Cambridge, MA
Harvard University Virology Seminar Series, Harvard University, Boston, MA
Partners HealthCare System, Inc. Annual Meeting, Massachusetts General Hospital,
Boston, MA
HIV and Women: Epidemiology, Immunology and Metabolism, Harvard Medical School,
Boston, MA
Harvard Medical School Program in Immunology Seminar Series, Harvard Medical
School, Boston, MA
Harvard Medical School Pasteur Clinical Champions Seminar Series, Harvard Medical
School, Boston, MA
Harvard Medical School/Brigham & Women’s Hospital Transfusion Medicine Grand
Rounds, Boston, MA
Harvard-MIT Hippocratic Society’s 2002 Conference on Infectious Disease, Harvard
University and Massachusetts Institute of Technology, Cambridge, MA
Harvard Programs on AIDS in Africa: A University Responds, Harvard University,
Boston, MA
MGH Chief of Service Conference on Pediatric HIV, Massachusetts General Hospital,
Boston, MA
HMS Virology Seminar, Harvard Medical School, Boston, MA
Brigham & Women’s Hospital Partners AIDS Research Center HIV Update Symposium,
Brigham and Women's, Cambridge, MA
Harvard Medical School Pasteur Case Study Series, Harvard Medical School, Boston, MA
Department of Medicine Academic Council Faculty Seminar Series, Massachusetts
General Hospital, Boston, MA
"Facing the Challenges of Global Health Today", Harvard University Committee on
University Resources Annual Meeting, Boston, MA
Harvard Medical School Physicians for Human Rights, Harvard Medical School, Boston,
MA
“AIDS 2004,” Massachusetts General Hospital Division of Primary Care, Boston, MA
“Immunology of AIDS,” Harvard School of Public Health Division of Biostatistics,
Boston, MA
Center for AIDS Research 8th Annual National Symposium, Harvard University, Boston,
MA
“AIDS Pathogenesis,”Consul General of France and Harvard Medical School Division of
AIDS, Boston, MA
“Building research capacity in resource scarce settings,” Harvard University Office of
International Programs, Boston, MA
Invited Speaker
Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA
15
2006
2006
2006
2006
2007
2007
2007
2007
2008
2008
2008
2008
2008
2008
2008
2008
2008
2008
2008
2008
2009
2010
2010
2010
2010
2011
2011
Partners Physician’s Day, Massachusetts General Hospital, Boston, MA
“Immune Control of HIV,” Broad Institute of MIT and Harvard, Cambridge, MA
Immune Control of HIV: a perspective from studies in Africa, Harvard Medical School Center for Population and Development Studies, Cambridge, MA
“Immune Control and Immune Failure in HIV Infection,” Program for Evolutionary
Dynamics at Harvard, Cambridge, MA
8th Annual Partners Physicians Day - Keynote Speaker, Massachustts General Hospital,
Boston, MA
Brigham and Women’s Hospital Research Conference, Brigham and Women's Hospital,
Boston, MA
Harvard Medical School Committee on Immunology Seminar, Harvard Medical School,
Boston, MA
AIDS Medicine: An Intensive Case-Based Course, Harvard Medical School, Boston, MA
HOPE Conference, Massachusetts General Hospital, Boston MA
Global Health Delivery Seminar Series, Harvard Medical School, Boston, MA
Harvard University Centers for AIDS Research Annual Symposium, Harvard Medical
School, Boston, MA
“HIV/AIDS and Global Health", MGH Center for Global Health, Boston, MA
"Missing Medicines, Harvard's Response to the Challenge of Global Neglected Diseases",
Harvard Global Health and AIDS Coalition, Cambridge, MA
Pasteur Case Study, Massachusetts General Hospital, Cambridge, MA
Harvard Medical School Committee on Immunology Seminar, Harvard Medical School,
Boston, MA
Program for Evolutionary Dynamics, Harvard University, Cambridge, MA
Training, Funding and Focus areas for Translation Research, Harvard School of Public
Health, Boston, MA
“T-cell mediated immunity to HIV plus human genetic polymorphisms affecting HIV
progression”, Massachusetts General Hospital, Boston, MA
AIDS in Africa: Long-Term Effects of ARV Therapy Symposium, Harvard Medical
School, Boston, MA
ECOR Celebration of Science, HIV Conference Series “How HIV Causes Disease: A 2009
Perspective”, Massachusetts General Hospital, Boston, MA
Harvard Virology Program “Immune Control and Immune Failure in HIV Infection”,
Harvard Medical School, Boston, MA
The Challenges of Developing Vaccines to HIV/AIDS
Massachusetts Institute of Technology, Boston, MA
Seminar for SURF Students
Harvard Institute of Global Health, Cambridge, MA
Practicing Global Health across Disciplines: Snapshots of Success, Global Health
Symposium
MGH Center for Global Health, Boston, MA
“Immununology of HIV/AIDS”
Harvard Medical School, Boston, MA
“Unraveling the Genetic Basis of HIV Control”
Brigham and Womens Hospital Pathology Grand Rounds Boston, MA
Global Health: South Africa
Center for Global Health Advisory Board meeting, MGH, Boston, MA
16
Report of Regional, National and International Invited Teaching and
Presentations
Invited Presentations and Courses
Regional
1989
1989
1990
1990
1991
1993
1993
1996
1997
1997, 2000,
2008
1997
1998
1998
1998
1998
1999
1999
2000
2000
2000
Dartmouth College Immunology Seminar Series
Dartmouth College, Hanover, NH
Medical Grand Rounds
Addison Gilbert Hospital, Gloucester, MA
Medical Grand Rounds
Repligen Corporation, Cambridge, MA
Brown University Immunology Seminar
Brown University, Providence, RI
Medical Grand Rounds
West Roxbury VA Hospital, Boston, MA
Contemporary Topics in Immunology
Boston, MA
Immunology Seminar Series
Dartmouth College, Hanover, NH
Hepatitus C and Beyond
Keystone Symposia, Burlington, VT
Infectious Disease Grand Rounds
Boston University, Boston, MA
Invited Speaker
Milton Academy, Milton, MA
Invited Speaker
Search for a Cure, Boston, MA
Invited Speaker
International AIDS Society-USA, Boston, MA
Invited Speaker
Harvard AIDS Institute Think Tank, Dedham, MA
Invited Speaker
Wellesley College, Wellesley, MA
World AIDS Conference Review
AIDS Action Committee, Boston, MA
Invited Discussant
Project Inform, Boston, MA
Invited Speaker
Boston Medical Center, Boston, MA
BIO 2000 TechTransfer Forum
Boston, MA
Grand Rounds
Lowell General Hospital, Lowell, MA
Invited Speaker
Dimmock Community Health Center, Boston, MA
17
2001
2001
2001
2001
2001
2001
2001
2001
2002
2002
2002
2002
2002
2003
2003
2003
2003
2004
2004
2004
2005
2005
2006
2006
Invited Discussant
Waterford Project Meeting, Boston, MA
Invited Lecturer
Infectious Diseases of Adults – 2001, Cambridge, MA
Boston Living Center’s 14th Annual Thanksgiving Dinner
Boston Living Center, Boston, MA
Federation of Clinical Immunology Societies Meeting
Boston, MA
Wyeth Research/Genetics Institute
Cambridge, MA
HIV and Women: Epidemiology, Immunology and Metabolism
Boston, MA
Pediatric Vaccine Immunology Workshop
Elizabeth Glaser Pediatric AIDS Foundation, Dedham, MA
International Health Organization 3rd AIDS in India Symposium
Boston, MA
Children’s Hospital Senior Rounds
Boston, MA
47th Annual Meeting of the Plastic Surgery Research Council
Boston, MA
BMS Metabolic & Cardiovascular Complications of HIV Preceptor Series
Boston, MA
Doris Duke Charitable Foundation Medical Research Program Clinical Scientist Meeting
Newport, RI
Children’s Hospital Senior Rounds
Children’s Hosptial, Boston, MA
Grand Rounds
New England Medial Center, Boston, MA
10th Conference on Retrovirus & Opportunistic Infection
Foundation for Retrovirology and Human Health, Boston, MA
American Transplant Congress 5th Joint American Transplant Meeting
American Transplant Congress, Boston, MA
Boston Living Center’s GlaxoSmithKline Dinner Series
Boston Living Center, Boston, MA
IDEAS Boston Conference Series
IDEAS Boston, Boston, MA
Howard Hughes Medical Institute Exceptional Research Opportunities Program
Howard Hughes Medical Institute, Cambridge, MA
New England Cytometry Users Group Presentation
New England Cytometry Users Group, Boston, MA
“Elite Control of HIV”
Boston Medical Center, Boston, MA
CENTRA Users Conference
Boston, MA
Invited Speaker
Counsel on Foreign Relations, Cambridge, MA
Invited Speaker
UMass Memorial Medical Center, Worcester, MA
18
2007
2007
2008
2008
2008
2008
2008
2009
2010
2010
Infectious Disease of Adults
HIV Pathogenesis, Boston, MA
Invited Speaker
Broad Institute of MIT and Harvard, Cambridge, MA
IAP Lecture Series - "The Molecular Basis of Infectious Disease"
Broad Institute of MIT and Harvard, Cambridge, MA
15th Conference on Retroviruses and Opportunistic Infections
Conference on Retroviruses and Opportunistic Infections, Boston, MA
AIDS: Evolution of an Epidemic
Broad Institute of MIT and Harvard, Cambridge, MA
Tuberculosis Retreat
Broad Institute of MIT and Harvard, Cambridge, MA
Improving Vaccination for Chronic Viral Infections –A Case for Emerging Immune
Modulatory Therapies Satellite Symposium
Clinical Immunology Society, Boston, MA
Amherst College Public Health Collaborative
Amherst College, Amherst, MA
Keynote: Immunogenetics of HIV Infection, FOCIS 2010
Federation of Clinical Immunology Societies, Boston, MA
Viruses and The Host Response, 50th Interscience Conference on Antimicrobial Agents
and Chemotherapy
American Society of Microbiology, Boston, MA
National
1987
1987
1988
1998
1998
1990
1991
1992
1992
1992
1992
1993
Keystone Symposium on AIDS Pathogenesis
Keystone Symposia, Keystone CO
Invited Speaker
3rd International AIDS Conference, Washington, D.C.
University of California Immunology Seminar Series
University of California at San Francisco, San Francisco, CA
HIV Information Network Publication
University of Alabama, Birmingham, Alabama
First National Cooperative Vaccine Development Group for AIDS
National Institute of Allergy and Infectious Diseases, Norfolk, VA
University of Alabama Immunology Seminar Series
University of Alabama, Birmingham, Alabama
Invited speaker
Clinical Immunology Society, Washington, DC
Stanford University Immunology Seminar Series
Stanford University School of Medicine, Stanford, CA
University of Washington Immunology Seminar Series
University of Washington, Seattle, WA
Invited Speaker
University of Colorado Health Sciences Center, Denver, CA
Invited Speaker
Chiron Corporation, Emeryville, CA
NIH Research Conference on Immunologic & Host Genetic Resistance to HIV Infection
& Disease
National Institutes of Health, Bethesda, MD
19
1993, 1995,
1998
1993
1993
1994
1994
1995
1995
1995
1995
1995
1995
1996
1996
1996
1996
1996
1996
1996
1996
1997
1997
1997
1998
1998
Immune Reconstitution Think Tank
Project Inform, Napa Valley, CA
Invited Speaker
American Association of Allergy & Immunology, Milwaukee, WI
Ad Hoc Review Panel/HIV Immunopathogenesis Program
National Institute of Health, Bethesda, MD
Grand Rounds
Hanneman Medical School, Philadelphia, PA
NIH Conference on HIV Infection of the Central Nervous System
National Institutes of Health, Bethesda, MD
Southwestern University Immunology Seminar
Southwestern University School of Medicine, Dallas, TX
Molecular Aspects of Viral Immunity
University of California at Los Angeles, Keystone, CO
Invited Speaker
New York Blood Center , New York, NY
International Immunology Congress
American Association of Immunologists, San Francisco, CA
Molecular Aspects of Infectious Diseases
Cold Spring Harbor, NY
Invited Speaker
Cell Genesys, San Francisco, CA
Merck Immunology Lecture
Merck & Co, Rahway, NJ
Vanderbilt University Immunology Seminar
Vanderbilt University, Nashville, TN
Mt. Sinai Hospital Immunology Seminar
Mt. Sinai Hospital, New York, NY
National Symposium on Basic Aspects of Immunology
National Institutes of Health, Bethesda, MD
American Association for the Advancement of Science Annual Meeting
American Association for the Advancement of Science, Baltimore, MD
University of North Carolina Immunology Seminar
University of North Carolina , Chapel Hill, NC
New Insights in HIV Infection and Disease
Cambridge Symposia, Hilton Head, SC
Invited Speaker
The Scripps Research Institute, La Jolla, CA
Invited Speaker
Aaron Diamond AIDS Research Center, New York, NY
4th Conference on Retroviruses & Opportunistic Infections
Washington, DC
AIDS Clinical Trials Group Meeting
National Institutes of Health, Arlington, VA
Keystone Symposium Conference on HIV Pathogenesis and Treatment
Keystone Symposia, Park City, UT
UCSF Center for AIDS Research Annual Symposium
20
1998
1998
1998
1998
1998
1998
1998
1998
1998
1998
1998
1998
1998
1998
1998
1998
1999
1999
1999
1999
1999
1999
1999
1999
University of California San Francisco, San Francisco, CA
5th Conference on Retroviruses & Opportunistic Infections
Foundation for Retrovirology and Human Health, Chicago, IL
7th International Conference on Lymphocyte Activation and Immune Regulation
University of California, Newport Beach, CA
Interscience Conference on Antimicrobial Agents and Chemotherapy Opening Session
American Society for Microbiology, San Diego, CA
5th International Conference on Dendritic Cell Biology
NIH, Pittsburgh, PA
Invited Speaker
Infectious Disease Society of America, Denver, CO
University of Alabama Center for AIDS Research Lecture Series
University of Alabama, Birmingham, AL
Immune Reconstitution in HIV Disease
Project Inform, New York, NY
University of Pennsylvania Immunology Seminar Series
University of Pennsylvania, Philadelphia, PA
Invited Speaker
Center for AIDS Research, University of California at San Diego, San Diego, CA
10th B. Frank Polk Symposium
Johns Hopkins University, Baltimore, MD
John T. Carey Memorial Lecture
Case Western Reserve University, Cleveland OH
Invited Speaker
International AIDS Society, New York, NY
Duke University Virology Seminar
Duke University, Durham, NC
Allegheny University AIDS Seminar Series
Allegheny University, Pittsburgh, PA
Chicago Center for AIDS Research Clinic Dedication
University of Illinois at Chicago, Chicago, IL
AIDS Vaccine Research Council
National Institutes of Health, Bethesda, MA
Co-Organizer and Presenter
IAS-USA HIV Symposium, Aspen, CO
Grand Rounds
University of Colorado Medical, Denver, CO
Invited Speaker
Physicians Research Network, New York, NY
Invited Lecturer
Institute for Advanced Study, Princeton, NY
Invited Speaker
Georgetown University, Washington, DC
Cornell University Immunology Seminar Series
Cornell University, New York, NY
Invited Speaker
Institute for Human Virology, Baltimore, MD
Keystone Symposium on HIV Vaccine Development
21
1999
1999
1999
1999
1999
2000
2000
2000
2000
2000
2000
2000
2001
2001
2001
2001
2001
2001
2001
2001
2001
2001
2001
Keystone Symposia, Keystone, CO
HIV Eradication Symposium
Chiron Corporation, Emeryville, CA
Invited Symposium Speaker
University of California at Los Angeles, Palm Springs, CA
Keystone Symposium on Molecular and Cellular Biology
Keystone Symposia, Keystone, CO
Invited Discussion Group Leader, IAVI Meeting
International AIDS Vaccine Initiative (IAVI), New York, NY
John F. Kennedy School of Government/Commonwealth Fund
Bipartisan Congressional Health Policy Conference, Aventura, FL
Invited speaker
Institute of Medicine of the National Academies, Bethesda, MD
Invited Lecturer
Scripps Research Institute, CA
Invited Speaker
Immune Response Corporation, CA
University of Washington Division of Virology
University of Washington, Seattle, WA
Invited Speaker
University of Washington Center for AIDS Research, Seattle, WA
CFAR Symposium
University of Pennsylvania, Philadelphia, PA
CFAR Symposium
University of Minnesota, Minneapolis Minnesota
Invited Discussant
Rockefeller Foundation, New York, NY
Palm Springs Symposium on HIV/AIDS
Palm Springs, CA
San Francisco Immunology Program Series
University of California at San Francisco, CA
GlaxoSmithKline Speaker Program
GlaxoSmithKline, Sacramento, CA
Invited Speaker
Bristol-Myers Squibb Immunology HIV Speakers’ Bureau, Sonoma, CA
Keystone Symposium on HIV Vaccine Development
Keystone Symposia, Keystone, CO
12th Annual Virology Symposium
University of Pittsburgh, Pittsburgh, PA
Invited Panelist, 11th Annual Clinical Care Options for HIV Symposium
Laguna Niguel, CA
Merck National HIV Consultants Meeting
Merck & Co, San Antonio, TX
Special Briefing to the United States Congress: “Solving the HIV/AIDS Drug Access
Crisis in Africa: Meeting the Challenge to Save Millions of Lives & to Mitigate the
Orphan Crisis”
United States Congress , Washington, DC
Invited Moderator
22
2001
2002
2002
2002
2002
2002
2002
2002
2002
2002
2002
2002, 2003
2003
2003
2004
2004
2004
2004
2004
2004
2004
2004
2004
2004
International Association of Physicians in AIDS Care Sessions 2001, Chicago, IL
“Rationale for Therapeutic Vaccines”
AIDS Vaccine 2001, Philadelphia, PA
Keystone Symposium on Immune Reconstitution and Therapeutic Vaccination
Keystone Symposia, Keystone, CO
Improving the Management of HIV Disease
Chicago, IL
Keynote Speaker, First Annual Meeting of the Doris Duke Clinical Fellows
Doris Duke Foundation, St. Louis, MO
International Meeting of the Institute of Human Virology
Institute of Human Virology, Baltimore, MD
Merck MESA Meeting
Merck & Co, Denver, CO
HIV Vaccine Trials Network Full Group Meeting
HIV Vaccine Trials Network, Seattle, WA
IDSA Fellows’ Day Program/40th Meeting of the IDSA
Infectious Diseases Society of America, Chicago, IL
6th National Symposium on the NIH Centers for AIDS Research
National Institutes of Health, Seattle, WA
Department of Microbiology and Immunology Seminar Series
Weill Medical College of Cornell University, New York, NY
Third HIV DRP Symposium on Antiviral Drug Resistance
HIV Drug Resistance Program, Chantilly, VA
Merck MESA Lecture Series
Merck & Co, Houston, TX
University of Alabama at Birmingham Centers for AIDS Research Dinner Lecture
University of Alabama, Birmingham, AL
Immunopathogenesis/Interactive Case Challenges
13th Annual Clinical Care Options for HIV Symposium, Scottsdale, AZ
Invited Panelist, HVTN Scientific Agenda Review Meeting
HIV Vaccine Trials Network, Bethesda, MD
Institute of Medicine Antiretroviral Drug Use Workshop
Institutes of Medicine, Washington DC
Confronting the Global HIV Epidemic
Physicians Research Network, New York, NY
11th Annual Conference on Retroviruses and Opportunistic Infections
San Francisco, CA
Stop the Silence HIV/AIDS Symposium
University of Colorado, Boulder, CO
Conference on World Affairs
University of Colorado, Boulder, CO
Invited Speaker
New York University Center for AIDS Research, New York, NY
Walter Reed Army Institute of Research 10th National Symposium
Walter Reed Army Institute of Research, Silver Spring, MD
Acute Infection Early Disease Research Program International Workshop
National Institute of Allergy and Infectious Diseases, Washington, DC
Invited Speaker
23
2004
2004
2004
2004
2005
2005-Present
2005
2005
2005
2005
2005
2006
2006
2006
2006
2006
2007
2007
2007
2007
2007
2007
2007
2007
Howard Hughes Medical Institute, Chevy Chase, MD
Invited Speaker
Merck & Co., Denver, CO
Duke University HIV Meeting
Duke University. Durham, NC
Invited Speaker
Howard Hughes Medical Institute, Chevy Chase, MD
Invited Speaker
National Institute of Health Division of AIDS, Bethesda, MD
HHMI Global Health Symposium
Howard Hughes Medical Institute, Washington, DC
HHMI Science Meeting
Howard Hughes Medical Institute, Chevy Chase, MD
Invited Speaker
University of Wisconsin, Madison, WI
23rd Annual Symposium on Nonhuman Primate Models for AIDS Research
NIH, Portland, OR
Vanderbilt University Grand Rounds
Vanderbilt University, Nashville, TN
Invited Speaker
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
Keystone Symposia on Integrating Knowledge
Keystone Symposia, Keystone, CO
Scott Thaler Memorial Lecture at Merck & Co.
Merck & Co., West Point, PA
Clinical Care Options Symposium
Key Biscayne, FL
Los Angeles Intercity HIV Rounds
AIDS Healthcare Foundation, Los Angeles, CA
7th Annual HIV/AIDS Conference
Cedars Sinai Hospital, Los Angeles, CA
Arthur Ashe Endowment Lecture: "An Academic Response to the Global AIDS Crisis" Weill Medical College of Cornell University, New York, NY
Immunology Club Seminar Series
New York University School of Medicine, New York, NY
Albert Einstein CFAR symposium
NYC Medical School, New York, NY
14th Conference on Retroviruses and Opportunistic Infections
Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA
Invited Speaker
Scripps Green Hospital, San Diego, CA
Scientific Advisory BoardMeeting
GlobeImmune , Denver, CO
International AIDS Society – USA
International AIDS Society, New York, NY
Keystone Symposium on HIV Pathogenesis
Keystone Symposia, Keystone, CO
Invited Speaker
24
2007
2007
2007
2007
2007
2007
2007
2007
2007
2008
2008
2008
2008
2008
2008
2009
2009
2009
2010
2010
2010
Aaron Diamond AIDS Research Center, New York, NY
St. Vincent’s Comprehensive HIV Medical Center Grand Rounds
St. Vincent’s Comprehensive HIV Medical Center, New York, NY
Invited Speaker, Immune Control and Immune Failure in HIV Infection
The Library of Congress, Washington, DC
Invited Speaker
Federation of Clinical Immunology Societies (FOCIS), San Diego, CA
Invited Speaker
New York University, New York, NY
Collaborative Institute of Virology Directors Meeting
Collaborative Institute of Virology, Chicago, IL
Fifth Annual Clinical Investigator Student Trainee Forum
National Institutes of Health, Bethsada, MD
National Center for AIDS Research Directors Meeting
University of California Centers for AIDS Research, San Diego, CA
Stanford Institute for Immunity Transplantation and Infection
Stanford Institute, Stanford, CA
Penn Center for AIDS Research Seminar Series
University of Pennsylvania, Pennsylvania, PA
IAVI-R&D Retreat
International AIDS Vaccine Initiative, New York, NY
HIV Vaccine Strategy Meeting
Merck Vaccines and Infectious Diseases, Branchburg, New Jersey
“Why do we not yet have an HIV vaccine?”
Institute for Advanced Study, Princeton University, Princeton, NJ
Invited Speaker
Division of Infectious Diseases and International Health, University of Virginia Health
System, Charlottesville, VA
Invited Speaker
International AIDS Vaccine Initiative, New York, NY
Enders lecture
Interscience Conference on Antimicrobial Agents and Chemotherapy/Infectious Dissease
Society of America, Washington, DC
Immune regulation of HIV infection
Keystone Symposia, Keystone, CO
Keystone Symposium on Prevention of HIV/AIDS (X3) “HIV Controllers: A Model for
T Cell Vaccination?“
Keystone Symposia, Keystone, CO
Invited Speaker/Opening Remarks
HIV Management 2009: The New York Course, New York, NY
Immune Control and Immune Failure in HIV Infection
National Jewish Health, Denver, CO
HIV Exposed and Uninfected: Time for a Collaborative Approach?
NIH/NIAID, Rockville, MD
IV Elite Controllers: Implications for prophylatic and therapeutic vaccines, Leon Smith
Honorary Lecture
ID Care, Newark, NJ
25
International
1987
1989
1991
1992
1993
1993
1993
1994
1994
1994
1994
1995
1995
1995
1995
1997
1998
1998
1998
1998
1998
1998
1999
1999
AIDS Pathogenesis
Cent Gardes Meeting on AIDS Pathogenesis Pasteur Merrieux, Paris, France
Invited Speaker
Cambridge University, Cambridge, UK
Invited Speaker
African AIDS Conference, Dakar, Senegal
Invited Speaker
US-Japan Hepatitis Panel, Kofu, Japan
Invited Speaker
International AIDS Meeting, Berlin, Germany
International Meeting on the Biology, Immunology & Clinic of Hepatitis Viruses
[Parma, Italy
Immunology Seminar
University of Würzburg, Wurzburg, Germany
"Pathogenesis of AIDS MRC"
Medical Research Council of Great Britain, London, UK
Invited Speaker
University of Zurich, Switzerland
“AIDS, From Basic Science to Diagnosis and Therapy"
Florence, Italy
Cent Gardes AIDS Meeting/Pasteur Merrieux
Pasteur Insitute, Paris, France
Harold Neu ID Conference
Toronto, Canada
Zurich University Immunology Seminar
Zurich University, Zurich, Switzerland
Invited Speaker
Pasteur Institute, Paris, France
"Setting a New AIDS Agenda"
CIBA Foundation, London, England
Invited Speaker
Gesellschaft fur Virologie, Hamburg, Germany
12th World AIDS Conference
Geneva, Switzerland
Oxford University Immunology Seminar Series
Oxford, England
VII Annual Canadian Conference on HIV/AIDS Research
Quebec, Canada
2nd International Symposium of the EU Concerted Action
Oxford, England
Nobel Forum Conference on AIDS Pathogenesis
Stockhold, Sweden
Invited Speaker
University of Lausanne, Lausanne, Switzerland
Puerto Rico AIDS Symposium
San Juan, Puerto Rico
Invited Lecturer
26
1999
2000
2000
2000, 2001
2001
2001
2001
2001
2001
2001
2001
2001
2001
2002
2002
2003
2003
2003
2003
2003
2004
2004
2004
2004
Hopital Pitie-Salpetriere, Paris, France
13th Swiss GlaxoSmithKline Workshop “Challenge in Virology”
Saanen, Switzerland
Wurzburg Symposium on Infectious Diseases
University of Würzburg, Würzburg, Germany
4th Modeling Panel Meeting
Oxford University, Oxford, England
Colloque Manon Lescaut
Manon Scientific Research Program, Paris, France
Programa VII Simposio SITGES 2001
Barcelona, Spain
German AIDS Meeting
Frankfurt, Germany
First IAS Conference on HIV Pathogenesis and Treatment
Buenos Aires, Argentina
Invited Speaker
Tokyo Medical Science Institute
Invited Speaker
National Institutes of Health Japan, Tokyo, Japan
Invited Speaker
Tokyo Medical and Dental University, Tokyo, Japan
Invited Speaker
Shenyang University, Shenyang, China
19th Annual Symposium on Nonhuman Primate Models for AIDS
San Juan, Puerto, Rico
Welcome Workshop on HIV & TB
University of Cape Town, Cape Town, South Africa
International Symposium on Therapeutic Vaccines Against HIV & Cancers
Fondation Merieux, Annecy, France
XIV International AIDS Conference
Barcelona, Spain
Virology: A New Perspective
GlaxoSmithKline, Queensland, Australia
Keystone Symposium
Keystone Symposia, Banff, Canada
5th International Congress of the Federation of African Immunological Socieities
Federation of African Immunological Societies, Victoria Falls, Zimbabwe
8th International Meeting of the GEMHEP
Groupe Francais D’Etudes Moléculaires des Hépatites, Paris, France
2nd IAS Conference on HIV Pathogenesis and Treatment
International AIDS Society, Paris, France
Keystone Conference on HIV Vaccine Development
Keystone Symposia, Whistler, Canada
European Primary HIV Infection Symposium
Abbot Virology, Berlin, Germany
Keynote Speaker, 15th Annual Vietnam National Immunity Conference
Harvard Medical School, Ho Chi Minh City and Hanoi, Vietnam
Co-Chair, AIDS Vaccine Science Secretariat 2004 Symposium on Therapeutic Vaccines
27
2005
2005
2006
2006
2006
2007, 2008
2007
2007
2007
2008
2008
2008
2008
2008
2008
2009
2009
2010
2010
2010
2010
2011
AIDS Vaccine Science Secretariat, Laussanne, Switzerland
Keystone Conference on HIV Pathogenesis
Keystone Symposia, Banff Springs, Canada
Vienna Vaccines 2nd Annual Symposium
Semmering, Austria
Elite Control of HIV: Humoral, cellular and virologic factors
5th Intl Summit of Protection from HIV Infection and Disease, Amsterdam, Netherlands
Controllers of HIV: Implications for Vaccines
5th AIDS Vaccine Conference, Amsterdam, Netherlands
3rd Annual Scientific Advisory Meeting
National Center for AIDS/STD Control and Prevention, China CDC, Beijing, China
Scientific Board Meeting
Objectif Recherche Vaccins SIDA (ORVACS), Paris, France
HIV CHE Meeting
Gilead Sciences Canada, Montreal, Quebec / Toronto, Ontario
4th IAS Conference
International AIDS Society, Sydney, Australia
Keystone HIV Pathogenesis Symposium
Keystone Symposia, Banff, Alberta, Canada
"25 Years of HIV"
Institut Pasteur, Paris, France
Axel Key Symposium
Stockholm University, Stockholm, Sweden
Third Bernard Halpern Symposium of Immunology
Collège de France, Paris, France
"Elite control of HIV: Implications for vaccine design” - AIDS Vaccine 2008 Conference
University of Cape Town, Cape Town, South Africa
Invited Speaker
Institute of Medical Science, University of Tokyo, Tokyo, Japan
Keynote Speaker, 100th anniversary of the Nobel Prize to Elie Metchnikoff and Paul
Ehrlich
Max Planck Institute for Infection Biology, Berlin, Germany
“Philanthropy and the Fight against AIDS”
Barcelona, Spain
Creating Cohorts: Experiences from the International HIV Controllers Study
International Centre for Infectious Diseases, Winnepeg, Manitoba
Keynote Speaker: Durable Control of HIV Infection:Implications for Vaccine Design
Keystone Symposia, Banff, Alberta, Canada
Plan for Looking at Correlates
Center for the AIDs Programme of Research in South Africa, Durban, South Africa
Eradication and Vaccine: the Two Goals in HIV Research,
IrsiCaize 15th Anniversary Event, Barcelona, Spain
Beyond the Intellectual Silos: A new Model of Scientific Collaboration to Make the World
a Better Place
Prince de Girona Foundation, Barcelona, Spain
Keynote Speaker “Unraveling the Genetic Basis of HIV Control”
Annual Meeting for the Society for Virology, Freiberg Germany
28
Report of Clinical Activities and Innovations
Current Licensure and Certification
1980
Massachusetts Medical License
Practice Activities
1980 - present Patients with
HIV/AIDS
Infectious Disease Outpatient Unit, Massachusetts General
Hospital
Clinical Innovations
Development of immunotherapeutic approaches to HIV treatment.
Report of Education of Patients and Service to the Community
Activities
Those activities below sponsored by outside entities are so noted and the sponsor(s) is (are) identified.
HHMI Holiday Lecture “AIDS: Evolution of an Epidemic (Howard Hughes Medical
Institute)
Series of lectures given to high school students and filmed for DVD.
2007
Recognition
2003
2003
2003
2010
Illuminator Award
Commitment to Children Award
Outstanding Citizen Award
Presidents Award for Service
Cambridge Cares About AIDS
Elizabeth Glaser Pediatric AIDS Foundation
Boston Living Center
Greater Boston Business Council
Report of Scholarship
Publications
Peer reviewed publications in print or other media
Original Articles:
1.
Walker BD, Chakrabarti S, Moss B, Paradis TJ, Flynn T, Durno AG, Blumberg RS, Kaplan JC,
Hirsch MS, Schooley RT. HIV-specific cytotoxic T lymphocytes in seropositive inidividuals.
Nature. 1987;328(6128):345-8.
2.
Walker BD, Kowalski M, Goh WC, Krieger M, Rosen CR, Rohrschneider L, Haseltine WA,
Sodroski J. Inhibition of human immunodeficiency virus syncytium formation and virus
29
replication by castanospermine. Proc Natl Acad Sci USA. 1987;84:8120-8124.
3.
Fisher RA, Bertonis JM, Meier W, Johnson VA, Costopoulos DS, Liu T, Tizard R, Walker BD,
Hirsch MS, Schooley RT, Flavell RA. HIV infection is blocked in vitro by recombinant soluble
CD4. Nature 1988;331:76-78.
4.
Hussey RE, Richardson NE, Kowalski M, Brown NR, Chang HC, Siliciano RF, Dorfman T,
Walker BD, Sodroski J, Reinherz EL. A soluble CD4 protein selectively inhibits HIV replication
and syncytium formation. Nature 1988;331:78-81.
5.
Walker BD, Flexner C, Paradis TJ, Fuller T, Hirsch MS, Schooley RT, Moss B. HIV-1 reverse
transcriptase is a target for cytotoxic T lymphocytes in infected individuals. Science 1988;240:6466.
6.
Johnson VA, Walker BD, Barlow MA, Paradis TJ, Chou T-C, Hirsch MS. Synergistic inhibition
of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and
3'-azido-3'-deoxythymidine. Antimicrob Agents Chemother 1989;33:53-57.
7.
Johnson VA, Barlow MA, Chou T-C, Fisher RA, Walker BD, Hirsch MS, Schooley RT.
Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by
recombinant soluble CD4 and 3'-azido-3'-deoxythymidine. J Infect Dis 1989;159:837-844.
8.
Walker BD, Flexner C, Birch-Limberger K, Fisher L, Paradis TJ, Aldovini A, Young R, Moss B,
and Schooley RT. Long-term culture and fine specificity of human cytotoxic T-lymphocyte
clones reactive with human immunodeficiency virus type 1. Proc Natl Acad Sci USA
1989;86:9514-9518.
9.
Goldfeld A, Birch-Limberger K, Schooley RT and Walker B. HIV-1 infection does not induce
tumor necrosis factor- or interferon- gene transcription. JAIDS 1991;4:41-47.
10.
Poznansky MC, Walker BD, Haseltine WA, Sodroski J, Langhoff E. A rapid method for
quantitating the frequency of peripheral blood cells containing HIV-1 DNA. JAIDS 1991;4:368373.
11.
Johnson RP, Trocha A, Yang L, Mazarra GP, Panicalli DL, Buchanan TM, Walker BD. HIV-1gag-specific CTL recognize multiple highly conserved epitopes: Fine specificity of the gagspecific response defined using unstimulated PBMC and cloned effector cells. J Immunol
1991;147:1512-1521.
12.
Tsomedis TJ, Walker BD, Eisen H. An optimal viral peptide recognized by CD8+ T cells binds
very tightly to the restricting class I major histocompatibnility complex protein on intact cells but
not to the purified class I protein. Proc Natl Acad Sci USA 1991;88:11276-11280.
13.
Johnson RP, Trocha A, Buchanan TM, Walker BD. Identification of overlapping HLA class Irestricted cytotoxic T cell epitopes in a conserved region of the HIV-1 envelope glycoprotein:
Definition of minimum epitopes and analysis of the effects of sequence variation. J Exp Med
1992;175:961-971.
30
14.
Jassoy C, Johnson RP, Navia BA, Worth J, Walker BD. Detection of a vigorous HIV-1-specific
cytotoxic T lymphocyte response in cerebrospinal fluid from infected persons with AIDS
dementia complex. J Immunol 1992;149:3113-3119.
15.
Koziel MJ, Dudley D, Wong J, Houghton M, Ralston R, Walker BD. Intrahepatic cytotoxic T
lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol
1992;149:3339-3344.
16.
Johnson RP, Trocha A, Buchanan TM and Walker BD. Recognition of a highly conserved region
of human immunodeficiency virus type I gp120 by a HLA-Cw4-restricted cytotoxic T-lymphocyte
clone. J Virol 1993;67:438-445.
17.
Curiel TJ, Wong JT, Gorczyca PF, Schooley RT, Walker BD. CD4+ HIV-1 envelope-specific
cytotoxic T-lymphocytes derived from the peripheral blood cells of an HIV-1 infected individual.
AIDS Res Hum Retro 1993;9:61-68.
18.
Jassoy C, Harrer T, Rosenthal T, Navia BA, Worth J, Johnson RP, Walker BD. HIV-1-specific
cytotoxic T lymphocytes release interferon, tumor necrosis factor (TNF-) and TNF- when they
encounter their target antigen. J Virol 1993;67:2844-2852.
19.
Zweerink HJ, Gammon MC, Utz U, Sauma SY, Harrer T, Hawkins JC, Johnson RP, Sirotina A,
Hermes JD, Walker BD, Biddison WE. Presentation of endogenous peptides to MHC class I
restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J Immunol
1993;150:1763-1771.
20.
Harrer T, Jassoy C, Harrer E, Johnson RP, Walker BD. Induction of HIV-1 replication in a
chronically infected T cell line by cytotoxic T lymphocytes. JAIDS 1993;6:865-871.
21.
Koziel MJ, Dudley D, Afdhal N, Choo Q-L, Houghton M, Ralston R, Walker BD. Hepatitis C
Virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope
proteins of HCV. J Virol 1993;67:7522-7532.
22.
Kalams SA, Johnson RP, Trocha AK, Dynan MJ, Ngo HS, D'Aquila RT, Kurnick JT, Walker BD.
Longitudinal analysis of T cell receptor (TCR) gene usage by HIV-1 envelope-specific cytotoxic T
lymphocytes clones reveals a limited TCR repertoire. J Exp Med 1994;179:1261-1271.
23.
Johnson RP, Hammond SA, Trocha A, Siliciano RF, Walker BD. Induction of MHC class Irestricted cytotoxic T lymphocyte responses to a highly conserved region of (HIV-1) gp120 in
seronegative humans immunized with a candidate HIV-1 vaccine. J Virol 1994;68:3145-3153.
24.
Tsomides TJ, Aldovini A, Johnson RP, Walker BD, Young RA, Eisen HN. Naturally processed
viral peptides recognized by cytotoxic T lymphocytes on cells chronically infected by human
immunodeficiency virus type 1. J Exp Med 1994;180:1283-1293.
25.
Delwart EL, Sheppard HW, Walker BD, Goudsmit J, Mullins JI. Human immunodeficiency virus
type 1 evolution in vivo tracked by DNA heteroduplex mobility assays. J Virol 1994;68:66726683.
31
26.
Jassoy C, Heinkelein M, Klinker H, and Walker BD. HIV Type 1-specific cytotoxic T
lymphocytes stimulate HLA class I and intercellular adhesion molecule type 1 expression, and
increase 2-microglobulin levels in vitro. AIDS Res Human Retro 1994;10:1685-1693.
27.
Price P, Johnson RP, Scadden DT, Jassoy C, Rosenthal T, Kalams S, Walker, BD. Cytotoxic
CD8+ lymphocytes reactive with HIV-1 produce GM-CSF and variable amounts of interleukins 2,
3 and 4 following stimulation with the cognate epitope. Clin Immunol & Immunopath
1995;74:100-106.
28.
Wilson C, Wong JT, Girard DD, Merrill DP, Dynan M, An DD, Kalams SA, Johnson RP, Hirsch
MS, D'Aquila RT, Walker BD. Ex vivo expansion of CD4 lymphocytes from human
immunodeficiency virus type 1-infected persons in the presence of combination antiretroviral
agents. J Infect Dis 1995;172:88-96.
29.
Iversen AK, Shpaer EG, Rodrigo AG, Hirsch MS, Walker BD, Sheppard HW, Merigan TC,
Mullins JI. Persistence of attenuated rev genes in a human immunodeficiency virus type 1infected asymptomatic individual. J Virol 1995;69:5743-5753.
30.
Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice C, Choo Q-L, Houghton M, Walker BD. HLA
class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus: identification of multiple
epitopes and characterization of patterns of cytokine release. J Clin Invest 1995;96:2311-2321.
31.
Hammond SA, Johnson RP, Kalams SA, Walker BD, Takiguchi M, Safrit JT, Koup RA, Siliciano
RF. An epitope-selective, transporter associated with antigen presentation (TAP)1/2-independent
pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of
the HIV-1 envelope glycoprotein by CD8+ CTL. J Immunol 1995;154:6140-6156.
32.
Heinkelein M, Schneider-Schaulies J, Walker BD, Jassoy C. Inhibition of cytotoxicity and
cytokine release of CD8+ HIV-specific cytotoxic T lymphocytes by pentoxifylline. JAIDS
1995;10:417-424.
33.
Harrer E, Harrer T, Barbosa P, Feinberg M, Johnson RP, Buchbinder S, Walker BD. Recognition
of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse
transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term
nonprogressor. J Infect. Dis 1996;173:476-479.
34.
Kalams SA, Johnson RP, Dynan M, Hartman K, Harrer T, Harrer E, Trocha AK, Buchbinder S,
Walker BD. T-cell receptor (TCR) usage and fine specificity of HIV-1-specific cytotoxic T
lymphocyte (CTL) clones: analysis of quasispecies recognition reveals a dominant response
directed against a minor in vivo variant. J Exp Med 1996;183:1669-1679.
35.
Harrer T, Harrer E, Kalams SA, Barbosa P, Trocha AK, Johnson RP, Elbeik T, Feinberg M,
Buchbinder S, Walker BD. Cytotoxic T lymphocytes in asymptomatic long-term non-progressing
HIV-1 infection: breadth and specificity of the response and relation to in vivo viral quasispecies
in a person with prolonged infection and low viral load. J Immunol 1996;156:2616-2623.
36.
Harrer T, Harrer E, Kalams SA, Elbeik T, Feinberg M, Cao Y, Ho DD, Yilma T, Caliendo AM,
Johnson RP, Buchbinder S, Walker BD. Strong cytotoxic T cell and weak neutralizing antibody
32
responses in a subset of persons with stable non-progressing HIV-1 infection. AIDS Res Hum
Retro 1996;12:585-592.
37.
Yang OO, Kalams SA, Rosenzweig M, Trocha A, Jones N, Koziel M, Walker BD, Johnson RP.
Efficient lysis of human immunodeficiency virus type 1-infected cells by cytotoxic T
lymphocytes. J Virol 1996;70:5799-5806.
38.
Yang OO, Kalams SA, Trocha A, Cao H, Luster A, Johnson RP, Walker BD. Suppression of
human immunodeficiency virus type 1 replication by CD8+ cells: Evidence for HLA class Irestricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997;71:3120-3128.
39.
Walter JB, Brander C, Mammen M, Garboczi DN, Kalams SA, Whitesides GM, Walker BD,
Eisen HN. Stimulation of human cytotoxic T cells with HIV-1-derived peptides presented by
recombinant HLA-A2 peptide complexes. International Immunol 1997;9:451-459.
40.
Sipsas NV, Kalams SA, Trocha A, He S, Blattner WA, Walker BD, Johnson RP. Identification of
type-specific cytotoxic T lymphocyte responses to homologous viral proteins in laboratory
workers accidentally infected with HIV-1. J Clin Invest 1997;99:752-762.
41.
Cao Y, Krogstad P, Korber BT, Koup RA, Muldoon M, Macken C, Song J-L, Zhao J-Q, Clapp S,
hen ISY, Ho DD, Ammann AJ, & The Ariel Project Investigators. Maternal HIV-1 viral load and
vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from
mother to infant. Nat Med 1997;3:549-552.
42.
Wilson CC, Kalams S, Wilkes B, Ruhl D, Gao F, Hahn BH, Wolinsky S, Koup R, Johnson P,
Walker BD. Overlapping epitopes in HIV-1 gp120 presented by HLA A, B and C molecules:
Effects of viral variation on cytotoxic T lymphocyte recognition. J Virol 1997;71:1256-1264.
43.
Koziel MJ, Wong DKH, Dudley D, Houghton M, Walker BD. Hepatitis C virus-specific cytolytic
T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 1997;176:859866.
44.
Threlkeld SC, Wentworth PA, Kalams SA, Wilkes BM, Ruhl DJ, Keogh E, Sidney J, Southwood
S, Walker BD, Sette A. Degenerate and promiscuous recognition by cytotoxic T lymphocyte
(CTL) of peptides presented by the MHC class I A3-like superfamily: Implications for vaccine
development. J Immunol 1997;159:1648-1657.
45.
Cao, H, Kanki P, Sankale J-L, Dieng-Sarr A, Mazzara GP, Kalams SA, Korber B, MBoup S,
Walker BD. CTL cross-reactivity among different HIV-1 clades: Implications for vaccine
development. J Virol 1997;71:8615-8623.
46.
Yang OO, Tran-Chen A, Kalams SA, Johnson RP, Roberts MR, Walker BD. Lysis of HIV-1infected cells and inhibition of viral replication by universal receptor T cells. Proc Natl Acad Sci
USA 1997;94:11478-11483.
47.
Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax P, Kalams SA, Walker BD.
Vigorous HIV-1-specific CD4+ T cell responses correlate with control of viremia. Science
1997;278:1447-1450.
33
48.
Delwart El, Mullins JI, Gupta P, Learn GH, Holodniy M, Katzenstein D, Walker BD and Singh
MK. Human immunodeficiency virus type I populations in blood and semen. J Virol
1998;72:617-623.
49.
Collins K, Chen BK, Kalams S, Walker BD, Baltimore D. HIV-1 Nef protein protects infected
primary humans cells against killing by cytotoxic T lymphocytes. Nature 1998;391:397-401.
50.
Wong DKH, Dudley DD, Afdhal NH, Dienstag J, Rice CM, Wang L, Houghton M, Walker BD,
Koziel MJ. Liver-derived cytotoxic T lymphocytes in hepatitis C virus infection: Breadth and
specificity of responses in a cohort of persons with chronic infection. J Immunol 1998;160:14791488.
51.
Wagner L, Yang OO, Garcia-Zepeda EA, Ge Y, Kalams SA, Walker BD, Pasternack MS, Luster
AD. -chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to
proteoglycans. Nature 1998;391:908-911.
52.
Connor RI, Korber BTM, Graham BS, Hahn BH, Ho DD, Walker BD, Neumann AU, Vermund
SH, Mestecky J, Jackson S, Fenamore E, Cao Y, Gao F, Kalams S, Kunstman KJ, McDonald D,
McWilliams N, Trkola A, Moore JP, Wolinsky SM. Immunological and virological analyses of
persons infected by human immunodeficiency virus type 1 while participating in trials of
recombinant gp120 subunit vaccines. J Virol 1998;72:1552-1576.
53.
Brander C, Hartman KE, Trocha AJ, Jones NG, Johnson RP, Korber B, Wentworth P, Buchbinder
SP, Wolinsky S, Walker BD, Kalams SA. Lack of strong immune selection pressure by the
immunodominant, HLA-A*0201 restricted CTL response in chronic HIV-1 infection. J Clin
Invest 1998;101:2559-2566.
54.
Centers for Disease Control and Prevention. Report of the NIH panel to define principles of
therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults
and adolescents. MMWR 1998;47 (No. RR-5):1-91.
55.
Jin X, Roberts CGP, Nixon DF, Cao Y, Ho DD, Walker BD, Muldoon M, Korber BTM, Koup
RA, and the Ariel Project Investigators. Longitudinal and cross-sectional analysis of cytotoxic T
lymphocyte responses and their relationship to vertical human immunodeficiency virus
transmission. J Infect Dis 1998;178:1317-1326.
56.
Harrer T, Harrer E, Barbosa P, Weber C, Halden JR, Feinberg M, Johnson RP, Buchbinder S,
Walker BD. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a longterm non-progressing HIV-1 infected individual. J Immunol 1998;161:4875-4881.
57.
Walter JB, Garboczi DN, Fan QU, Zhou X, Walker BD, Eisen HN. A mutant human beta2microglobulin can be used to generate diverse multimeric class I peptide complexes as specific
probes for T cell receptors. J Immunol Methods 1998;214(102):41-50.
58.
Merrill DP, Martinez-Picado J, Tremblay C, Sax PE, Boswell SL, Wong JT, D’Aquila RT, Walker
BD, Hirsch MS. Improved CD4 Lymphocyte Outgrowth in response to effective antiretroviral
therapy. J Infect Dis 1999;179:345-351.
34
59.
Van Dyke RB, Korber BT, Popek E, Macken C, Widmayer SM, Bardeguez A, Hanson IC, Wiznia
A, Luzuriaga K, Viscarello RR, Wolinsky S, and the Ariel Core Investigators. The Ariel Project:
A prospective cohort study of maternal-child transmission of human immunodeficiency virus type
1 in the era of maternal antiretroviral therapy. J Infect Dis 1999;179:319-328.
60.
Wagner R, Leschonsky B, Harrer E, Paulus C, Weber C, Walker BD, Buchbinder S, Wolf H,
Kalden JR, Harrer T. Molecular and functional analysis of a conserved CTL epitope in HIV-1 p24
recognized by a long-term non-progressor: Constrains on immune escape associated with
targeting a sequence essential for viral replication. J Immunol 1999;162:3727-3734.
61.
Rodrigo AG, Shpaer EG, Delwart EL, Iversen AKN, Gallo MV, Brojatsch J, Hirsch MS, Walker
BD, Mullins JI. Coalescent estimates of HIV-1 generation time in vivo. Proc Natl Acad Sci USA
1999;96:2187-2191.
62.
Wilson CC, Brown RC, Korber BT, Wilkes BM, Ruhl DJ, Sakamoto D, Kunstman K, Luzuriaga
K, Hanson IC, Widmayer SM, Wiznia A, Clapp S, Ammann AJ, Koup RA, Wolinsky SM, Walker
BD, an the Ariel Project Investigators. Frequent detection of escape from cytotoxic T-lymphocyte
recognition in perinatal human immunodeficiency virus (HIV) type 1 transmission: the Ariel
Project for the prevention of transmission of HIV from mother to infant. J Virol 1999;73:39753985.
63.
Brander C, Goulder PJR, Luzuriaga K, Yang OO, Hartman KE, Jones NG, Walker BD, Kalams
SA. Persistent HIV-1-specific CTL clonal expansion despite high viral burden post in utero HIV1 infection. J Immunol 1999;162:4796-4800.
64.
Hay CM, Ruhl BJ, Basgoz NO, Wilson CC, Billingsley JM, DePasquale MP, D’Aquila RT,
Wolinsky SM, Crawford JM, Montefiori DC, Walker BD. Lack of viral escape and defective in
vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in
rapidly progressive infection. J Virol 1999;73:5509-5519.
65.
Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK,
Trocha AK, Walker BD. Association between virus-specific cytotoxic T lymphocyte and helper
responses in human immunodeficiency virus type 1 infection. J Virol 1999;73:6715-6720.
66.
Yang OO, Swanberg SL, Lu Z, Dziejman M, McCoy J, Luster AD, Walker BD, Herrmann SH.
Enhanced inhibition of human immunodeficiency virus type 1 by Met-stromal derived factor 1
correlates with down-modulation of CXCR4. J Virol 1999;73:4582-4589.
67.
Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Walker BD. Levels of human
immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses
decline after suppression of viremia with highly active antiretroviral therapy. J. Virol. 1999 Aug;
73(8): 6721-8
68.
Little SJ, Daar ES, D’Aquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS,
Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD, Richman DD. Reduced
antiretroviral drug susceptibility among patients with primary HIV infection. JAMA
1999;282(12):1142-1149.
35
69.
Rosenberg ES, Caliendo AM, Walker BD. Acute HIV infection among patients tested for
mononucleosis. NEJM 1999;340(12):969.
70.
Lori F, Rosenberg E, Lieberman J, Foli A, Maserati R, Seminari E, Alberici F, Walker B,
Lisziewicz J. Hydroxyurea and Didanosine long-term treatment prevents HIV breakthrough and
normalizes immune parameters. AIDS Res Hum Retro 1999;(15):1333-1338.
71.
Finzi D, Blankson J, Siliciano JD, Margolick JB, Rosenberg E, Walker B, Gange S, Gallant J,
Siliciano RF, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong
persistence of HIV-1. Nat Med 1999;5(5):512-517.
72.
Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalso L, Siliciano R, Walker B, Lori F.
Control of HIV despite the discontinuation of antiretroviral therapy. NEJM 1999;340:1683-4.
73.
Brander C, Yang OO, Jones N, Lee Y, Goulder P, Johnson RP, Trocha A, Colbert D, Hay C,
Buchbinder S, Bergmann C, Zweerink H, Wolinsky S, Blattner W, Kalams S, Walker. BD.
Efficient processing of the immunodominant, HLA-A *0201-restricted human immunodeficiency
virus type 1 cytotoxic T-lymphocyte epitope despite multiple variations in the epitope flanking
sequences. J Virol 1999;73:10191-10198.
74.
Goulder P, Brander C, Annamalais K, Mngqundaniso N, Govender U, Tang Y, He S, Hartman
KE, O’Callaghan CA, Ogg GS, Altfeld MA, Rosenberg E, Cao H, Kalams SA, Hammond M,
Bunce M, Pelton SI, Burchett SA, McIntosh K, Coovadia HM, Walker B. Differential narrow
focusing of immunodominant human immunodeficiency virus gag-specific cytotoxic Tlymphocyte responses in infected African and Caucasoid adults and children. J Virol
2000;74(12):5679-5690.
75.
Alexander L, Weiskopf E, Greenough T, Gaddis N, Auerbach M, Salim M, O’Brien S, Walker B,
Sullivan J, Desrosiers R. Unusual polymorphisms in human immunodeficiency virus type 1
associated with nonprogressive infection. J Virol 2000 May; 74(9):4361-4376.
76.
Lechner F, Wong DKH, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips
R, Klenerman P, Walker BD. Analysis of successful immune responses in persons infected with
hepatitis C virus. J Exp Med 2000;(191):1499-1512
77.
Tremblay CL, Giguel F, Merrill DP, Wong JT, Rosenberg E, Kalams S, Walker BD, D’Aquila
RT, Hirsch MS. Marked differences in quality of infectious human immunodeficiency virus type
1 detected in persons with controlled plasma viremia by a simple enhanced culture method. J Clin
Microbiol 2000;38:4246-8.
78.
Brander C, Suscovich T, Lee Y, Nguyen PT, O’Connor P, Seebach J, Jones NG, van Gorder M,
Walker BD, Scadden DT. Impaired CTL recognition of cells latently infected with Kaposi’s
sarcoma-associated herpes virus. J Immunol 2000;165:2077-83.
79.
Martinez-Picado J, DePasquale MP, Kartsonis N, Hanna GJ, Wong J, Finzi D, Rosenberg E,
Gunthard HF, Sutton L, Savara A, Petropoulos CJ, Hellmann N, Walker BD, Richman DD,
Siliciano R, D’Aquila RT. Antiretroviral resistance during successful therapy of HIV type 1
36
infection. Proc Natl Acad Sci USA 2000;97:10948-53.
80.
Cao H, Mani I, Vincent R, Mugerwa R, Mugyenyi P, Kanki P, Ellner J, Walker BD. Cellular
immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine
trials in Uganda. J Infect Dis 2000;182 (5):1350-6.
81.
Le Gall S, Buseyne F, Trocha A, Walker BD, Heard JM, Schwartz O. Distinct trafficking
pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I
down-regulation. J Virol 2000;74:9256-66.
82.
Schooley RT, Spino C, Kuritzkes D, Walker BD, Valentine FA, Hirsch MS, Cooney6 E, Friedland
G, Kundu S, Merigan Jr TC, McElrath MJ, Collier A, Plaeger S, Mitsuyasu R, Kahn J, Haslett P,
Uherova P, deGruttola V, Chiu S, Zhang B, Jones G, Bell D, Ketter N, Twadell T, Chernoff D,
Rosandich M. Two double-blinded, randomized, comparative trials of 4 human
immunodeficiency virus type 1 (HIV-1) envelope vaccines in HIV-1 infected individuals across a
spectrum of disease severity. ACTG 209 and 214. J Infect Dis 2000;182:1357-64.
83.
Severino ME, Sipsas NV, Nguyen PT, Kalams SA, Walker BD, Johnson RP, Yang OO.
Inhibition of HIV-1 replication in primary CD4+ T lymphocytes, monocytes, and dendritic cells
by cytotoxic T lymphocytes. J Virol 2000; 74:6695-9.
84.
Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK,
D’Aquila RT, Goulder PJ, Walker BD. Immune control of HIV-1 after early treatment of acute
infection. Nature 2000;407(6803):523-6.
85.
Altfeld MA, Trocha A, Eldridge RL, Rosenberg ES, Phillips MN, Addo MM, Sekaly RP, Kalams
SA, Burchett SA, McIntosh K, Walker BD, Goulder PJ. Identification of dominant optimal HLAB60- and HLA-B61 restriced cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of
CTL responses by enzyme-linked immunospot assay. J Virol 2000;74(18) 8541-8549.
86.
Goulder PJ, Tang Y, Brander C, Betts MR, Altfeld M, Annamalai K, Trocha A, He S, Rosenberg
ES, Ogg G, O'Callaghan CA, Kalams SA, McKinney RE, Jr., Mayer K, Koup RA, Pelton SI,
Burchett SK, McIntosh K, Walker BD. Functionally inert HIV-specific cytotoxic T lymphocytes
Do not play a major role in chronically infected adults and children. J Exp Med
2000;192(12):1819-32.
87.
Goulder PJ, Lechner F, Klenerman P, McIntosh K, Walker BD. Characterization of a novel
respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope. J Virol
2000;74(16):7694-7.
88.
Goulder PJ, Tang Y, Pelton SI, Walker BD. HLA-B57-restricted cytotoxic T-lymphocyte activity
in a single infected subject toward two optimal epitopes, one of which is entirely contained within
the other. J Virol 2000;74:5291.
89.
Ostrowski M, Justement S, Ehler L, Mizell S, Lui S, Mican J, Walker BD, Thomas E, Seder R,
Fauci A. The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1
specific memory cytotoxic CD8+ T cell responses. J Immunol 2000;165:6133-6.
37
90.
Goulder PJ, Altfeld MA, Rosenberg ES, Nguyen T, Tang Y, Eldridge RL, Addo MM, He S,
Mukherjee JS, Phillips MN, Bunce M, Kalams SA, Sekaly RP, Walker BD, Brander C. Substantial
Differences in Specificity of HIV-specific Cytotoxic T Cells in Acute and Chronic HIV Infection.
J Exp Med 2001;193:181-94.
91.
Goulder PJ, Addo MM, Altfeld MA, Rosenberg ES, Tang Y, Govender U, Mngqundaniso N,
Annamalai K, Vogel TU, Hammond M, Bunce M, Coovadia HM, Walker BD. Rapid Definition of
Five Novel HLA-A*3002-Restricted Human Immunodeficiency Virus-Specific Cytotoxic TLymphocyte Epitopes by Elispot and Intracellular Cytokine Staining Assays. J Virol
2001;75:1339.
92.
Altfeld MA, Livington B, Reshamwala N, Nguyen PT, Addo MM, Shea A, Newman M, Fikes J,
Sidney J, Wentworth P, Chesnut R, Eldridge RL, Rosenberg ES, Robbins GK, Brander C, Sax PE,
Boswell S, Flynn T, Buchbinder S, Goulder PJ, Walker BD, Sette A, Kalams SA. Identification of
novel HLA-A2-restricted human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte
epitopes predicted by theHLA-A2 supertype peptide-binding motif. J Virol. 2001 Feb;75(3):130111.
93.
Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, Addo MM,
Poon SH, Phillips MN, Robbins GK, Sax PE, Boswell S, Kahn JO, Brander C, Goulder PJ, Levy
JA, Mullins JI, Walker BD. Cellular Immune Responses and Viral Diversity in Individuals
Treated during Acute and Early HIV-1 Infection. J Exp Med 2001; 169-80.
94.
Wong DK, Dudley DD, Dohrenwend PB, Lauer GM, Chung RT, Thomas DL, Walker BD.
Detection of Diverse Hepatitis C Virus (HCV)-Specific cytotoxic T Lymphocytes in peripheral
blood of infected persons by screening for responses to all translated proteins of HCV. J Virol
2001;75:1229.
95.
Flores-Villanueva PO, Yunis EJ, Delgado JC, Vittinghoff E, Buchbinder S, Leung JY, Uglialoro
AM, Clavijo OP, Rosenberg ES, Kalams SA, Braun JD, Boswell SL, Walker BD, Goldfeld AE.
Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4
homozygosity. Proc Natl Acad Sci USA 2001; 98:5140-5.
96.
Brander C, Matter-Reissmann UB, Jones NG, Walker BD, Sachs DH, Seebach JD. Inhibition of
human NK cell-mediated cytotoxicity by exposure to ammonium chloride. J of Immunol Methods
2001; 252 (1-2):1-14.
97.
Day CL, Shea AK, Altfeld MA, Olson DP, Buckbinder SP, Hecht FM, Rosenberg ES, Walker BD,
Kalams SA. Relative Dominance of Epitope-Specific Cytotoxic T-Lymphocyte Responses in
Human Immunodeficiency Virus Type 1-Infected Persons with Shared HLA Alleles. J Virol
2001;75(14):6279-91.
98.
Brander C, O'Connor P, Suscovich T, Jones NG, Lee Y, Kedes D, et al. Definition of an optimal
cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpes virus
kaposin protein. J Infect Dis 2001;184(2):119-26.
99.
Addo MM, Altfeld M, Rosenberg ES, Eldridge RL, Philips MN, Habeeb K, Khatri A, Brander C,
Trocha A, Mazzara GP, Goulder PJ, Walker BD. Analysis of cytotoxic T-lymphocyte (CTL)
38
responses against the regulatory HIV-1 proteins Rev and Tat in HIV-1-infected individuals. Proc.
Natl. Acad. Sci. 2001; 98(4):1781-6.
100.
Goulder PJ, Brander, C, Tang Y, Tremblay C, Colbert RA, Addo MA, Rosenberg ES, Nguyen T,
Allen R, Trocha A, Altfeld M, He S, Bunce M, Funkhouser R, Pelton SI, Burchett SK, McIntosh
K, Korber BTM, Walker BD. Evolution and transmission of stable CTL escape mutations in HIV
infection. Nature. 2001;412(6844):334-8.
101.
Walensky RP, Rosenberg ES, Ferraro MJ, Losina E, Walker BD, Freedberg KA. Investigation of
primary human immunodeficiency virus infection in patients who test positive for heterophile
antibody. Clin Infect Dis 2001;33(4):570-2.
102.
Geiben-Lynn R, Kursar M, Brown NV, Kerr EL, Luster AD, Walker BD. Noncytolytic Inhibition
of X4 Virus by Bulk CD8(+) Cells from Human Immunodeficiency Virus Type 1 (HIV-1)Infected Persons and HIV-1- Specific Cytotoxic T Lymphocytes Is Not Mediated by betaChemokines. J Virol 2001;75(17):8306-16.
103.
Altfeld M, Addo MM, Eldridge RL, Yu XG, Thomas S, Khatri A, Strick D, Phillips MN, Cohen
GB, Islam SA, Kalams SA, Brander C, Goulder PJ, Rosenberg ES, Walker BD. Vpr is
preferentially targeted by CTL during HIV-1 infection. J Immunol 2001;167(5):2743-52.
104.
Norris PJ, Sumaroka M, Brander C, Moffett HF, Boswell SL, Nguyen T, Sykulev Y, Walker BD,
Rosenberg ES. Multiple effector functions mediated by human immunodeficiency virus-specific
CD4(+) T-cell clones. J Virol. 2001 Oct;75(20):9771-9.
105.
Montefiori DC, Hill TS, Vo HT, Walker BD, Rosenberg ES. Neutralizing antibodies associated
with viremia control in a subset of individuals after treatment of acute human immunodeficiency
virus type 1 infection. J Virol. 2001 Nov;75(21):10200-7.
106.
Goulder PJ, Pasquier C, Holmes EC, Liang B, Tang Y, Izopet J, Saune K, Rosenberg ES, Burchett
SK, McIntosh K, Barnardo M, Bunce M, Walker BD, Brander C, Phillips RE. Mother-to-child
transmission of HIV infection and CTL escape through HLA-A2-SLYNTVATL epitope sequence
variation. Immunol. Letters 2001 Nov 1;79(1-2):109-16.
107.
Yang OO, Nguyen PT, Kalams SA, Dorfman T, Gottlinger HG, Stewart S, Chen IS, Threlkeld S
and Walker BD. Nef-mediated resistance of human immunodeficiency virust type 1 to antiviral
cytotoxic T lympocytes. J Virol. 2002;76(4):1626-31.
108.
Yu XG, Shang H, Addo MM, Eldridge RL, Phillips MN, Feeney ME, Strick D, Brander C,
Goulder PJR, Rosenberg ES, Walker BD, Altfeld M, HIV Study Collaboration. Important
contribution of p15 Gag-specific responses to the total Gag-specific CTL responses. AIDS. 2002
Feb 15;16(3):321-8.
109.
Lauer GM, Nguyen TN, Day CL, Robbins GK, Flynn T, McGowan K, Rosenberg ES, Lucas M,
Klenerman P, Chung RT, Walker BD. Human Immunodeficiency Virus Type 1-Hepatitis C Virus
Coinfection: Intraindividual Comparison of Cellular Immune Responses against Two Persistent
Viruses. J Virol. 2002;76(6):2817-26.
39
110.
Altfeld M, van Lunzen J, Frahm N, Yu XG, Schneider C, Eldridge RL, Feeney ME, Meyer-Olson
D, Stellbrink HJ, Walker BD. Expansion of pre-existing, lymph node-localized CD8+ T cells
during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest.
2002;109:837-43.
111.
Yang OO, Garcia-Zepeda EA, Walker BD, Luster AD. Monocyte chemoattractant protein-2 (CC
chemokine ligand 8) inhibits replication of human immunodeficiency virus type 1 via CC
chemokine receptor 5. J Infect Dis. 2002 Apr 15;185(8):1174-8.
112.
Addo MM, Altfeld M, Rathod A, Yu M, Yu XG, Goulder PJR, Rosenberg ES. HIV-1 Vpu
represents a minor target for cytotoxic T lymphocytes in HIV-1 infection. AIDS. 2002 May
3;16(7):1071-3.
113.
Lauer GM, Ouchi K, Chung RT, Nguyen TN, Day CL, Purkis DR, Reiser M, Kim AY, Lucas M,
Klenerman P, Walker BD. Comprehensive analysis of CD8(+)-T-cell responses against hepatitis
C virus reveals multiple unpredicted specificities. J Virol. 2002 Jun;76(12):6104-13.
114.
Brander C, Raje N, O'Connor PG, Davies J, Chauhan D, Hideshima T, Martin J, Osmond D,
Kedes DH, Walker BD, Scadden DT, Anderson KC. Absence of biologically important Kaposi
sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in
multiple myeloma. Blood. 2002 Jul 15;100(2):698-700.
115.
Yu XG, Addo MM, Rosenberg ES, Rodriguez WR, Lee PK, Fitzpatrick CA, Johnston MN, Strick
D, Goulder PJR, Walker BD, Altfeld M. Consistent patterns in the development and
immunodominance of human immunodeficiency virus type 1 (HIV-1) specific CD8+ T-cell
responses following acute HIV-1 infection. J. Virol. 2002 Sept;76(17):8690-701.
116.
Addo MM, Yu XG, Rosenberg ES, Walker BD, Altfeld M. Cytotoxic T-Lymphocyte (CTL)
Responses Directed against Regulatory and Accessory Proteins in HIV-1 Infection. DNA Cell
Biol. 2002 Sept 21(9);671-8.
117.
Geiben-Lynn R, Brown N, Walker BD, Luster AD. Purification of a Modified Form of Bovine
Antithrombin III as an HIV-1 CD8+ T-cell Antiviral Factor. J Biol Chem. 2002 Nov
1;277(44):42352-7.
118.
Altfeld M, Allen TM, Yu XG, Johnston MN, Agrawal D, Korber BT, Montefiori DC, O'Connor
DH, Davis BT, Lee PK, Maier EL, Harlow J, Goulder PJR, Brander C, Rosenberg ES, Walker
BD. HIV superinfection despite broad CD8+ T-cell responses containing replication of the
primary virus. Nature. 2002 Nov 28;420:434-9.
119.
Day CL, Lauer GM, Robbins GK, McGovern B, Wurcel AG, Gandhi RT, Chung RT, Walker BD.
Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus
infection. J Virol. 2002 Dec;76(24):12584-95.
120.
Geiben-Lynn R, Kursar M, Brown NV, Addo MM, Shau H, Lieberman J, Luster AD, Walker BD.
HIV-1 antiviral of recombinant natural killer cell enhancing factors, NKEF-A and KNEF-B,
members of the peroxiredoxin family. J. Biol. Chem. 2003 Jan 17; 278(3): 1569-74.
40
121.
Addo MM, Yu XG, Rathod A, Cohen D, Eldridge RL, Strick D, Johnston MN, Corcoran C,
Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgoz N, Draenert R, Stone DR,
Brander C, Goulder PJ, Rosenberg ES, Altfeld M, Walker BD. Comprehensive epitope analysis of
human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the
entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral
load. J Virol. 2003 Feb;77(3):2081-92.
122.
Bobbitt KR, Addo MM, Altfeld M, Filzen T, Onafuwa AA, Walker BD, Collins KL. Rev Activity
Determines Sensitivity of HIV-1-Infected Primary T Cells to CTL Killing. Immunity. 2003
Feb;18(2):289-99.
123.
Severino ME, Sarkis PT, Walker BD, Yang OO. Chimeric immune receptor T cells bypass class I
requirements and recognize multiple cell types relevant in HIV-1 infection. Virology. 2003 Feb
15;306(2):371-5.
124.
Cao H, Kaleebu P, Hom D, Flores J, Agrawal D, Jones N, Serwanga J, Okello M, Walker C,
Sheppard H, El-Habib R, Klein M, Mbidde E, Mugyenyi P, Walker B, Ellner J, Mugerwa R.
Immunogenicity of a Recombinant Human Immunodeficiency Virus (HIV)-Canarypox Vaccine in
HIV-Seronegative Ugandan Volunteers: Results of the HIV Network for Prevention Trials 007
Vaccine Study. J Infect Dis. 2003 Mar 15;187(6):887-95.
125.
Montefiori DC, Altfeld M, Lee PK, Bilska M, Zhou J, Johnston MN, Gao F, Walker BD,
Rosenberg ES. Viremia Control Despite Escape from a Rapid and Potent Autologous Neutralizing
Antibody Response After Therapy Cessation in an HIV-1-Infected Individual. J Immunol. 2003
Apr 1;170(7):3906-14.
126.
Draenert R, Altfeld M, Brander C, Basgoz N, Corcoran C, Wurcel AG, Stone DR, Kalams SA,
Trocha A, Addo MM, Goulder PJ, Walker BD. Comparison of overlapping peptide sets for
detection of antiviral CD8 and CD4 T cell responses. J Immunol Methods. 2003 Apr 1;275(12):19-29.
127.
Tremblay CL, Hicks JL, Sutton L, Giguel F, Flynn T, Johnston M, Sax PE, Walker BD, Hirsch
MS, Rosenberg ES, D'Aquila RT. Antiretroviral resistance associated with supervised treatment
interruptions in treated acute HIV infection. AIDS. 2003 May 2;17(7):1086-9.
128.
Yang OO, Sarkis PT, Ali A, Harlow JD, Brander C, Kalams SA, Walker BD. Determinant of
HIV-1 mutational escape from cytotoxic T lymphocytes. J Exp Med. 2003 May 19;197(10):136575.
129.
Robbins GK, Addo MM, Troung H, Rathod A, Habeeb K, Davis B, Heller H, Basgoz N, Walker
BD, Rosenberg ES. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1
infection by therapeutic immunization. AIDS. 2003 May 23:17(8):1121-6.
130.
Somsouk M, Lauer GM, Casson D, Terella A, Day CL, Walker BD, Chung RT. Spontaneous
resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression.
Gastroenterology. 2003 Jun;124(7):1946-9.
131.
Altfeld M, Addo MM, Shankarappa R, Lee PK, Allen TM, Yu XG, Rathod A, Harlow J,
41
O'Sullivan K, Johnston MN, Goulder PJ, Mullins JI, Rosenberg ES, Brander C, Korber B, Walker
BD. Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to
highly variable regions by using peptides based on autologous virus sequences. J Virol. 2003
Jul;77(13):7330-40.
132.
Feeney ME, Roosevelt KA, Tang Y, Pfafferott KJ, McIntosh K, Burchett SK, Mao C, Walker BD,
Goulder PJ. Comprehensive screening reveals strong and broadly directed human
immunodeficiency virus type 1-specific CD8 responses in perinatally infected children. J Virol.
2003 Jul;77(13):7492-501.
133.
Day CL, Seth NP, Lucas M, Appel H, Gauthier L, Lauer GM, Robbins GK, Szczepiorkowski ZM,
Casson DR, Chung RT, Bell S, Harcourt G, Walker BD, Klenerman P, Wucherpfennig KW. Ex
vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II
tetramers. J Clin Invest. 2003 Sept;112(6):831-42.
134.
Yang OO, Sarkis PT, Trocha A, Kalams SA, Johnson RP, Walker BD. Impacts of avidity and
specificity on the antiviral efficiency of HIV-1-specific CTL. J Immunol. 2003 Oct 1;171(7):371824.
135.
Delgado JC, Leung JY, Baena A, Clavijo OP, Vittinghoff E, Buchbinder S, Wolinsky S, Addo M,
Walker BD, Yunis EJ, Goldfeld AE. The -1030/-862-linked TNF promoter single-nucleotide
polymorphisms are associated with the inability to control HIV-1 viremia. Immunogenetics. 2003
Oct;55(7):497-501.
136.
Altfeld M, Addo MM, Rosenberg ES, Hecht FM, Lee PK, Vogel M, Yu XG, Draenert R, Johnston
MN, Strick D, Allen TM, Feeney ME, Kahn JO, Sekaly RP, Levy JA, Rockstroh JK, Goulder PJ,
Walker BD. Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1
infection. AIDS. 2003 Dec 5;17(18):2581-91.
137.
Feeney ME, Draenert R, Roosevelt KA, Pelton SI, McIntosh K, Burchett SK, Mao C, Walker BD,
Goulder PJ. Reconstitution of virus-specific CD4 proliferative responses in pediatric HIV-1
infection. J Immunol. 2003 Dec 15;171(12):6968-75.
138.
Gandhi RT, Wurcel A, Rosenberg ES, Johnston MN, Hellman N, Bates M, Hirsch MS, Walker
BD. Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo
after transmission of a multiply drug-resistant virus. Clin Infect Dis. 2003 Dec 15;37(12):1693-8.
139.
Draenert R, Verrill CL, Tang Y, Allen TM, Wurcel AG, Boczanowski M, Lechner A, Kim AY,
Suscovich T, Brown NV, Addo MM, Walker BD. Persistent recognition of autologous virus by
high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection.
J Virol. 2004 Jan;78(2):630-41.
140.
Lucas M, Varga-Cuero AL, Lauer GM, Barnes E, Willberg CB, Semmo N, Walker BD, Phillips
R, Klenerman P. Pervasive influence of hepatitis C virus on the phenotype of antiviral CD8+ T
cells. J Immunol. 2004 Feb 1;172(3):1744-53.
141.
Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, Tang Y, Holmes EC, Allen
T, Prado JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P, Thomas SA, St. John A, Roach
42
TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall H, Tudor-Williams G, Novelli V, MartinezPicado J, Kiepiela P, Walker BD, Goulder PJ. HIV evolution: CTL escape mutation and reversion
after transmission. Nat Med. 2004 Mar;10(3):282-9.
142.
Frahm N, Korber BT, Adams CM, Svinger JJ, Draenert R, Addo MM, Feeney ME, Yusim K,
Sango K, Brown NV, SenGupta D, Piechocka-Trocha A, Simonis T, Marincola FM, Wurcel AG,
Stone DR, Russell CJ, Adolf P, Cohen D, Roach T, St. John A, Khatri A, Davis K, Mullins J,
Goulder PJ, Walker BD, Brander C. Consistent cytotoxic-T-lymphocyte targeting of
immunodominant regions in human immunodeficiency virus across multiple ethnicities. J Virol.
2004 Mar;78(5):2187-200.
143.
Norris PJ, Moffett HF, Brander C, Allen TM, O'Sullivan KM, Cosimi LA, Kaufmann DE, Walker
BD, Rosenberg ES. Fine specificity and cross-clade reactivity of HIV type 1 Gag-specific CD4+ T
cells. AIDS Res Hum Retroviruses. 2004 Mar;20(3):315-25.
144.
Hess C, Altfeld M, Thomas SY, Addo MM, Rosenberg ES, Allen TM, Draenert R, Eldridge RL,
van Lunzen J, Stellbrink HJ, Walker BD, Luster AD. HIV-1 specific CD8+ T cells with an
effector phenotype and control of viral replication. Lancet. 2004 Mar 13;363(9412):863-6.
145.
Draenert R, Brander C, Yu XG, Altfeld M, Verrill CL, Feeney ME, Walker BD, Goulder PJ.
Impact of intrapeptide epitope location on CD8 T cell recognition: implications for design of
overlapping peptide panels. AIDS. 2004 Apr 9;18(6):871-6.
146.
Draenert R, Le Gall S, Pfafferott KJ, Leslie AJ, Chetty P, Brander C, Holmes EC, Change SC,
Feeney ME, Addo MM, Ruiz L, Ramduth D, Jeena P, Altfeld M, Thomas S, Tang Y, Verrill CL,
Dixon C, Prado JG, Kiepiela P, Martinez-Picado J, Walker BD, Goulder PJ. Immune Selection for
Altered Antigen Processing Leads to Cytotoxic T Lymphocyte Escape in Chronic HIV-1
Infection. J Exp Med. 2004 Apr 5;199(7):905-15.
147.
Kaufmann DE, Bailey PM, Sidney J, Wagner B, Norris PJ, Johnston MN, Cosimi LA, Addo MM,
Lichterfeld M, Altfeld M, Frahm N, Brander C, Sette A, Walker BD, Rosenberg ES.
Comprehensive Analysis of Human Immunodeficiency Virus Type 1-Specific CD4 Responses
Reveals Marked Immunodominance of gag and nef and the Presence of Broadly Recognized
Peptides. J Virol. 2004 May 1;78(9):4463-4477.
148.
Brainard DM, Tharp WG, Granado E, Miller N, Trocha AK, Ren XH, Conrad B, Terwilliger EF,
Wyatt R, Walker BD, Poznansky MC. Migration of antigen-specific T cells away from CXCR4binding human immunodeficiency virus type 1 gp120. J Virol. 2004 May;78(10):5184-93.
149.
Rodriguez WR, Addo MM, Rathod A, Fitzpatrick CA, Yu XG, Perkins BA, Rosenberg ES,
Altfeld M, Walker BD. CD8+ T lymphocyte responses target functionally important regions of
Protease and Integrase in HIV-1 infected subjects. J Transl Med. 2004 May 21;2 (1):15
150.
Yu XG, Addo MM, Perkins BA, Wej F, Rathod A, Geer SC, Parta M, Cohen D, Stone DR,
Russell CJ, Tanzi G, Mei S, Wurcel AG, Frahm N, Lichterfeld M, Heath L, Mullins JI, Marincola
F, Goulder PJ, Brander C, Allen T, Cao Y, Walker BD, Altfeld M. Differences in the Expressed
HLA Class I Alleles Effect the Differential Clustering of HIV Type 1-Specific T Cell Responses
in Infected Chinese and Caucasions. AIDS Res Hum Retroviruses. 2004 May;20(5):557-64.
43
151.
Suscovich TJ, Paulose-Murphy M, Harlow JD, Chen Y, Thomas SY, Mellott TJ, Walker BD,
Scadden DT, Zeichner S, Brander C. Defective Immune Function of Primary Effusion Lymphoma
Cells is Associated with Distinct KSHV Gene Expression Profiles. Leukemia & Lymphoma. 2004
June;45(6):1223-38.
152.
Allen TM, Altfeld M, Yu X, O'Sullivan KM, Lichterfeld M, Le Gall S, John M, Mothe BR, Lee
PK, Kalife ET, Cohen DE, Freedberg KA, Strick DA, Johnston MN, Sette A, Rosenberg ES,
Mallal SA, Goulder PJ, Brander C, Walker BD. Selection, transmission and reversion of an
antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus
type 1 infection. J Virol. 2004 Jul;78(13):7069-78.
153.
Lichterfeld M, Yu XG, Waring MT, Mui SK, Johnston M, Cohen D, Addo MM, Zaunders J, Alter
G, Pae E, Strick D, Allen TM, Rosenberg ES, Walker BD, Altfeld M. HIV-1-specific cytotoxicity
is preferentially mediated by a subset of CD8+ T cells producing both interferon-{gamma} and
tumor-necrosis factor-{alpha}. Blood. 2004 Jul 15;104 (2): 487-94
154.
Lichterfeld M, Yu XG, Cohen D, Addo MM, Malenfant J, Perkins B, Pae E, Johnston MN, Strick
D, Allen TM, Rosenberg ES, Korber B, Walker BD, Altfeld M. HIV-1 Nef is preferentially
recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic
diversity. AIDS. 2004 Jul 2;18(10):1383-1392.
155.
Feeney ME, Tang Y, Roosevelt KA, Leslie AJ, McIntosh K, Karthas N, Walker BD, Goulder PJ.
Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and
broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-termnonprogressing child. J Virol. 2004 Aug;78(16):8927-30.
156.
SenGupta D, Norris PJ, Suscovich TJ, Hassan-Zahraee M, Moffett HF, Trocha A, Draenert R,
Goulder PJ, Binder RJ, Levey DL, Walker BD, Srivastava PK, Brander C. Heat shock proteinmediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J Immunol.
2004 Aug 1;173(3):1987-93.
157.
Zavala-Ruiz Z, Strug I, Walker BD, Norris PJ, Stern LJ. A hairpin turn in a class II MHC-bound
peptide orients residues outside the binding groove for T cell recognition. Proc Natl Acad Sci U S
A. 2004 Sep 7;101(36):13279-84. Epub 2004 Aug 26.
158.
Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR,
Reiser M, Dusheiko G, Allen TM, Chung RT, Walker BD, Klenerman P. High resolution analysis
of cellular immune responses in resolved and persistent hepatitis C virus infection.
Gastroenterology. 2004 Sep;127(3):924-36.
159.
Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, Cohen D, Robbins GK,
Pae E, Alter G, Wurcel A, Stone D, Rosenberg ES, Walker BD, Altfeld M. Loss of HIV-1specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced
HIV-1-specific CD4+ T cells. J Exp Med. 2004 Sep 20;200(6):701-12.
160.
Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, Wagner BS, Kalife
ET, Strick D, Rosenberg ES, Walker BD. Limited Durability of Viral Control following Treated
44
Acute HIV Infection. PLoS Med. 2004 Nov;1(2):e36. Epub 2004 Oct 26.
161.
Hess C, Means TK, Autissier P, Woodberry T, Altfeld M, Addo MM, Frahm N, Brander C,
Walker BD, Luster AD. IL-8 responsiveness defines a subset of CD8 T cells poised to kill. Blood.
2004 Dec 1;104(12):3463-71. [Epub 2004 Aug 3].
162.
Lebedeva T, Anikeeva N, Kalams SA, Walker BD, Gaidarov I, Keen JH, Sykulev Y. Major
histocompatibility complex class I-intercellular adhesion molecule-1 association on the surface of
target cells: implications for antigen presentation to cytotoxic T lymphocytes. Immunology. 2004
Dec;113(4):460-71.
163.
Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, Rathnavalu P, Moore
C, Pfafferott KJ, Hilton L, Zimbwa P, Moore S, Allen T, Brander C, Addo MM, Altfeld M, James
I, Mallal S, Bunce M, Barber LD, Szinger J, Day C, Klenerman P, Mullins J, Korber B, Coovadia
HM, Walker BD and Goulder PJR. Dominant influence of HLA-B in mediating the potential coevolution of HIV and HLA. Nature. 2004 Dec 9;432(7018):769-75.
164.
Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, Pillay T, Ouchi K, Reyor LL,
Zur Wiesch JS, Gandhi RT, Chung RT, Bhardwaj N, Klenerman P, Walker BD, Allen TM. CD8
epitope escape and reversion in acute HCV infection. J Exp Med. 2004 Dec 20;200(12):1593-604.
165.
Kim AY, Lauer GM, Ouchi K, Addo MM, Lucas M, Wiesch JS, Timm J, Boczanowski M,
Duncan JE, Wurcel AG, Casson D, Chung RT, Draenert R, Klenerman P, Walker BD. The
magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell
count in individuals coinfected with HIV-1. Blood. 2005 Feb 1;105(3):1170-8. Epub 2004 Sep 30.
166.
Zhai S, Kang WZ, Yu X, Wang SY, Walker BD, Altfeld M, Sun YT. [Specific immune responses
to human immunodeficiency virus type 1 Gag, Tat, Rev and Nef proteins.] Xi Bao Yu Fen Zi
Mian Yi Xue Za Zhi. 2005 Mar;21(2):175-9. Chinese.
167.
Leslie A, Kavanagh D, Honeyborne I, Pfafferott K, Edwards C, Pillay T, Hilton L, Thobakgale C,
Ramduth D, Draenert R, Le Gall S, Luzzi G, Edwards A, Brander C, Sewell AK, Moore S,
Mullins J, Moore C, Mallal S, Bhardwaj N, Yusim K, Phillips R, Klenerman P, Korber B,
Kiepiela P, Walker B, Goulder P. Transmission and accumulation of CTL escape variants drive
negative associations between HIV polymorphisms and HLA. J Exp Med. 2005 Mar
21;201(6):891-902.
168.
Altfeld M, Allen TM, Kalife ET, Frahm N, Addo MM, Mothe BR, Rathod A, Reyor LL, Harlow
J, Yu XG, Perkins B, Robinson LK, Sidney J, Alter G, Lichterfeld M, Sette A, Rosenberg ES,
Goulder PJ, Brander C, Walker BD. The majority of currently circulating human
immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses
against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine
design. J Virol. 2005 Apr;79(8):5000-5.
169.
Feeney ME, Tang Y, Pfafferott K, Roosevelt KA, Draenert R, Trocha A, Yu XG, Verrill C, Allen
T, Moore C, Mallal S, Burchett S, McIntosh K, Pelton SI, St. John MA, Hazra R, Klenerman P,
Altfeld M, Walker BD, Goulder PJ. HIV-1 Viral Escape in Infancy Followed by Emergence of a
Variant-Specific CTL Response. J Immunol. 2005 Jun 15;174(12):7524-30.
45
170.
Koibuchi T, Allen TM, Lichterfeld M, Mui SK, O'Sullivan KM, Trocha A, Kalams SA, Johnson
RP, Walker BD. Limited Sequence Evolution within Persistently Targeted CD8 Epitopes in
Chronic Human Immunodeficiency Virus Type 1 Infection. J Virol.2005 July;79(13):8171-81.
171.
Rodriguez WR, Christodoulides N, Floriano PN, Graham S, Mohanty S, Dixon M, Hsiang M,
Peter T, Zavahir S, Thior I, Romanovicz D, Bernard B, Goodey AP, Walker BD, McDevitt JT.A
microchip CD4 counting method for HIV monitoring in resource-poor settings.PLoS Med. 2005
Jul;2(7):e182. Epub 2005 Jul 19.
172.
Frahm N, Adams S, Kiepiela P, Linde CH, Hewitt HS, Lichterfeld M, Sango K, Brown NV, Pae
E, Wurcel AG, Altfeld M, Feeney ME, Allen TM, Roach T, St John MA, Daar ES, Rosenberg E,
Korber B, Marincola F, Walker BD, Goulder PJ, Brander C. HLA-B63 presents HLA-B57/B58restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency
virus load. J Virol. 2005 Aug; 79(16):10218-25.
173.
Woodberry T, Suscovich TJ, Henry LM, Martin JN, Dollard S, O'Connor PG, Davis JK, Osmond
D, Lee TH, Kedes DH, Khatri A, Lee J, Walker BD, Scadden DT, Brander C.Impact of Kaposi
sarcoma-associated herpesvirus (KSHV) burden and HIV coinfection on the detection of T cell
responses to KSHV ORF73 and ORF65 proteins.J Infect Dis. 2005 Aug 15;192(4):622-9. Epub
2005 Jul 15.
174.
Yu XG, Lichterfeld M, Perkins B, Kalife E, Mui S, Chen J, Cheng M, Kang W, Alter G, Brander
C, Walker BD, Altfeld M.High degree of inter-clade cross-reactivity of HIV-1-specific T cell
responses at the single peptide level. AIDS. 2005 Sep 23;19(14):1449-56.
175.
Zaunders JJ, Munier ML, Kaufmann DE, Ip S, Grey P, Smith D, Ramacciotti T, Quan D,
Finlayson R, Kaldor J, Rosenberg ES, Walker BD, Cooper DA, Kelleher AD. Early proliferation
of CCR5+ CD38+++ antigen-specific CD4+ Th1 effector cells during primary HIV-1 infection.
Blood. 2005 Sep 1;106(5):1660-7. 2005 May 19; [Epub ahead of print].
176.
Lauer GM, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Wiesch JS, Paranhos-Baccala G,
Sheridan I, Casson DR, Reiser M, Gandhi RT, Li B, Allen TM, Chung RT, Klenerman P, Walker
BD.Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early
therapy.J Virol. 2005 Oct;79(20):12979-88.
177.
Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, Cheng M, Allgaier RL, Mui S,
Frahm N, Alter G, Brown NV, Johnston MN, Rosenberg ES, Mallal, SA, Brander C, Walker BD,
Altfeld M.. “De novo generation of escape variant-specific CD8+ T-cell responses following
cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection.” J.
Virol 2005 Oct; 79(20):12952-60.
178.
Ramduth D, Chetty P, Mngquandaniso NC, Nene N, Harlow JD, Honeyborne I, Ntumba N,
Gappoo S, Henry C, Jeena P, Addo MM, Altfeld M, Brander C, Day C, Coovadia H, Kiepiela P,
Goulder P, Walker B.Differential Immunogenicity of HIV-1 Clade C Proteins in Eliciting CD8+
and CD4+ Cell Responses.J Infect Dis. 2005 Nov 1;192(9):1588-96.
179.
Woodberry T, Suscovich TJ, Henry LM, Davis JK, Frahm N, Walker BD, Scadden DT, Wang F,
46
Brander C.Differential Targeting and Shifts in the Immunodominance of Epstein-Barr VirusSpecific CD8 and CD4 T Cell Responses during Acute and Persistent Infection.J Infect Dis. 2005
Nov 1;192(9):1513-24. Epub 2005 Sep 26.
180.
Allen, T.M., M. Altfeld, S.C. Geer, E.T. Kalife, C. Moore, M. O’Sullivan K, I. Desouza, M.E.
Feeney, R.L. Eldridge, E.L. Maier, D.E. Kaufmann, M.P. Lahaie, L. Reyor, G. Tanzi, M.N.
Johnston, C. Brander, R. Draenert, J.K. Rockstroh, H. Jessen, E.S. Rosenberg, S.A. Mallal, and
B.D. Walker.. Selective escape from CD8+ T-cell responses represents a major driving force of
human immunodeficiency virus type 1 (HIV- 1) sequence diversity and reveals constraints on
HIV-1 evolution. J Virol 2005; Nov 79:13239-13249.
181.
Frahm N, Kiepiela P, Adams S, Linde C, Hewitt H, Sango K, Feeney M, Addo M, Lichterfeld M,
Lahaie M, Pae E, Wurcel A, Roach T, St. John M, Altfeld M, Marincola F, Moore C, Mallah S,
Carrington M, Heckerman D, Allen T, Mullins J, Korber B, Goulder P, Waker B, Brander C.
Control of Human Immunodeficiency Virus Replication by Cytotoxic T Lymphocytes targeting
subdominant Epitopes. Nat. Immuno. 2006 Feb.; 7 (2):173-78.
182.
Komatsu H, Lauer G, Pybus OG, Ouchi K, Wong D, Ward S, Walker BD, Klenerman P. Do
antiviral CD8+ T cells select hepatitis C virus escape mutants? Analysis in diverse epitopes
targeted by human intrahepatic CD8+ T lymphocytes. J Viral Hepat. 2006 Feb;13(2):121-30.
183.
Brockman MA, Tanzi GO, Walker BD, Allen TM. Use of a novel GFP reporter cell line to
examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry. J Virol
Methods. 2006 Feb;131(2):134-42.
184.
Zuniga R, Lucchetti A, Galvan P, Sanchez S, Sanchez C, Hernandez A, Sanchez H, Frahm N,
Linde CH, Hewitt HS, Hildebrand W, Altfeld M, Allen TM, Walker BD, Korber BT, Leitner T,
Sanchez J, Brander C. Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is
Associated with Human Immunodeficiency Virus Control. J Virol. 2006 Mar;80(6):3122-5.
185.
Draenert R, Allen T, Yang L, Wrin T, Chappey C, Verrill C, Guillem S, Eldridge R, Lahaie M,
Ruiz L, Bonaventura C, Petropoulos C, Walker B, Martinze-Picado J. Constraints on HIV-1
evolution and immunodominance revealed in monozygotic adult twins infected with the same
virus. JEM. 2006 Mar 20; 203 (3): 529-39.
186.
Kavanagh DG, Kaufmann DE, Sunderji S, Frahm N, Le Gall S, Boczkowski D, Rosenberg ES,
Stone DR, Johnston MN, Wagner BS, Zaman MT, Brander C, Gilboa E, Walker BD, Bhardwaj N.
Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA
encoding cytoplasm- or lysosome-targeted Nef Blood. 2006 Mar 1;107(5):1963-9.
187.
Meyer-Olson, D., K.W. Brady, M.T. Bartman, K.M. O’Sullivan, B.C. Simons, J.A. Conrad, C.B.
Duncan, S. Lorey, A. Siddique, R. Draenert, M. Addo, M. Altfeld, E. Rosenberg, T.M. Allen, B.D.
Walker, and S.A. Kalams. 2006. Fluctuations of functionally distinct CD8+ T-cell clonotypes
demonstrate flexibility of the HIV-specific TCR repertoire. Blood 2006 Mar 15; (6)107:23732383.
188.
Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, Thobakgale C,
Honeyborne I, Crawford H, Matthews P, Pillay T, Rousseau C, Mullins JI, Brander C, Walker BD,
47
Stuart DI, Kiepiela P, Goulder P. Fitness cost of escape mutations in p24 Gag in association with
control of human immunodeficiency virus type 1. J Virol. 2006 Apr;80(7):3617-23.
189.
Bihl F, Frahm N, Di Giammarino L, Sidney J, John M, Yusim K, Woodberry T, Sango K, Hewitt
HS, Henry L, Linde CH, Chisholm JV 3rd, Zaman TM, Pae E, Mallal S, Walker BD, Sette A,
Korber BT, Heckerman D, Brander C. Impact of HLA-B alleles, epitope binding affinity,
functional avidity, and viral coinfection on the immunodominance of virus-specific CTL
responses. J Immunol. 2006 Apr 1;176(7):4094-101.
190.
Kassutto S., Maghsoudi K., Johnston M.N., Robbins GK., Burgett NC., Sax PE., Cohen., Pae E.,
Davis B., Zachary K., Basgoz N., D’agata EM., DeGruttola V., Walker B.D., Rosenberg ES.
Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or
early HIV type 1 infection. Clin Infect Dis. 2006 Apr 1;42(7):1024-31.
191.
Honeyborne I, Rathod A, Buchli R, Ramduth D, Moodley E, Rathnavalu P, Chetty S, Day C,
Brander C, Hilderbrand W, Walker BD, Kiepiela P, Goulder PJ. Motif inference reveals optimal
CTL epitiopes presented by HLA class I alleles highly prevalent in southern Africa. J Immunol.
2006 Apr 15;176(8):4699-705.
192.
Rousseau CM, Birditt BA, McKay AR, Stoddard JN, Lee TC, McLaughlin S, Moore SW, Shindo
N, Learn GH, Korber BT, Brander C, Goulder PJ, Kiepiela P, Walker BD, Mullins JI. Large-scale
amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. J Virol
Methods. 2006 May 13; 136(1-2):118-25. Epub 2006 May 15.
193.
McGovern BH, Wurcel A, Kim AY, Schulze zur Wiesch J, Bica I, Zaman MT, Timm J, Walker
BD, Lauer GM. Acute hepatitis C virus infection in incarcerated injection drug users. Clin Infect
Dis. 2006 Jun15;42(12):1663-70. Epub 2006 May 11.
194.
Lichterfeld M., Williams K.L., Mui SK., Shah S.S., Mothe BR., Sette A., Kim A., Johnston M.N.,
Burgett N., Frahm N., Cohen D., Brander C., Rosenberg ES., Walker B.D., Altfeld M., Yu X.G. T
cell receptor cross-recognition of an HIV-1 CD8+ T cell epitope presented by closely related
alleles from the HLA-A3 superfamily. Int Immunol. 2006 Jul;18(7):1179-88.
195.
Martinez-Hackert E., Anikeeva N., Kalams S.A., Walker B.D., Hendrickson W.A., Sykulev Y.
Structural basis for degenerate recognition of natural HIV peptide variants by cytotoxic
lymphocytes. J Biol Chem. 2006 Jul 21;281(29):20205-12.
196.
Wang S., Zhuang Y., Zhai S., Zhao S., Kang W., Li X., Yu X.G., Walker B.D., Altfeld M.A., Sun
Y. Association between HIV Type 1-specific T cell responses and CD4+ T cell counts or
CD4+:CD8+ T cell ratios in HIV Type 1 subtype B infection in China. AIDS Res Hum
Retroviruses. 2006 Aug;22(8):780-787.
197.
Streeck H., Jessen H., Alter G., Teigen N., Waring MT., Jessen A., Stahmer I., van Lunzen J.,
Lichterfeld M., Gao X., Allen T.M., Carrington M., Walker B.D., Rockstroh J.K., Altfeld M.
Immunological and virological impact of highly active antiretroviral therapy initiated during acute
HIV-1 infection. J Infect Dis. 2006 Sep 15;194(6):734-739.
198.
Day C.L., Kaufmann D.E., Kiepiela P., Brown JA., Moodley ES., Reddy S., Mackey EW., Miller
48
J.D., Leslie A.J., DePierres C., Mncube Z., Duraiswamy J., Zhu B., Eichbaum Q., Altfeld M.,
Wherry E.J., Coovadia H.M., Goulder P.J., Klenerman P., Ahmed R., Freeman GJ., Walker B.D.
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease
progression. Nature. 2006 Sep 21;443(7109):350-4.
199.
Wherry E.J., Day C.L., Draenert R., Miller J.D., Kiepiela P., Woodberry T., Brander C., Addo M.,
Klenerman P., Ahmed R., Walker B.D. HIV-specific CD8 T cells express low levels of IL7Ralpha: implications for HIV-specific T cell memory. Virology. 2006 Sep 30;353(2):366-373.
200.
Zaunders J.J., Ip S., Munier ML., Kaufmann D.E., Suzuki K., Brereton C., Sasson SC., Seddiki N.,
Koelsch K., Landay A., Grey P., Finlayson R., Kaldor J., Rosenberg ES., Walker B.D., Fazekas de
St Groth B., Cooper D.A., Kelleher AD. Infection of CD127+ (interleukin-7 receptor+) CD4+
cells and over expression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during
primary human immunodeficiency virus type 1 infection. J Virol. 2006 Oct;80(20):10162-72.
201.
Leslie A., Price D.A., Mkhize P., Bishop K., Rathod A., Day C., Crawford H., Honeyborne I.,
Asher T.E., Luzzi G., Edwards A., Rousseau CM., Mullins J.I., Tudor-Williams G., Novelli V.,
Brander C., Douek D.C., Kiepiela P., Walker B.D., Goulder P.J. Differential selection pressure
exerted on HIV by CTL targeting identical epitopes but restricted by distinct HLA alleles from the
same HLA supertype. J Immunol. 2006 Oct 1;177(7):4699-4708.
202.
Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, Burgett N, Swartz ME, Yang
A, Alter G, Yu XG, Meier A, Rockstroh JK, Allen TM, Jessen H, Rosenberg ES, Carrington M,
Walker BD. HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to
the Initial CD8(+) T Cell Response against HIV-1. PLoS Med. 2006 Oct;3(10):e403.
203.
Kim AY, zur Wiesch JS, Kuntzen T, Timm J, Kaufmann DE, Duncan JE, Jones AM, Wurcel AG,
Davis BT, Gandhi RT, Robbins GK, Allen TM, Chung RT, Lauer GM, Walker BD. Impaired
hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection. PLoS
Med. 2006 Dec;3(12):e492.
204.
Day CL, Kiepiela P, Leslie AJ, van der Stok M, Nair K, Ismail N, Honeyborne I, Crawford H,
Coovadia HM, Goulder PJ, Walker BD, Klenerman P. Proliferative capacity of epitope-specific
CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus
type 1 infection. J Virol. 2007 Jan;81(1):434-8. Epub 2006 Oct 18.
205.
Wang S., Sun Y., Zhai S., Zhuang Y., Zhao S., Kang W., Li X., Huang D., Yu X.G., Walker B.D.,
Altfeld M.A. Identification of HLA-A11-restricted HIV-1-specific cytotoxic T-lymphocyte
epitopes in China. Curr HIV Res. 2007 Jan;5(1):119-28.
206.
Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de
Pierres C, Mncube Z, Mkhwanazi N, Bishop K, van der Stok M, Nair K, Khan N, Crawford H,
Payne R, Leslie A, Prado J, Prendergast A, Frater J, McCarthy N, Brander C, Learn GH, Nickle D,
Rousseau C, Coovadia H, Mullins JI, Heckerman D, Walker BD, Goulder P. CD8(+) T-cell
responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007
Jan;13(1):46-53. Epub 2006 Dec 17.
207.
Fischer W, Perkins S, Theiler J, Bhattacharya T, Yusim K, Funkhouser R, Kuiken C, Haynes B,
49
Letvin NL, Walker BD, Hahn BH, Korber BT. Polyvalent vaccines for optimal coverage of
potential T-cell epitopes in global HIV-1 variants. Nat Med. 2007 Jan;13(1):100-6. Epub 2006
Dec 24.
208.
Yu XG, Lichterfeld M, Chetty S, Williams KL, Mui SK, Miura T, Frahm N, Feeney ME, Tang Y,
Pereyra F, Labute MX, Pfafferott K, Leslie A, Crawford H, Allgaier R, Hildebrand W, Kaslow R,
Brander C, Allen TM, Rosenberg ES, Kiepiela P, Vajpayee M, Goepfert PA, Altfeld M, Goulder
PJ, Walker BD. Mutually exclusive T cell receptor induction and differential susceptibility to
HIV-1 mutational escape associated with a two amino acid difference between HLA class I
subtypes. J Virol. 2007 Feb;81(4):1619-31. J Virol. 2006 Nov 22; Epub 2006 Nov 22.
209.
Zhao S., Zhai S., Zhuang Y., Wang S., Huang D., Kang W., Li X., Yu X.G., Walker B.D., Altfeld
MA, Sun Y. Inter-clade cross-reactivity of HIV-1-specific T cell responses in human
immunodeficiency virus type 1 infection in China. Curr HIV Res. 2007 Mar;5(2):251-9.
210.
Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, Kadie C, Carlson J, Yusim K,
McMahon B, Gaschen B, Mallal S, Mullins JI, Nickle DC, Herbeck J, Rousseau C, Learn GH,
Miura T, Brander C, Walker B, Korber B. Founder effects in the assessment of HIV
polymorphisms and HLA allele associations. Science. 2007 Mar 16;315(5818):1583-6.
211.
Gasser O., Bihl FK., Wolbers M., Loggi E., Steffen I., Hirsch HH., Gunthard HF., Walker B.D.,
Brander C., Battegay M., Hess C.; for the Swiss HIV Cohort Study. HIV Patients Developing
Primary CNS Lymphoma Lack EBV-Specific CD4(+) T Cell Function Irrespective of Absolute
CD4(+) T Cell Counts. PLoS Med. 2007 Mar 27;4(3):e96 [Epub ahead of print].
212.
Addo MM., Draenert R., Rathod A., Verrill C.L., Davis BT., Gandhi RT., Robbins GK., Basgoz
NO., Stone DR., Cohen D.E., Johnston M.N., Flynn T., Wurcel AG., Rosenberg ES., Altfeld M.,
Walker B.D. Fully Differentiated HIV-1 Specific CD8+ T Effector Cells Are More Frequently
Detectable in Controlled than in Progressive HIV-1 Infection. PLoS ONE. 2007 Mar 28;2:e321.
213.
Honeyborne I., Prendergast A., Pereyra F., Leslie A., Crawford H., Payne R., Reddy S., Bishop
K., Moodley E., Nair K., van der Stok M., McCarthy N., Rousseau CM., Addo M., Mullins J.I.,
Brander C., Kiepiela P., Walker B.D., Goulder P.J. Control of human immunodeficiency virus
type 1 is associated with HLA-B*13 and targeting of multiple gag-specific CD8+ T-cell epitopes.
J Virol. 2007 Apr;81(7):3667-72. 2007 Jan 24.
214.
Lichterfeld M., Yu X.G., Mui SK., Williams K.L., Trocha A., Brockman M.A., Allgaier R.L.,
Waring MT., Koibuchi T., Johnston M.N., Cohen D., Allen T.M., Rosenberg ES., Walker B.D.,
Altfeld M. Selective depletion of high-avidity human immunodeficiency virus type 1 (HIV-1)specific CD8+ T cells after early HIV-1 infection. J Virol. 2007 Apr;81(8):4199-214. Epub 2007
Feb 7.
215.
Streeck H., Schweighardt B., Jessen H., Allgaier RL., Wrin T., Stawiski EW., Jessen AB., Allen
T.M., Walker B.D., Altfeld M. Loss of HIV-1-specific T-cell responses associated with very rapid
HIV-1 disease progression. AIDS. 2007 Apr 23;21(7):889-891.
216.
Rousseau CM., Learn GH., Bhattacharya T., Nickle D.C., Heckerman D., Chetty S., Brander C.,
Goulder P.J., Walker B.D., Kiepiela P., Korber BT., Mullins J.I. Extensive intrasubtype
50
recombination in South African human immunodeficiency virus type 1 subtype C infections. J
Virol. 2007 May;81(9):4492-500. Epub 2007 Feb 21.
217.
Streeck H, Lichterfeld M, Alter G, Meier A, Teigen N, Yassine-Diab B, Sidhu HK, Little S,
Kelleher A, Routy JP, Rosenberg ES, Sekaly RP, Walker BD, Altfeld M. Recognition of a defined
region within p24 Gag by CD8+ T cells during primary HIV-1 infection in individuals expressing
protective HLA class I alleles. J Virol. 2007 Jul;81(14):7725-31. May 9; [Epub ahead of print].
218.
Timm J., Neukamm M., Kuntzen T., Kim A.Y., Chung RT., Brander C., Lauer GM., Walker B.D.,
Allen T.M. Characterization of full-length hepatitis C virus genotype 4 sequences. J Viral Hepat.
2007 May;14(5):330-7.
219.
Sabado RL, Babcock E, Kavanagh DG, Tjomsland V, Walker BD, Lifson JD, Bhardwaj N,
Larsson M. Pathways utilized by dendritic cells for binding, uptake, processing and presentation
of antigens derived from HIV-1. Eur J Immunol. 2007 May 29;37(7):1752-1763.
220.
Mphatswe W, Blanckenberg N, Tudor-Williams G, Prendergast A, Thobakgale C, Mkhwanazi N,
McCarthy N, Walker BD, Kiepiela P, Goulder P. High frequency of rapid immunological
progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS. 2007
Jun;21(10):1253-1261.
221.
Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S, Brown EE, Shupert WL,
Phair J, Goedert JJ, Buchbinder S, Kirk GD, Telenti A, Connors M, O'brien SJ, Walker BD,
Parham P, Deeks SG, McVicar DW, Carrington M. Innate partnership of HLA-B and KIR3DL1
subtypes against HIV-1. Nat Genet. 2007 Jun;39(6):733-40. Epub 2007 May 13.
222.
Frater A.J., Brown H., Oxenius A., Gunthard HF., Hirschel B., Robinson N., Leslie A.J., Payne R.,
Crawford H., Prendergast A., Brander C., Kiepiela P., Walker B.D., Goulder P.J., McLean A.,
Phillips RE. Effective T cell responses select HIV-1 mutants and slow disease progression. J
Virol. 2007 Jun;81(12):6742-51. Epub 2007 Apr 4.
223.
Crawford H, Prado JG, Leslie A, Hue S, Honeyborne I, Reddy S, van der Stok M, Mncube Z,
Brander C, Rousseau C, Mullins JI, Kaslow R, Goepfert P, Allen S, Hunter E, Mulenga J, Kiepiela
P, Walker BD, Goulder PJ. Compensatory mutation partially restores fitness and delays reversion
of escape mutation within the immunodominant HLA-B*5703-restricted gag epitope in chronic
hiv-1 infection. J Virol. 2007 Aug;81(15):8346-51.May 16; Epub 2007 May 16.
224.
Brainard DM, Tager AM, Misdraji J, Frahm N, Lichterfeld M, Draenert R, Brander C, Walker
BD, Luster AD. Decreased CXCR3+ CD8 T-cells in advanced HIV infection suggests a homing
defect contributes to CTL dysfunction. J Virol Aug;81(16):8439-50. 2007 Jun 6; Epub 2007 Jun 6.
225.
Brockman MA, Schneidewind A, Lahaie M, Schmidt A, Miura T, Desouza I, Ryvkin F, Derdeyn
CA, Allen S, Hunter E, Mulenga J, Goepfert PA, Walker BD, Allen TM. Escape and
compensation from early HLA-B57-mediated CTL pressure on HIV-1 Gag alters capsid
interactions with cyclophilin A. J Virol. 2007 Nov;81(22):12608-18. Epub 2007 Aug 29.
226.
Chen J, Hong K, Jia M, Liu H, Zhang Y, Liu S, Zhang X, Zhao H, Peng H, Ma P, Xing H, Ruan
Y, Williams KL, Yu XG, Altfeld M, Walker BD, Shao Y. Human immunodeficiency virus type 1
51
specific cytotoxic T lymphocyte responses in Chinese infected with HIV-1 B'/C Recombinant
(CRF07_BC). Retrovirology. 2007 Aug 30;4(1):62 [Epub ahead of print]
227.
Frahm N, Yusim K, Suscovich TJ, Adams S, Sidney J, Hraber P, Hewitt HS, Linde CH, Kavanagh
DG, Woodberry T, Henry LM, Faircloth K, Listgarten J, Kadie C, Jojic N, Sango K, Brown NV,
Pae E, Zaman MT, Bihl F, Khatri A, John M, Mallal S, Marincola FM, Walker BD, Sette A,
Heckerman D, Korber BT, Brander C. Extensive HLA class I allele promiscuity among viral CTL
epitopes. Eur J Immunol. 2007 Sep;37(9):2419-33.
228.
Schulze Zur Wiesch J, Lauer GM, Timm J, Kuntzen T, Neukamm M, Berical A, Jones AM, Nolan
BE, Longworth SA, Kasprowicz V, McMahon C, Wurcel A, Lohse AW, Lewis-Ximenez LL,
Chung RT, Kim AY, Allen TM, Walker BD. Immunologic evidence for lack of heterologous
protection following resolution of HCV in patients with non-genotype 1 infection. Blood. 2007
Sep 1;110(5):1559-69. Epub 2007 May 2.
229.
Rolland M, Nickle DC, Deng W, Frahm N, Brander C, Learn GH, Heckerman D, Jojic, N, Jojic V,
Walker BD, Mullins JI. Recognition of HIV-1 peptides by host CTL is related to HIV-1 similarity
to human proteins. PLoS ONE. 2007 Sep 5;2(9):e823.
230.
Yu XG, Lichterfeld M, Williams KL, Martinez-Picado J, Walker BD. Random TCR recruitment
in HIV-1-specific CD8+ T cells from genetically identical twins infected with the same HIV-1
strain. J Virol. 2007 Nov;81(22):12666-9. Epub 2007 Sep 5.
231.
Le Gall S, Stamegna P, Walker BD. Portable flanking sequences modulate CTL epitope
processing. J Clin Invest. 2007 Nov;117(11):3563-75. PMID: 17975674
232.
Frahm N, Kaufmann DE, Yusim K, Muldoon M, Kesmir C, Linde CH, Fischer W, Allen TM, Li
B, McMahon BH, Faircloth KL, Hewitt HS, Mackey EW, Miura T, Khatri A, Wolinsky S,
McMichael A, Funkhouser RK, Walker BD, Brander C, Korber BT. Increased Sequence
Diversity Coverage Improves Detection of HIV-Specific T Cell Responses. J Immunol. 2007 Nov
15;179(10):6638-50.
233.
Lichterfeld M, Kavanagh DG, Williams KL, Moza B, Mui SK, Miura T, Sivamurthy R, Allgaier
R, Pereyra F, Trocha A, Feeney M, Gandhi RT, Rosenberg ES, Altfeld M, Allen TM, Allen R,
Walker BD, Sundberg EJ, Yu XG. A viral CTL escape mutation leading to immunoglobulin-like
transcript 4 mediated functional inhibition of myelomonocytic cells. J Exp Med. 2007 Nov
26;204(12):2813-24. Epub 2007 Nov 19.
234.
Dolan MJ, Kulkarni H, Camargo JF, He W, Smith A, Anaya JM, Miura T, Hecht FM, amtani M,
Pereyra F, Marconi V, Mangano A, Sen L, Bologna R, Clark RA, Anderson SA, Delmar J,
O'Connell RJ, Lloyd A, Martin J, Ahuja SS, Agan BK, Walker BD, Deeks SG, Ahuja SK.
CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via
viral entry-independent mechanisms. Nat Immunol. 2007 Dec;8(12):1324-1336. Epub 2007 Oct
21.
235.
Thobakgale CF, Ramduth D, Reddy S, Mkhwanazi N, de Pierres C, Moodley E, Mphatswe W,
Blanckenberg N, Cengimbo A, Prendergast A, Tudor-Williams G, Dong K, Jeena P, Kindra G,
Bobat R, Coovadia H, Kiepiela P, Walker BD, Goulder PJ. Human Immunodeficiency Virus52
Specific CD8+ T-Cell Activity Is Detectable from Birth in the Majority of In Utero-Infected
Infants. J Virol. 2007 Dec;81(23):12775-84. Epub 2007 Sep 19.
236.
Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, Palmer S,
Brockman M, Rathod A, Piechocka-Trocha A, Baker B, Zhu B, Le Gall S, Waring MT, Ahern R,
Moss K, Kelleher AD, Coffin JM, Freeman GJ, Rosenberg ES, Walker BD.Upregulation of
CTLA-4 by HIV-specific CD4(+) T cells correlates with disease progression and defines a
reversible immune dysfunction.Nat Immunol. 2007 Nov;8(11):1246-54. Epub 2007 Sep 30.
237.
Ngumbela KC, Day CL, Mncube Z, Nair K, Ramduth D, Thobakgale C, Moodley E, Reddy S, de
Pierres C, Mkhwanazi N, Bishop K, van der Stok M, Ismail N, Honeyborne I, Crawford H,
Kavanagh DG, Rousseau C, Nickle D, Mullins J, Heckerman D, Korber B, Coovadia H, Kiepiela
P, Goulder PJ, Walker BD. Targeting of a CD8 T cell env epitope presented by HLA A-B*5802 is
associated with markers of HIV disease progression and lack of selection pressure. AIDS Res
Hum Restroviruses. 2008 Jan; 24 (1): 72-82.
238.
Rolland M, Heckerman D, Deng W, Rousseau CM, Coovadia H, Bishop K, Goulder PJ, Walker
BD, Brander C, Mullins JI. Broad and Gag baised HIV – 1 epitopeprepertoires are associated with
lower viral loads. PLoS One. 2008 Jan 9; 3(1):e1424.
239.
Joseph A, Zheng JH, Follenzi A, Dilorenzo T, Sango K, Hyman J, Chen K, Piechocka-Trocha A,
brander C, Hooijberg E, Vignali DA, Walker BD, Goldstein H. Lentiviral vectors encoding human
immunodeficiency virus type 1 (HIV-1)-specific T-cell receptor genes efficiently convert
peripheral blood CD8 T lymphocytes into cytoxic T lymphocytes with potent in vitro and in vivo
HIV – 1 specific inhibitory activity. J Virol. 2008 Mar; 82(6):3078-89. Epub 2008 Jan 9.
240.
Northfield JW, Kasprowicz V, Lucas M, Kersting N, Bengsh B, Kim A, Phillips RE, Walker BD,
Thimme R, Lauer G, Klenerman P. CD 161 expression on hepatitis C virus-specific CD8+ T cells
suggests a distinct pathway of T cell differentiation. Hepatology 2008 Feb; 47 (2):396-406.
241.
Ramduth D, Thobakgale CF, Mkhwanazi NP, De Pierres C, Reddy S, van der Stok M, Mncube Z,
Mphatswe W, Blanckenberg N, Cengimbo A, Prendergast A, Tudor-Williams G, Dong K, Jeena
P, Coovadia HM, Day CL, Kiepiela P, Goulder PJ, Walker BD. Detection of HIV type 1 gagspecific CD4(+) T cell responses in acutely infected infants. AIDS Res Hum Retroviruses. 2008
Feb;24(2):265-70.
242.
Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg
R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ. Rosenberg ES, Walker BD.
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence
of therapy. J Infect Dis. 2008 Feb 15; 197(4):563-71.
243.
Frahm N, Nickle DC, Linde CH, Cohen DE, Zuniga R, Lucchetti A, Roach T, Walker BD, Allen
TM, Korber BT, Mullins JI, Brander C. Increased detection of HIV specific T cell responses by
combination of central sequences with comparable immunogenicity. AIDS. 2008 Feb
19;22(4):447-56.
244.
Kasprowicz V, Ward SM, Turner A, Grammatikos A, Nolan BE, Lewis-Ximenez L, Sharp C,
Woodruff J, Fleming VM, Sims S, Walker BD, Sewell AK, Lauer GM, Klenerman P. Defining the
53
directionality and quality of influenza virus-specific CD8+ T cell cross-reactivity in individuals
infected with hepatitis C virus. J Clin Invest. 2008 Mar;118(3):1143-53.
245.
Day CL, Mkhwanazi N, Reddy S, Mncube Z, van der Stok M, Klenerman P, Walker BD.
Detection of polyfunctional Mycobacterium tuberculosis-specific T cells and association with viral
load in HIV – 1 infected persons. J Infect Dis. 2008 Apr 1;197(7):990-9.
246.
Zhuang Y, Sun Y, Zhai S, Huang D, Zhao S, Wang S, Kang W, Li X, Walker BD, Altfeld M, Yu
XG. Relative dominance of Env-gp41 – specific cytotoxic T lymphocytes responses in HIV – 1
advanced infection. Curr HIV Res. 2008 Apr 1;197(7):990-9.
247.
Schneidewind A, Brockman MA, Sidney J, Wang YE, Chen H, Suscovich TJ, Li B, Adam RI,
Allgaier RL, Mothé BR, Kuntzen T, Oniangue-Ndza C, Trocha A, Yu XG, Brander C, Sette A,
Walker BD, Allen TM. Structural and functional constraints limit options for cytotoxic Tlymphocyte escape in the immunodominant HLA-B27-restricted epitope in human
immunodeficiency virus type 1 capsid. J Virol. 2008 Jun;82(11):5594-605. Epub 2008 Apr 2.
248.
Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, Prendergast A, Matthews P,
Payne R, Rolland M, Raugi DN, Maust BS, Learn GH, Nickle, DC, Coovadia H, Ndung’u T,
Frahm N, Brander C, Walker BD, Goulder PJ, Bhattacharya T, Heckerman DE, Korber BT,
Mullins JI. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype c
proteome: immune escape and viral load. J Virol. 2008 Jul;82(13):6434-46. Epub 2008 Apr 23.
249.
Streek H, Brumme ZL, Anastario M, Cohen Kw, Jolin JS, Meier A, Brumme CJ, Rosenberg ES,
Alter G, Allen TM, Walker BD, Atfeld, M. Antigen load and viral sequence diversification
determine the fuctional profile of HIV – 1 specific CD8+ T cells. PLoS Med. 2008 May
6;5(5):e100.
250.
Marconi VC, Sunpath H, Lu Z, Gordon M, Koranteng-Aoeagyei K, Hampton J, Carpenter S,
Giddy J, Ross D, Holst H, Losina E, Walker BD, Kuritzkes DR, South Afric Resistance Cohort
Study Team. Prevalence of HIV – 1 drug resistance after failure of a first highly active
antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis. 2008 May 15;
46(10):1589-97.
251.
Miura T, Brockman MA, Brumme CJ, Brumme ZL, Carlson JM, Pereyra F, Trocha A, Addo MM,
Block BL, Rothchild AC, Baker BM, Flynn T, Schneidewind A, Li B, Wang YE, Heckerman D,
Allen, TM, Walker BD. Genetic Characterization of Human Immunodecficency Virus type 1 in
Elite Controllers: Lack of gross genetic defects or common amino acid changes. J Virol. 2008 Jun
18.
252.
Alter G, Rihn S, Streeck H, Teigen N, Piechocka-Trocha A, Moss K, Cohen K, Meier A, Pereyra
F, Walker B, Altfeld M. Ligand-independent exhaustion of killer immunoglobulin-like receptorpositive CD8+ T cells in human immunodeficiency virus type 1 infection. J Virol. 2008
Oct;82(19):9668-77. Epub 2008 Jun 25.
253.
Matthews PC, Prendergast A, Leslie A, Crawford H, Payne R, Rousseau C, Rolland M,
Honeyborne I, Carlson J, Kadie C, Brander C, Bishop K, Mlotshwa N, Mullins JI, Coovadia H,
Ndung'u T, Walker BD, Heckerman D, Goulder PJ. Central role of reverting mutations in HLA
54
associations with human immunodeficiency virus set point. J Virol. 2008 Sep;82(17):8548-59.
Epub 2008 Jul 2.
254.
Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, McCarthy
N, Morris L, Walker BD, Goulder P. Early virological suppression with three-class antiretroviral
therapy in HIV-infected African infants. AIDS. 2008 Jul 11;22(11):1333-43.
255.
Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B, Gatell J, Staszewski S, Wincker N,
Assoumou L, El-Habib R, Calvez V, Walker B, Katlama C; ORVACS Study Group. Greater viral
rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the
ALVAC-HIV vaccine (vCP1452). AIDS. 2008 Jul 11;22(11):1313-22.
256.
Brumme ZL, Tao I, Szeto S, Brumme CJ, Carlson JM, Chan D, Kadie C, Frahm N, Brander C,
Walker B, Heckerman D, Harrigan PR. Human leukocyte antigen-specific polymorphisms in
HIV-1 Gag and their association with viral load in chronic untreated infection. AIDS. 2008 Jul
11;22(11):1277-86.
257.
Brumme ZL, Brumme CJ, Carlson J, Streeck H, John M, Eichbaum Q, Block BL, Baker B, Kadie
C, Markowitz M, Jessen H, Kelleher AD, Rosenberg E, Kaldor J, Yuki Y, Carrington M, Allen
TM, Mallal S, Altfeld M, Heckerman D, Walker BD. Marked epitope- and allele-specific
differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef
cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infection. J Virol. 2008 Sep;82(18):921627. Epub 2008 Jul 9.
258.
Haining WN, Ebert BL, Subrmanian A, Wherry EJ, Eichbaum Q, Evans JW, Mak R, Rivoli S,
Pretz J, Angelosanto J, Smutko JS, Walker BD, Kaech SM, Ahmed R, Nadler LM, Golub TR.
Identification of an evolutionarily conserved transcriptional signature of CD8 memory
differentiation that is shared by T and B cells. J Immunol. 2008 Aug 1;181(3):1859-68.
259.
Rousseau CM, Daniels MG, Carlson JM, Kadie C, Crawford H, Prendergast A, Matthews P,
Payne R, Rolland M, Raugi DN, Maust BS, Learn GH, Nickle DC, Coovadia H, Ndung'u T,
Frahm N, Brander C, Walker BD, Goulder PJ, Bhattacharya T, Heckerman DE, Korber BT,
Mullins JI. HLA class I-driven evolution of human immunodeficiency virus type 1 subtype
cproteome: immune escape and viral load.
J Virol. 2008 Jul;82(13):6434-46. Epub 2008 Apr 23.
260.
Lichterfeld M, Mou D, Cung TD, Williams KL, Waring MT, Huang J, Pereyra F, Trocha A,
Freeman GJ, Rosenberg ES, Walker BD, Yu XG. Telomerase activity of HIV-1-specific CD8+ T
cells: Constitutive upregulation in controllers and selective increase by blockade of PD ligand 1 in
progressors. Blood. 2008 Aug 26.
261.
Carlson JM, Brumme ZL, Rousseau CM, Brumme CJ, Matthews P, Kadie C, Mullins JI, Walker
BD, Harrigan PR, Goulder PJ, Heckerman D. Phylogenetic dependency networks: inferring
patterns of CTL escape and codon covariation in HIV-1 Gag. PLoS Comput Biol. 2008
Nov;4(11):e1000225. Epub 2008 Nov 21. PubMed PMID: 19023406; PubMed Central PMCID:
PMC2579584.
262.
Lichterfeld M, Mou D, Cung TD, Williams KL, Waring MT, Huang J, Pereyra F, Trocha A,
55
Freeman GJ, Rosenberg ES, Walker BD, Yu XG. Telomerase activity of HIV-1-specific CD8+ T
cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in
progressors. Blood. 2008 Nov 1;112(9):3679-87. Epub 2008 Aug 26. PubMed PMID: 18728248;
PubMed Central PMCID: PMC2572795.
263.
Minkis K, Kavanagh DG, Alter G, Bogunovic D, O'Neill D, Adams S, Pavlick A, Walker BD,
Brockman MA, Gandhi RT, Bhardwaj N. Type 2 Bias of T cells expanded from the blood of
melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res.
2008 Nov 15;68(22):9441-50. PubMed PMID: 19010919; PubMed Central PMCID:
PMC2628575.
264.
Huang S, Dunkley-Thompson J, Tang Y, Macklin EA, Steel-Duncan J, Singh-Minott I, Ryland
EG, Smikle M, Walker BD, Christie CD, Feeney ME. Deficiency of HIV-Gag-specific T cells in
early childhood correlates with poor viral containment. J Immunol. 2008 Dec 1;181(11):8103-11.
PubMed PMID: 19018003; PubMed Central PMCID: PMC2714370.
265.
Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, Lee B, Heckerman D, Carlson
J, Reyor LL, Kleyman M, McMahon CM, Birch C, Schulze Zur Wiesch J, Ledlie T, Koehrsen M,
Kodira C, Roberts AD, Lauer GM, Rosen HR, Bihl F, Cerny A, Spengler U, Liu Z, Kim AY,
Xing Y, Schneidewind A, Madey MA, Fleckenstein JF, Park VM, Galagan JE, Nusbaum C,
Walker BD, Lake-Bakaar GV, Daar ES, Jacobson IM, Gomperts ED, Edlin BR, Donfield SM,
Chung RT, Talal AH, Marion T, Birren BW, Henn MR, Allen TM. Naturally occurring dominant
resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve
patients. Hepatology. 2008 Dec;48(6):1769-78. PubMed PMID: 19026009; PubMed Central
PMCID: PMC2645896.
266.
Lubong Sabado R, Kavanagh DG, Kaufmann DE, Fru K, Babcock E, Rosenberg E, Walker B,
Lifson J, Bhardwaj N, Larsson M. In vitro priming recapitulates in vivo HIV-1 specific T cell
responses, revealing rapid loss of virus reactive CD4 T cells in acute HIV-1 infection. PLoS One.
2009;4(1):e4256. Epub 2009 Jan 23. PubMed PMID: 19165342; PubMed Central PMCID:
PMC2626278.
267.
Ramduth D, Day CL, Thobakgale CF, Mkhwanazi NP, de Pierres C, Reddy S, van der Stok M,
Mncube Z, Nair K, Moodley ES, Kaufmann DE, Streeck H, Coovadia HM, Kiepiela P, Goulder
PJ, Walker BD. Immunodominant HIV-1 Cd4+ T cell epitopes in chronic untreated clade C HIV-1
infection. PLoS One. 2009;4(4):e5013. Epub 2009 Apr 7. PubMed PMID: 19352428; PubMed
Central PMCID: PMC2661367.
268.
Streeck H, Frahm N, Walker BD. The role of IFN-gamma Elispot assay in HIV vaccine research.
Nat Protoc. 2009;4(4):461-9. PubMed PMID: 19282851.
269.
Miura T, Brockman MA, Brumme ZL, Brumme CJ, Pereyra F, Trocha A, Block BL,
Schneidewind A, Allen TM, Heckerman D, Walker BD. HLA-associated alterations in replication
capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human
immunodeficiency virus type 1. J Virol. 2009 Jan;83(1):140-9. Epub 2008 Oct 29. PubMed PMID:
18971283; PubMed Central PMCID: PMC2612337.
270.
Mahalanabis M, Jayaraman P, Miura T, Pereyra F, Chester EM, Richardson B, Walker B,
56
Haigwood NL. Continuous viral escape and selection by autologous neutralizing antibodies in
drug-naive human immunodeficiency virus controllers. J Virol. 2009 Jan;83(2):662-72. Epub 2008
Nov 5. PubMed PMID: 18987151; PubMed Central PMCID: PMC2612349.
271.
Streeck H, Jessen H, Kuecherer C, Li B, Jessen AB, Dupke S, Baumgarten A, Stahmer I, van
Lunzen J, Altfeld M, Walker BD, Allen TM. Epidemiologically linked transmission of HIV-1
illustrates the impact of host genetics on virological outcome. AIDS. 2009 Jan 14;23(2):259-62.
PubMed PMID: 19098497.
272.
Wang YE, Li B, Carlson JM, Streeck H, Gladden AD, Goodman R, Schneidewind A, Power KA,
Toth I, Frahm N, Alter G, Brander C, Carrington M, Walker BD, Altfeld M, Heckerman D, Allen
TM. Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated
with viral escape mutations located in highly conserved regions of human immunodeficiency virus
type 1. J Virol. 2009 Feb;83(4):1845-55. Epub 2008 Nov 26. PubMed PMID: 19036810; PubMed
\Central PMCID: PMC2643763.
273.
Miura T, Brockman MA, Schneidewind A, Lobritz M, Pereyra F, Rathod A, Block BL, Brumme
ZL, Brumme CJ, Baker B, Rothchild AC, Li B, Trocha A, Cutrell E, Frahm N, Brander C, Toth I,
Arts EJ, Allen TM, Walker BD. HLA-B57/B*5801 human immunodeficiency virus type 1 elite
controllers select for rare gag variants associated with reduced viral replication capacity and strong
cytotoxic T-lymphocyte [corrected] recognition. J Virol. 2009 Mar;83(6):2743-55. Epub 2008 Dec
30. Erratum in: J Virol. 2009 Jun;83(11):5961. PubMed PMID: 19116253; PubMed Central
PMCID: PMC2648254.
274.
Apuzzo LG, Vaida F, Gallant JE, Ernstrom KB, Little SJ, Routy JP, Collier AC, Conway B,
Markowitz MH, Hecht FM, Walker BD, Connick E, Margolick JB. Tolerability and efficacy of PI
versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection.
J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):267-75. PubMed PMID: 19194317.
275.
Rousseau CM, Lockhart DW, Listgarten J, Maley SN, Kadie C, Learn GH, Nickle DC,
Heckerman DE, Deng W, Brander C, Ndung'u T, Coovadia H, Goulder PJ, Korber BT, Walker
BD, Mullins JI. Rare HLA drive additional HIV evolution compared to more frequent alleles.
AIDS Res Hum Retroviruses. 2009 Mar;25(3):297-303. PubMed PMID: 19327049; PubMed
Central PMCID: PMC2693345.
276.
Schneidewind A, Brumme ZL, Brumme CJ, Power KA, Reyor LL, O'Sullivan K, Gladden A,
Hempel U, Kuntzen T, Wang YE, Oniangue-Ndza C, Jessen H, Markowitz M, Rosenberg ES,
Sékaly RP, Kelleher AD, Walker BD, Allen TM. Transmission and long-term stability of
compensated CD8 escape mutations. J Virol. 2009 Apr;83(8):3993-7. Epub 2008 Dec 17. PubMed
PMID: 19091871; PubMed Central PMCID: PMC2663262.
277.
Miura T, Brumme CJ, Brockman MA, Brumme ZL, Pereyra F, Block BL, Trocha A, John M,
Mallal S, Harrigan PR, Walker BD. HLA-associated viral mutations are common in human
immunodeficiency virus type 1 elite controllers. J Virol. 2009 Apr;83(7):3407-12. Epub 2009 Jan
19. PubMed PMID: 19153230; PubMed Central PMCID: PMC2655568.
278.
Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, Baker BM, Rothchild AC,
Block BL, Schneidewind A, Koibuchi T, Pereyra F, Allen TM, Walker BD. Differential
57
neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by
HIV-specific cytotoxic T lymphocytes. J Virol. 2009 Apr;83(7):3138-49. Epub 2009 Jan 21.
PubMed PMID: 19158248; PubMed Central PMCID: PMC2655558.
279.
Kawashima Y, Pfafferott K, Frater J, Matthews P, Payne R, Addo M, Gatanaga H, Fujiwara M,
Hachiya A, Koizumi H, Kuse N, Oka S, Duda A, Prendergast A, Crawford H, Leslie A, Brumme
Z, Brumme C, Allen T, Brander C, Kaslow R, Tang J, Hunter E, Allen S, Mulenga J, Branch S,
Roach T, John M, Mallal S, Ogwu A, Shapiro R, Prado JG, Fidler S, Weber J, Pybus OG,
Klenerman P, Ndung'u T, Phillips R, Heckerman D, Harrigan PR, Walker BD, Takiguchi M,
Goulder P. Adaptation of HIV-1 to human leukocyte antigen class I. Nature. 2009 Apr
2;458(7238):641-5. Epub 2009 Feb 25. PubMed PMID: 19242411.
280.
Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, Ott RG, Anthony RM,
Zebroski H, Hurley A, Phogat A, Chakrabarti B, Li Y, Connors M, Pereyra F, Walker BD,
Wardemann H, Ho D, Wyatt RT, Mascola JR, Ravetch JV, Nussenzweig MC. Broad diversity of
neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature. 2009
Apr 2;458(7238):636-40. Epub 2009 Mar 15. PubMed PMID: 19287373.
281.
Crawford H, Lumm W, Leslie A, Schaefer M, Boeras D, Prado JG, Tang J, Farmer P, Ndung'u T,
Lakhi S, Gilmour J, Goepfert P, Walker BD, Kaslow R, Mulenga J, Allen S, Goulder PJ, Hunter
E. Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and
their transmission recipients. J Exp Med. 2009 Apr 13;206(4):909-21. Epub 2009 Mar 23.
PubMed PMID: 19307327; PubMed Central PMCID: PMC2715113.
282.
Scheid JF, Mouquet H, Feldhahn N, Walker BD, Pereyra F, Cutrell E, Seaman MS, Mascola JR,
Wyatt RT, Wardemann H, Nussenzweig MC. A method for identification of HIV gp140 binding
memory B cells in human blood. J Immunol Methods. 2009 Apr 15;343(2):65-7. Epub 2008 Dec
25. PubMed PMID: 19100741; PubMed Central PMCID: PMC2754789.
283.
Matthews PC, Leslie AJ, Katzourakis A, Crawford H, Payne R, Prendergast A, Power K, Kelleher
AD, Klenerman P, Carlson J, Heckerman D, Ndung'u T, Walker BD, Allen TM, Pybus OG,
Goulder PJ. HLA footprints on human immunodeficiency virus type 1 are associated with
interclade polymorphisms and intraclade phylogenetic clustering. J Virol. 2009 May;83(9):460515. Epub 2009 Feb 25. PubMed PMID: 19244334; PubMed Central PMCID: PMC2668443.
284.
Walley NM, Julg B, Dickson SP, Fellay J, Ge D, Walker BD, Carrington M, Cohen MS, de
Bakker PI, Goldstein DB, Shianna KV, Haynes BF, Letvin NL, McMichael AJ, Michael NL,
Weintrob AC. The Duffy antigen receptor for chemokines null promoter variant does not influence
HIV-1 acquisition or disease progression. Cell Host Microbe. 2009 May 8;5(5):408-10; author
reply 418-9. PubMed PMID: 19454339; PubMed Central PMCID: PMC2720554.
285.
Julg B, Reddy S, van der Stok M, Kulkarni S, Qi Y, Bass S, Gold B, Nalls MA, Nelson GW,
Walker BD, Carrington M, Ndung'u T. Lack of Duffy antigen receptor for chemokines: no
influence on HIV disease progression in an African treatment-naive population. Cell Host
Microbe. 2009 May 8;5(5):413-5; author reply 418-9. PubMed PMID: 19454341; PubMed Central
PMCID: PMC2749504.
286.
Brumme ZL, Walker BD. Tracking the culprit: HIV-1 evolution and immune selection revealed by
58
single-genome amplification. J Exp Med. 2009 Jun 8;206(6):1215-8. Epub 2009 Jun 1. PubMed
PMID: 19487418; PubMed Central PMCID: PMC2715053.
287.
Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, Hart WK, Shin HS, Brooks SF, Knight
HL, Eichbaum Q, Yang YG, Sykes M, Walker BD, Freeman GJ, Pillai S, Westmoreland SV,
Brander C, Luster AD, Tager AM. Induction of robust cellular and humoral virus-specific adaptive
immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol.
2009 Jul;83(14):7305-21. Epub 2009 May 6. PubMed PMID: 19420076; PubMed Central
PMCID: PMC2704767.
288.
Brockman MA, Kwon DS, Tighe DP, Pavlik DF, Rosato PC, Sela J, Porichis F, Le Gall S, Waring
MT, Moss K, Jessen H, Pereyra F, Kavanagh DG, Walker BD, Kaufmann DE. IL-10 is upregulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific
T cells. Blood. 2009 Jul 9;114(2):346-56. Epub 2009 Apr 13. PubMed PMID: 19365081; PubMed
Central PMCID: PMC2714209.
289.
Lazaro E, Godfrey SB, Stamegna P, Ogbechie T, Kerrigan C, Zhang M, Walker BD, Le Gall S.
Differential HIV epitope processing in monocytes and CD4 T cells affects cytotoxic T lymphocyte
recognition. J Infect Dis. 2009 Jul 15;200(2):236-43. PubMed PMID: 19505257.
290.
Streeck H, Jolin JS, Qi Y, Yassine-Diab B, Johnson RC, Kwon DS, Addo MM, Brumme C, Routy
JP, Little S, Jessen HK, Kelleher AD, Hecht FM, Sekaly RP, Rosenberg ES, Walker BD,
Carrington M, Altfeld M. Human immunodeficiency virus type 1-specific CD8+ T-cell responses
during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J
Virol. 2009 Aug;83(15):7641-8. Epub 2009 May 20. PubMed PMID: 19458000;
291.
Brumme ZL, John M, Carlson JM, Brumme CJ, Chan D, Brockman MA, Swenson LC, Tao I,
Szeto S, Rosato P, Sela J, Kadie CM, Frahm N, Brander C, Haas DW, Riddler SA, Haubrich R,
Walker BD, Harrigan PR, Heckerman D, Mallal S. HLA-associated immune escape pathways in
HIV-1 subtype B Gag, Pol and Nef proteins. PLoS One. 2009 Aug 19;4(8):e6687. PubMed PMID:
19690614; PubMed Central PMCID: PMC2723923.
292.
Liu Q, Sun Y, Rihn S, Nolting A, Tsoukas PN, Jost S, Cohen K, Walker B, Alter G. Matrix
metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular
cytotoxicity in human immunodeficiency virus type 1 infection. J Virol. 2009 Sep;83(17):870512. Epub 2009 Jun 24. PubMed PMID: 19553339; PubMed Central PMCID: PMC2738177.
293.
Pereyra F, Palmer S, Miura T, Block BL, Wiegand A, Rothchild AC, Baker B, Rosenberg R,
Cutrell E, Seaman MS, Coffin JM, Walker BD. Persistent low-level viremia in HIV-1 elite
controllers and relationship to immunologic parameters. J Infect Dis. 2009 Sep 15;200(6):984-90.
PubMed PMID: 19656066.
294.
Brumme Z, Wang B, Nair K, Brumme C, de Pierres C, Reddy S, Julg B, Moodley E, Thobakgale
C, Lu Z, van der Stok M, Bishop K, Mncube Z, Chonco F, Yuki Y, Frahm N, Brander C,
Carrington M, Freedberg K, Kiepiela P, Goulder P, Walker B, Ndung'u T, Losina E. Impact of
select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic
HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa. Clin Infect
Dis. 2009 Sep 15;49(6):956-64. PubMed PMID: 19663693.
59
295.
Thobakgale CF, Prendergast A, Crawford H, Mkhwanazi N, Ramduth D, Reddy S, Molina C,
Mncube Z, Leslie A, Prado J, Chonco F, Mphatshwe W, Tudor-Williams G, Jeena P,
Blanckenberg N, Dong K, Kiepiela P, Coovadia H, Ndung'u T, Walker BD, Goulder PJ. Impact of
HLA in mother and child on disease progression of pediatric human immunodeficiency virus type
1 infection. J Virol. 2009 Oct;83(19):10234-44. Epub 2009 Jul 15. PubMed PMID: 19605475;
PubMed Central PMCID: PMC2748050.
296.
Singh A, Page T, Moore PL, Allgaier RL, Hiramen K, Coovadia HM, Walker BD, Morris L,
Ndung'u T. Functional and genetic analysis of coreceptor usage by dualtropic HIV-1 subtype C
isolates. Virology. 2009 Oct 10;393(1):56-67. Epub 2009 Aug 19. PubMed PMID: 19695656.
297.
Prado JG, Prendergast A, Thobakgale C, Molina C, Tudor-Williams G, Ndung'u T, Walker BD,
Goulder P. Replicative Capacity of Mother-to-Child transmitted virus is associated with pediatric
HIV-1 disease progression rate. J Virol. 2009 Oct 14. Epub ahead of print] PubMed PMID:
19828603.
298.
Thomas R, Apps R, Qi Y, Gao X, Male V, O'hUigin C, O'Connor G, Ge D, Fellay J, Martin JN,
Margolick J, Goedert JJ, Buchbinder S, Kirk GD, Martin MP, Telenti A, Deeks SG, Walker BD,
Goldstein D, McVicar DW, Moffett A, Carrington M. HLA-C cell surface expression and control
of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet. 2009 Dec;41(12):12904.PMID: 19935663.
299.
Ferreira MA, Mangino M, Brumme CJ, Zhao ZZ, Medland SE, Wright MJ, Nyholt DR, Gordon S,
Campbell M, McEvoy BP, Henders A, Evans DM, Lanchbury JS, Pereyra F; International HIV
Controllers Study, Walker BD, Haas DW, Soranzo N, Spector TD, de Bakker PI, Frazer IH,
Montgomery GW, Martin NG. Quantitative trait loci for CD4:CD8 lymphocyte ratio are
associated with risk of type 1 diabetes and HIV-1 immune control. Am J Hum Genet. 2010
Jan;86(1):88-92. Epub 2009 Dec 31.PMID: 20045101.
300.
Prado JG, Prendergast A, Thobakgale C, Molina C, Tudor-Williams G, Ndung'u T, Walker BD,
Goulder P. Replicative capacity of human immunodeficiency virus type 1 transmitted from mother
to child is associated with pediatric disease progression rate. J Virol. 2010 Jan;84(1):492-502.
Epub .PMID: 19828603.
301.
Bansal A, Carlson J, Yan J, Akinsiku OT, Schaefer M, Sabbaj S, Bet A, Levy DN, Heath S, Tang
J, Kaslow RA, Walker BD, Ndung'u T, Goulder PJ, Heckerman D, Hunter E, Goepfert PA. CD8 T
cell response and evolutionary pressure to HIV-1 cryptic epitopes derived from antisense
transcription. J Exp Med. 2010 Jan 18;207(1):51-9. Epub 2010 Jan 11.PMID: 20065064.
302.
Spentzou A, Bergin P, Gill D, Cheeseman H, Ashraf A, Kaltsidis H, Cashin-Cox M, Anjarwalla I,
Steel A, Higgs C, Pozniak A, Piechocka-Trocha A, Wong J, Anzala O, Karita E, Dally L, Gotch F,
Walker B, Gilmour J, Hayes P. Viral inhibition assay: a CD8 T cell neutralization assay for use in
clinical trials of HIV-1 vaccine candidates. J Infect Dis. 2010 Mar;201(5):720-9.PMID: 20132004.
303.
Banerjee K, Klasse PJ, Sanders RW, Pereyra F, Michael E, Lu M, Walker BD, Moore JP. IgG
subclass profiles in infected HIV type 1 controllers and chronic progressors and in uninfected
recipients of Env vaccines. AIDS Res Hum Retroviruses. 2010 Apr;26(4):445-58.PMID:
60
20377426.
304.
Wong AH, Williams K, Reddy S, Wilson D, Giddy J, Alter G, Ghebremichael M, Carrington MN,
Ndung'u T, Walker BD, Altfeld M, Carr WH. Alterations in natural killer cell receptor profiles
during HIV type 1 disease progression among chronically infected South African adults. AIDS
Res Hum Retroviruses. 2010 Apr;26(4):459-69.PMID: 20380481.
305.
Košmrlj A, Read EL, Qi Y, Allen TM, Altfeld M, Deeks SG, Pereyra F, Carrington M, Walker
BD, Chakraborty AK. Effects of thymic selection of the T-cell repertoire on HLA class Iassociated control of HIV infection. Nature. 2010 May 5. [Epub ahead of print]PMID: 20445539.
306.
Hersperger AR, Pereyra F, Nason M, Demers K, Sheth P, Shin LY, Kovacs CM, Rodriguez B,
Sieg SF, Teixeira-Johnson L, Gudonis D, Goepfert PA, Lederman MM, Frank I, Makedonas G,
Kaul R, Walker BD, Betts MR. Perforin expression directly ex vivo by HIV-specific CD8 T-cells
is a correlate of HIV elite control. PLoS Pathog. 2010 May 27;6(5):e1000917. PubMed PMID:
20523897.
307.
Williams K, Seiss K, Beamon J, Pereyra F, Rosenberg ES, Walker BD, Yu XG, Lichterfeld M.
Epigenetic regulation of telomerase expression in HIV-1-specific CD8+ T cells. AIDS. 2010 Jul
31;24(12):1964-6. PubMed PMID: 20588158.
308.
Miura T, Brumme ZL, Brockman MA, Rosato P, Sela J, Brumme CJ, Pereyra F, Kaufmann DE,
Trocha A, Block BL, Daar ES, Connick E, Jessen H, Kelleher AD, Rosenberg E, Markowitz M,
Schafer K, Vaida F, Iwamoto A, Little S, Walker BD. Impaired replication capacity of acute/early
viruses in persons who become HIV controllers. J Virol. 2010 Aug;84(15):7581-91. Epub 2010
May 26. PubMed PMID: 20504921.
309.
Huang J, Burke PS, Cung TD, Pereyra F, Toth I, Walker BD, Borges L, Lichterfeld M, Yu XG.
Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of
circulating myeloid dendritic cells in HIV-1-infected elite controllers. J Virol. 2010
Sep;84(18):9463-71. Epub 2010 Jul 14. PubMed PMID: 20631139.
310.
Mkhwanazi N, Thobakgale CF, van der Stok M, Reddy S, Mncube Z, Chonco F, Walker BD,
Altfeld M, Goulder PJ, Ndung'u T. Immunodominant HIV-1-specific HLA-B- and HLA-Crestricted CD8+ T cells do not differ in polyfunctionality. Virology. 2010 Sep 30;405(2):483-91.
Epub 2010 Jul 17. PubMed PMID: 20638093.
311.
Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung'u T, Brander C, Coovadia H,
Walker BD, Heckerman D, Goulder PJ. Additive contribution of HLA class I alleles in the
immune control of HIV-1 infection. J Virol. 2010 Oct;84(19):9879-88. Epub 2010 Jul 21. PubMed
PMID: 20660184.
312.
Wright JK, Brumme ZL, Carlson JM, Heckerman D, Kadie CM, Brumme CJ, Wang B, Losina E,
Miura T, Chonco F, van der Stok M, Mncube Z, Bishop K, Goulder PJ, Walker BD, Brockman
MA, Ndung'u T. Gag-protease-mediated replication capacity in HIV-1 subtype C chronic
infection: associations with HLA type and clinical parameters. J Virol. 2010 Oct;84(20):10820-31.
Epub 2010 Aug 11. PubMed PMID: 20702636.
61
313.
Honeyborne I, Codoñer FM, Leslie A, Tudor-Williams G, Luzzi G, Ndung'u T, Walker BD,
Goulder PJ, Prado JG. HLA-Cw*03-restricted CD8+ T-cell responses targeting the HIV-1 gag
major homology region drive virus immune escape and fitness constraints compensated for by
intracodon variation. J Virol. 2010 Nov;84(21):11279-88. Epub 2010 Aug 25. PubMed PMID:
20739527.
314.
Brockman MA, Brumme ZL, Brumme CJ, Miura T, Sela J, Rosato PC, Kadie CM, Carlson JM,
Markle TJ, Streeck H, Kelleher AD, Markowitz M, Jessen H, Rosenberg E, Altfeld M, Harrigan
PR, Heckerman D, Walker BD, Allen TM. Early Selection in Gag by Protective HLA Alleles
Contributes to Reduced HIV-1 Replication Capacity That May Be Largely Compensated for in
Chronic Infection. J Virol. 2010 Nov;84(22):11937-49. Epub 2010 Sep 1. PubMed PMID:
20810731.
315.
Rolland M, Carlson JM, Manocheewa S, Swain JV, Lanxon-Cookson E, Deng W, Rousseau CM,
Raugi DN, Learn GH, Maust BS, Coovadia H, Ndung'u T, Goulder PJ, Walker BD, Brander C,
Heckerman DE, Mullins JI. Amino-acid co-variation in HIV-1 Gag subtype C: HLA-mediated
selection pressure and compensatory dynamics. PLoS One. 2010 Sep 1;5(9). pii: e12463. PubMed
PMID: 20824187.
316.
Kim AY, Kuntzen T, Timm J, Nolan BE, Baca MA, Reyor LL, Berical AC, Feller AJ, Johnson
KL, Schulze Zur Wiesch J, Robbins GK, Chung RT, Walker BD, Carrington M, Allen TM, Lauer
GM. Spontaneous control of HCV is associated with the expression of HLA-B*57 and
preservation of targeted epitopes. Gastroenterology. 2010 Sep 24. [Epub ahead of print] PubMed
PMID: 20875418.
317.
Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S, Artyomov MN, Pietzsch J,
Connors M, Pereyra F, Walker BD, Ho DD, Wilson PC, Seaman MS, Eisen HN, Chakraborty AK,
Hope TJ, Ravetch JV, Wardemann H, Nussenzweig MC. Polyreactivity increases the apparent
affinity of anti-HIV antibodies by heteroligation. Nature. 2010 Sep 30;467(7315):591-5. PubMed
PMID: 20882016.
318.
Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, Julg B, Jesneck JL,
Brosnahan K, Imam S, Russell K, Toth I, Piechocka-Trocha A, Dolfi D, Angelosanto J, Crawford
A, Shin H, Kwon DS, Zupkosky J, Francisco L, Freeman GJ, Wherry EJ, Kaufmann DE, Walker
BD, Ebert B, Haining WN. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD1 inhibits T cell function by upregulating BATF. Nat Med. 2010 Oct;16(10):1147-51. Epub 2010
Oct 3. PubMed PMID: 20890291
319.
Mureithi MW, Cohen K, Moodley R, Poole D, Mncube Z, Kasmar A, Moody BD, Goulder PJ,
Walker B, Altfeld M, Ndung'u T. Impairment of CD1d-restricted Natural Killer T cells in chronic
HIV-1 clade C infection. AIDS Res Hum Retroviruses. 2010 Oct 14. [Epub ahead of print]
PubMed PMID: 20942750.
320.
Singh R, Gaiha G, Werner L, McKim K, Mlisana K, Luban J, Walker BD, Abdool Karim SS,
Brass AL, Ndung'u T; the CAPRISA Acute Infection Study Team. Association of TRIM22 with
Type 1 Interferon Response and Viral Control during Primary HIV-1 Infection. J Virol. 2010 Oct
27. [Epub ahead of print] PubMed PMID: 20980524.
62
321.
Chevalier MF, Julg B, Pyo A, Flanders M, Ranasinghe S, Soghoian DZ, Kwon DS, Rychert J,
Lian J, Mueller M, Cutler S, McAndrew E, Jessen H, Pereyra F, Rosenberg ES, Altfeld M, Walker
BD, Streeck H. HIV-1-specific IL-21+ CD4+ T cell responses contribute to durable viral control
through the modulation of HIV-specific CD8+ T cell function. J Virol. 2010 Nov 3. [Epub ahead
of print] PubMed PMID: 21047960
322.
Rodríguez-García M, Porichis F, de Jong OG, Levi K, Diefenbach TJ, Lifson JD, Freeman GJ,
Walker BD, Kaufmann DE, Kavanagh DG. Expression of PD-L1 and PD-L2 on human
macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol.
2010 Nov 19. [Epub ahead of print]PMID: 21097698
323.
Pereyra F, Jia X, McLaren PJ, Telenti A, De Bakker P, Walker BD. The Major Genetic
Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation; The International HIV
Controller Study. Science 2010 Dec 10; 330(6010):1551-1557. [Epub ahead of print] 2010 Nov 4
PubMed PMID: 21051598
324.
Addo MM, Altfeld M, Brainard DM, Rathod A, Piechocka-Trocha A, Fideli U, Mulenga J, Shutes
E, Alvino DM, Hunter E, Allen SA, Walker BD. Lack of detectable HIV-1-specific CD8(+) T cell
responses in Zambian HIV-1-exposed seronegative partners of HIV-1-positive individuals. J Infect
Dis. 2011 Jan 15;203(2):258-62. Epub 2010 Dec 9. PubMed PMID: 21288826; PubMed Central
PMCID: PMC3071055.
325.
Brumme ZL, Li C, Miura T, Sela J, Rosato PC, Brumme CJ, Markle TJ, Martin E, Block BL,
Trocha A, Kadie CM, Allen TM, Pereyra F, Heckerman D, Walker BD, Brockman MA. Reduced
replication capacity of NL4-3 recombinant viruses encoding reverse transcriptase-integrase
sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):100-8.
PubMed PMID: 21124229; PubMed Central PMCID: PMC3078702.
326.
Julg B, Moodley ES, Qi Y, Ramduth D, Reddy S, Mncube Z, Gao X, Goulder PJ, Detels R,
Ndung'u T, Walker BD, Carrington M. Possession of HLA class II DRB1*1303 associates with
reduced viral loads in chronic HIV-1 clade C and B infection. J Infect Dis. 2011 Mar
15;203(6):803-9. Epub 2011 Jan 21. PubMed PMID: 21257739; PubMed Central PMCID:
PMC3071131.
327.
Thobakgale CF, Streeck H, Mkhwanazi N, Mncube Z, Maphumulo L, Chonco F, Prendergast A,
Tudor-Williams G, Walker BD, Goulder PJ, Altfeld M, Ndung'u T. CD8(+) T Cell
Polyfunctionality Profiles in Progressive and Nonprogressive Pediatric HIV Type 1 Infection.
AIDS Res Hum Retroviruses. 2011 Mar 21. [Epub ahead of print] PubMed PMID: 21288139.
328.
Wright JK, Novitsky V, Brockman MA, Brumme ZL, Brumme CJ, Carlson JM, Heckerman D,
Wang B, Losina E, Leshwedi M, van der Stok M, Maphumulo L, Mkhwanazi N, Chonco F,
Goulder PJ, Essex M, Walker BD, Ndung'u T. Influence of Gag-protease-mediated replication
capacity on disease progression in individuals recently infected with HIV-1 subtype C. J Virol.
2011 Apr;85(8):3996-4006. Epub 2011 Feb 2. PubMed PMID: 21289112; PubMed Central
PMCID: PMC3126116.
329.
Rodríguez-García M, Porichis F, de Jong OG, Levi K, Diefenbach TJ, Lifson JD, Freeman GJ,
Walker BD, Kaufmann DE, Kavanagh DG. Expression of PD-L1 and PD L2 on human
63
macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol.
2011 Apr;89(4):507-15. Epub 2010 Nov 19. PubMed PMID: 21097698; PubMed Central PMCID:
PMC3058820.
330.
Li JZ, Brumme ZL, Brumme CJ, Wang H, Spritzler J, Robertson MN, Lederman MM, Carrington
M, Walker BD, Schooley RT, Kuritzkes DR; AIDS Clinical Trials Group A5197 Study Team.
Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV1 gag vaccine trial. J Infect Dis. 2011 Apr 1;203(7):976-83. PubMed PMID: 21402549; PubMed
Central PMCID: PMC3068025.
331.
Chen H, Li C, Huang J, Cung T, Seiss K, Beamon J, Carrington MF, Porter LC, Burke PS, Yang
Y, Ryan BJ, Liu R, Weiss RH, Pereyra F, Cress WD, Brass AL, Rosenberg ES, Walker BD, Yu
XG, Lichterfeld M. CD4+ T cells from elite controllers resist HIV-1 infection by selective
upregulation of p21. J Clin Invest. 2011 Apr 1;121(4):1549-60. doi: 10.1172/JCI44539. Epub
2011 Mar 14. PubMed PMID: 21403397; PubMed Central PMCID: PMC3069774.
332.
Hersperger AR, Martin JN, Shin LY, Sheth PM, Kovacs CM, Cosma GL, Makedonas G, Pereyra
F, Walker BD, Kaul R, Deeks SG, Betts MR. Increased HIV-specific CD8+ T-cell cytotoxic
potential in HIV elite controllers is associated with T-bet expression. Blood. 2011 Apr
7;117(14):3799-808. Epub 2011 Feb 2. PubMed PMID: 21289310.
333.
Novitsky V, Ndungʼu T, Wang R, Bussmann H, Chonco F, Makhema J, De Gruttola V, Walker
BD, Essex M. Extended high viremics: a substantial fraction of individuals maintain high plasma
viral RNA levels after acute HIV-1 subtype C infection. AIDS. 2011 Apr 18. [Epub ahead of
print] PubMed PMID: 21505307.
334.
Huang KH, Goedhals D, Carlson JM, Brockman MA, Mishra S, Brumme ZL, Hickling S, Tang
CS, Miura T, Seebregts C, Heckerman D, Ndung'u T, Walker B, Klenerman P, Steyn D, Goulder
P, Phillips R; Bloemfontein-Oxford Collaborative Group, van Vuuren C, Frater J. Progression to
AIDS in South Africa is associated with both reverting and compensatory viral mutations. PLoS
One. 2011 Apr 22;6(4):e19018. PubMed PMID: 21544209; PubMed Central PMCID:
PMC3081339.
335.
Kulkarni S, Savan R, Qi Y, Gao X, Yuki Y, Bass SE, Martin MP, Hunt P, Deeks SG, Telenti A,
Pereyra F, Goldstein D, Wolinsky S, Walker B, Young HA, Carrington M. Differential microRNA
regulation of HLA-C expression and its association with HIV control. Nature. 2011 Apr
28;472(7344):495-8. Epub 2011 Apr 17. PubMed PMID: 21499264; PubMed Central PMCID:
PMC3084326.
336.
Mureithi MW, Cohen K, Moodley R, Poole D, Mncube Z, Kasmar A, Moody DB, Goulder PJ,
Walker BD, Altfeld M, Ndung'u T. Impairment of CD1d-restricted natural killer T cells in chronic
HIV type 1 clade C infection. AIDS Res Hum Retroviruses. 2011 May;27(5):501-9. doi:
10.1089/aid.2010.0237. Epub 2010 Dec 13. PubMed PMID: 20942750; PubMed Central PMCID:
PMC3083726.
337.
Streeck H, Kwon DS, Pyo A, Flanders M, Chevalier MF, Law K, Jülg B, Trocha K, Jolin JS,
Anahtar MN, Lian J, Toth I, Brumme Z, Chang JJ, Caron T, Rodig SJ, Milner DA Jr, PiechokaTrocha A, Kaufmann DE, Walker BD, Altfeld M. Epithelial adhesion molecules can inhibit HIV64
1-specific CD8⁺ T-cell functions. Blood. 2011 May 12;117(19):5112-22. Epub 2011 Mar 14.
PubMed PMID: 21403126.
338.
Ndhlovu ZM, Piechocka-Trocha A, Vine S, McMullen A, Koofhethile KC, Goulder PJ, Ndung'u
T, Barouch DH, Walker BD. Mosaic HIV-1 Gag Antigens Can Be Processed and Presented to
Human HIV-Specific CD8+ T Cells. J Immunol. 2011 Jun 15;186(12):6914-24. Epub 2011 May
16. PubMed PMID: 21576505; PubMed Central PMCID: PMC3129742.
339.
Dahirel V, Shekhar K, Pereyra F, Miura T, Artyomov M, Talsania S, Allen TM, Altfeld M,
Carrington M, Irvine DJ, Walker BD, Chakraborty AK. Coordinate linkage of HIV evolution
reveals regions of immunological vulnerability. Proc Natl Acad Sci U S A. 2011 Jun 20. [Epub
ahead of print] PubMed PMID: 21690407.
Non-peer reviewed scientific or medical publications/materials in print or other media
Proceedings of Meetings
1.
Zolla-Pazner S, Mathieson BJ, Walker MC, Walker BD. NCVDG Summary: Clinical
Immunology Working Group. AIDS Res Hum Retro 1992;8:1300-4.
2.
Johnson RP, Hammond SA, Trocha A, Siliciano RF, Walker BD. Epitope specificity of MHC
restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine. AIDS Res Human Retro
1994;10 Suppl 2:S73-75.
3.
Harrer T, Harrer E, Buchbinder B, Mann DL, Feinberg M, Yilma T, Johnson RP, Walker BD.
HIV-1-specific cytotoxic T lymphocyte response in healthy, long-term nonprogressing
seropositive persons. AIDS Res Human Retro 1994;10 Suppl 2:S77-78.
4.
Harrer T, Harrer E, Kalams S, Walker BD. HIV-1 specific immune responses in asymptomatic
long-term nonprogressing infection. Vaccines 1996;273-277.
5.
Centers for Disease Control Prevention. Report of the NIH panel to define principles of therapy of
HIV infection and guidelines for the use of antiretroviral agent sin HIV-infected adults and
adolescents. MMWR 1998;47 (No. RR-5): 1-91.
6.
Walker B. Advances in the Understanding of HIV Pathogenesis. Highlights from the 6th
Conference on Retroviruses and Opportunistic Infections, 1999. In: Improving the Management
of HIV Disease 1999;7:10-14.
7.
Walker BD. Cellular immune response in HIV-1 infection and effects of therapy on immunologic
parameters. In: Improving the Management of HIV Disease 1999;Volume 7, Issue 1:4-8.
8.
Walker BD. Immune Reconstitution: Is there a potential role for filgrastim (r-metHuG-CDSF)?
Hum Gene Therapy 1999 (suppl 1)8:S1-S2.
9.
Goulder PJR, Rowland-Jones SL, McMichael AJ, Walker BD. Anti-HIV cellular immunity:
Recent advances towards vaccine design. AIDS 1999;13(suppl A):S121-S136.
65
10.
Walker BD. HIV Pathogenesis and Prospects for Vaccine Development. Topics in HIV Medicine
2001; Volume 9, Issue 2:4-9.
Reviews, Chapters, and Editorials
1.
Walker BD, Paradis TJ, Charkabarti S, Moss B, Schooley RT. Cytotoxic T lymphocytes specific
for the HIV-1 polymerase gene product. In: Girard M, editor. Retroviruses of Human AIDS and
Related Animal Diseases. Pasteur Vaccines; 1987.
2.
Walker BD, Flexner C, Paradis TJ, Wong J, Hirsch MS, Moss B, Schooley RT. Characterization
of the cytotoxic T cell response to HIV-1 gene products. In: Oldstone and Brachiale, editors. Cell
Biology of Virus Entry, Replication and Pathogenesis. Alan R. Liss, Inc.; 1989.
3.
Walker, BD, Plata F. Cytotoxic T-lymphocytes against HIV. AIDS 1990;4(3):188-84.
4.
Walker BD. Cytotoxic T lymphocyte responses to HIV-1. In: Putney and Bolognesi, editors.
AIDS Vaccines: Basic Research and Clinical Trials. New York: Marcel Decker; 1990. p. 179194.
5.
Johnson VA, Walker BD. HIV-infected cell fusion assay. In: Aldovini A, Walker BD, editors.
Techniques in HIV Research. New York: Stockton Press; 1990. p. 92-95.
6.
Walker BD. HIV-1 specific cytotoxic T Lymphocytes. In: Aldovini A, Walker BD, editors.
Techniques in HIV Research. New York: Stockton Press; 1990. p. 201-210.
7.
Johnson RP, Walker BD. Identification of HIV-1 cytotoxic T-lymphocyte epitopes and
implications for vaccine development. Biotechnol Ther 1991;2:137-46.
8.
Zolla-Pazner S, Mathieson BJ, Walker MC, Walker BD. Summary: Clinical Immunology
Working Group. AIDS Res Hum Retroviruses 1992;8(8):1441-3.
9.
Walker BD. Immunology Related to AIDS. In: Cecil Textbook of Medicine. Philadelphia: WB
Saunders Company; 1992.
10.
Walker BD. Studies of HIV-1-Specific CTL: Recognition of Multiple Highly Conserved Epitopes
in the Gag and RT Proteins. In: Koff W, Wong-Staal F, editors. Annual Review of AIDS
Research. New York: Marcel Dekker, Inc. 1992; 2:349-360.
11.
Koziel MJ, Walker BD. Viruses, chemotherapy and immunity. Parasitology 1992;105
(Suppl):S85-92.
12.
Walker MC, Walker BD, Mestecky J, Mathieson BJ. Conference on the advances in AIDS
vaccine development—1993. Summary: Cytotoxic T-cell Immunity Workshop. AIDS Res Hum
Retroviruses 1994;10(Suppl 2):S177-9.
13.
Mestecky J, Walker MC, Mathieson BJ, Walker BD. Conference on advances in AIDS vaccine
development—1993. Summary: Mucosal Immunity Workshop. AIDS Res Hum Retroviruses
1994;10(Suppl 2):S165-70.
14.
Venet A, Walker BD. Cytotoxic T-cell epitopes in HIV/SIV Infection. AIDS 1993;7(Suppl 1):
66
S117-26.
15.
Johnson RP and Walker BD. Cytotoxic T lymphocytes in human immunodeficiency virus
infection: responses to structural proteins. Curr Top Microbiol Immunol 1994;189:35-63.
16.
Kalams SA and Walker BD. The cytotoxic T-lymphocyte response in HIV-1 infection. Clin Lab
Med 1994;14(2):271-99.
17.
Walker BD. Immunology Related to AIDS. In: Cecil Textbook of Medicine. Philadelphia: WB
Saunders; 1994.
18.
Harrer T, Harrer E, Kalams SA, Buchbunder S, Johnson RP, Walker BD. Longitudinal analysis of
HIV-1-specific CTL responses. In: Biotechnology Against AIDS: From Science to Prevention,
Diagnosis and Therapy; 1994. Firenze. 63-86.
19.
Walker BD. HIV-1-specific CTL response and TCR usage in HIV-1 infection. In: Retroviruses
of Human AIDS and Related Animal Diseases. Neuvieme Colloque Des Cent Gardes, Paris,
France; 1994. 21-8.
20.
McMichael AJ and Walker BD. Cytotoxic T lymphocyte epitopes: Implications for AIDS
vaccines. AIDS 1994;8 Suppl 1:155-173.
21.
Walker BD. The rationale for immunotherapy in HIV-1 infection. JAIDS 1994; Suppl 1:S6-13.
(Review).
22.
Walker BD. A new agenda for AIDS research. BMJ 1995 Dec 2; 311(7018):1448-1449.
23.
Jassoy C, Walker BD. T lymphocytes and their cytokines in human immunodeficiency virus
(HIV) infection: implications for associated neoplasias. Crit Rev in Oncog 1995; 6(3-6):275-89.
24.
Kalams SA, Walker BD. Cytotoxic T Lymphocytes and HIV-1-Related Neurologic Disorders.
Curr Top in Microbiol Immunol 1995; 202:79-88.
25.
Brander C, Walker BD. The HLA-class 1 Restricted CTL Response in HIV-1 Infection:
Identification of Optimal Epitopes. In: Korber BTM, Brander C, Walker BD, Koup R, Moore JP,
Haynes BF, Myers G, editors. HIV Molecular Immunology Database. New Mexico: Theoretical
Biology and Biophysics, Los Alamos National Laboratory; 1995.
26.
Brander C, Walker BD. The HLA class I restricted CTL response in HIV-1 infection: Systematic
identification of optimal epitopes. In: Korber BTM, Brander C, Walker BD, Koup R, Moore JP,
Haynes BF, Myers G, editors. HIV Molecular Immunology Database. New Mexico: Theoretical
Biology and Biophysics, Los Alamos National Laboratory 1996.
27.
Jassoy C, Walker BD. HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1
replication. Springer Seminars in Immunopathology 1997;18 (3):341-54.
28.
Koziel MJ, Walker BD. Characteristics of the intrahepatic cytotoxic T lymphocyte response in
chronic hepatitis C virus infection. Springer Seminars in Immunopathology 1997; 19 (1):69-83
29.
Yang OO, Walker BD. CD8+ cells in human immunodeficiency virus type 1 pathogenesis:
67
cytolytic and non-cytolytic inhibition of viral replication. Adv Immunol 1997;66:273-311.
30.
Koziel MJ, Walker BD. Characteristics of the intrahepatic CTL response in chronic HCV
infection. Seminars in Immunology 1997;19(1):69-83. Review
31.
Brander C, Walker BD. Optimal HLA class I restricted CTL epitopes in HIV-1 infection: 1997
update. In: Korber BTM, Brander C, Walker BD, Koup R, Moore JP, Haynes BF, Myers G,
editors. HIV Molecular Immunology Database. New Mexico: Theoretical Biology and
Biophysics, Los Alamos National Laboratory; 1997.
32.
Rosenberg ES, Walker BD. HIV type 1 specific helper T cells: a critical host defense. AIDS Res
Hum Retroviruses 1998;14(Suppl 2):S143-7.
33.
Walker BD. HIV pathogenesis. In: Richman DD, Benson CA, Fischl MA, Kessler HA, Saag MS,
Schooley RT, Volberding PA, editors. Improving the Management of HIV Disease. International
AIDS Society-USA, San Francisco, CA. 1998;6:11-13.
34.
Rosenberg ES, Walker BD. HIV Type 1-specific helper T cell: A critical host defense. AIDS
Res Hum Retro 1998;12:143-147.
35.
Kahn JO, Walker BD. Acute Human Immunodeficiency Virus Type 1 Infection. NEJM 1998 Jul
2;339 (1):33-39.
36.
Walker BD, Rosenberg ES, Hay CM, Basgoz N, Yang OO. Immune Control of HIV-1
Replication. Adv Exp Med Biol 1998;452:159-67.
37.
Walker BD, Basgoz N. Treat HIV-1 infection like other infections -- treat it. JAMA 1998;
280(1):91-93.
38.
Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T
lymphocyte responses. J Exp Med 1998 Dec 21; 188(12):2199-204.
39.
Wong DKH, Walker, BD. Hepatitis C Virus. In: McCance, editor. Human Tumor Viruses.
Washington, D.C.: American Society for Microbiology Press; 1998:301-29
40.
Walker BD, Rosenberg ES, Hay CM, Basgoz N, Yang OO. Immune control of HIV-1 replication.
Adv. Exp. Med. Boil. 1998; 452:159-67
41.
Mani I, Cao H, Hom D, Johnson JL, Mugerwa RD, Travers KU, Caliendo AM, Walker BD, Kanki
PJ. Plasma RNA viral load as measured by the bDNA and nucleic acid sequece-based
amplification assays of HIV-1 subtypes A and D in Uganda (letter). JAIDS 1999;22:208. NASBA
assays of HIV-1 subtypes A and D in Uganda.
42.
Brander C, Walker BD. T lymphocyte responses in HIV-1 infection: implications for vaccine
development. Current Opinion in Immunol 1999;11:451-459.
43.
Goulder P, Walker BD. The Great Escape: AIDS Viruses and Immune Control. Nat Med
1999;(5):1233-1235.
44.
Goulder PJ, Walker BD. The great escape - AIDS viruses and immune control. Nat Med
68
1999;5(11):1233-5.
45.
Walker BD. Immune resconstitution: is there a potential role for Filgrastim (r-metHuG-CSF). J.
Hematother Stem Cell Res. 1999; 8 Suppl 1:S1-2
46.
Rosenberg ES, LaRosa L, Flynn T, Robbins G, Walker BD. Characterization of HIV-1-specific Thelper cells in acute and chronic infection. Immunol Letters 1999;66(1-3):89-93.
47.
D'Aquila R, Walker B. Exploring the benefits and limits of highly active antiretroviral therapy.
JAMA 1999;282(17):1668-9.
48.
Kahn JO, Walker BD. Primary HIV Infection: Guides to Diagnosis, Treatment, and Managment.
In: Cohen PT, Sande MA, Volberding PA, editors. The AIDS Knowledge Base, Third Edition.
Philadelphia: Lippincott Williams & Wilkins: 1999;195-200.
49.
Kahn JO, Hecht FM, Chesney MA, Walker BD. Early Intervention: Acute HIV Infection
Syndrome. In: Dolin R, Masur H, Saag MS, editors. AIDS Therapy. Philadelphia: Churchill
Livingstone: 1999; 229-35.
50.
Walker, BD. Immunopathogenesis and immune reconstitution in HIV disease. In: Richman DD,
Benson CA, Fischl MA, Kessler HA, Saag MS, Schooley RT, Volberding PA, editors. Improving
the Management of HIV Disease. International AIDS Society-USA, San Francisco, CA. 1999;
6:4-7.
51.
Walker BD. Effects of antiviral therapy on immune responses in HIV infection. In:The PRN
Notebook 1999;(4)21-24.
52.
Goulder PJ, Rowland-Jones SL, McMichael AJ, Walker BD. Anti-HIV cellular immunity: recent
advances towards vaccine design. AIDS 1999; 13 Suppl A:S121-36
53.
Walker BD. Plasma RNA viral load as measured by the branched DNA and nucleic acid
sequence-based amplification assays of HIV-1 subtypes A and D in Uganda. JAIDS 1999;22:208212.
54.
Rosenberg ES, caliendo AM, Walker BD. Acute HIV infection among patients tested for
mononucleosis. 1999 Mar 25; 340 (12): 969
55.
Walker BD. Can immune responses to human immunodeficiency virus be preserved, enhanced, or
restored? AIDS Clin Rev. 2000:101-14.
56.
Walker BD, Goulder PJ. AIDS. Escape from the immune system. Nature 2000;407(6802):313-4.
57.
Walker BD, Rosenberg ES. Containing HIV after infection. Nat Med 2000;6(10):1094-5.
58.
Cao H, Walker BD. Immunopathogenesis of HIV-1 infection. Clin Dermatol 2000 JulAug;18(4):401-10.
59.
Brander C, Walker BD. Modulation of host immune responses by clinically relevant human DNA
and RNA viruses. Curr Opin Microbiol 2000;3:379.
69
60.
Walker BD, Korber BT. Immune control of HIV: the obstacles of HLA and viral diversity. Nat
Immunol 2001 Jun;2(6):473-5.
61.
Cohen DE, Walker BD. Human immunodeficiency virus pathogenesis and prospects for immune
control in patients with established infection. Clin Infect Dis 2001;32(12):1756-68.
62.
Letvin NL, Walker BD. HIV versus the immune system: another apparent victory for the virus. J
Clin Invest 2001 Feb;107(3):273-5.
63.
Cohen, O. J. and Fauci, A. S. (2001). Kuritzkes DR, Walker BD. Pathogenesis and medical
aspects of HIV-1 infection. In Fields Virology. 4th ed., pp. 2043–2094. Lippincott Williams &
Wilkins, Philadelphia
64.
Cohen DE, Walker BD. Human immunodeficiency virus pathogenesis and prospects for immune
control in patients with established infection. Clin. Infect. Dis. 2001 Jun 15; 31(12): 1756-68
65.
Altfeld M, Walker BD. Less is more? The prospects and problems with supervised treatment
interruption in acute and chronic HIV infection. Nat Med 2001 Aug;7(8):881-4.
66.
Wilson CC, Walker BD. Acquired Immunodeficiency Syndrome. In: Rich RR, Fleisher TA,
Shearer WT, Kotzin BL, Schroeder HW Jr., editors. Clinical Immunology: Principles and
Practice, Second Edition. England: Mosby International Ltd.; 2001. 38.1-38.28.
67.
Lauer G, Walker BD. Medical Progress: Hepatitis C Virus Infection. NEJM. 2001Jul 5;345
(1):41-52.
68.
Kalams SA, Walker BD. HIV Vaccines 2000: Prospects and Challenges. In: Emini EA, editor.
The Human Immunodeficiency Virus: Biology, Immunology and Therapy. Princeton: Princeton
University Press; 2002:481-509.
69.
Ward S, Lauer G, Isba R, Walker B, Klenerman P. Cellular immune responses against hepatitis C
virus: the evidence base 2002. Clin Exp Immunol. 2002 May;128(2):195-203.
70.
Gandhi RT, Walker BD. Promises and pitfalls in the reconstitution of immunity in patients who
have HIV-1 infection. Curr Opin Immunol. 2002 Aug 14(4):487-94.
71.
Walker BD, Krahn AD, Skanes AC, Yee R. Syncope and polymorphic ventricular tachycardia.
Pacing. Clin. Electrophysiol. 2002 Aug; 25(8): 1259-61
72.
Goulder PJ, Walker BD. HIV-1 superinfection--a word of caution. NEJM. 2002 Sept
5;347(10):756-8.
73.
Allen T, Kelleher A, Zaunders J, Walker B. STI and beyond: the prospects of boosting anti-HIV
immune responses. Trends Immunol. 2002 Sept;23(9):456-60.
74.
Gandhi RT and Walker BD. Immunologic Control of HIV-1. In: Caskey CT, Austin C, Hoxie J,
editors. Annual Review of Medicine: Selected Topics in the Clinical Sciences. Palo Alto,
California: Annual Reviews. 2002; 53:149-72.
70
75.
Cohen DE and Walker BD. Human Immunodeficiency Virus Pathogenesis and Prospects for
Immune Control in Patients with Established Infection. In: Mayer KH, editor. Currents Topics in
HIV Medicine: Using Basic Science to Inform Best Clinical Practice. Infectious Diseases Society
of American, U.S.A.; 2002:4-16.
76.
Barnes E, Lauer G, Walker B, Klenerman P. T cell failure in hepatitis C virus infection. Viral
Immunol. 2002 15(2):285-93.
77.
Bhardwaj N, Walker BD. Immunotherapy for AIDS virus infections: Cautious optimism for cellbased vaccine. Nat Med. 2003 Jan;9(1):13-4.
78.
Autran B, Debre P, Walker B, Katlama C. Therapeutic vaccines against HIV need international
partnerships. Nat Rev Immunol. 2003 Jun;3(6):503-8.
79.
Letvin NL, Walker BD. Immunopathogenesis and immunotherapy in AIDS virus infections. Nat
Med. 2003 Jul;9(7):861-6.
80.
Brander C & Walker BD. Gradual adaptation of HIV to human host populations: good or bad
news? Nat Med. 2003 November:9(11);1359-62.
81.
Walker BD, Krahn AD, Klein GJ, Skanes AC, Yee R. Drug induced QT prolongation: lessons
from congenital and acquired long QT syndromes. Curr. Drug Targets Cardiovasc. Haematol
Disord. 2003 Dec; 3(4): 327-35
82.
Day CL, Walker, BD. Progress in defining CD4 helper cell responses in chronic viral infections. J
Exp Med. 2003 Dec 15;198(12):1773-7.
83.
Deeks SG, Walker BD. The immune response to AIDS virus infection: good, bad or both? J Clin
Invest. 2004 Mar;13(6):808-10.
84.
Smith DE, Walker BD, Cooper DA, Rosenberg ES, Kaldor JM. Is antiretroviral treatment of
primary HIV infection clinically justified on the basis of current evidence? AIDS. 2004 Mar
26;18(5):709-18.
85.
Brander C, Frahm N, Walker BD. The challenges of host and viral diversity in HIV vaccine
design. Curr Opin Immunol. 2006 Aug;18(4):430-7.
86.
Kaufmann SH, Walker BD. Host-pathogen interactions. Curr Opin Immunol. 2006
Aug;18(4):371-3.
87.
Walker BD. HIV controllers: an untapped source of clues to overcoming HIV infection. Res Initiat
Treat Action. 2007 Winter;12(2):21-2.
88.
Walker BD, Burton DR. Toward an AIDS vaccine. Science. 2008 May 9;320(5877):760-4.
Review.
89.
Julg B, Walker BD. The paradox of incomplete CD4+ cell count restoration despite successful
antiretroviral treatment and the need to start highly active antiretroviral therapy early. Clin Infect
Dis. 2009 Mar 15;48(6):795-7. PubMed PMID: 19196173.
71
90.
Kaufmann DE, Walker BD. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection
and the potential for therapeutic intervention. J Immunol. 2009 May 15;182(10):5891-7. Review.
PubMed PMID: 19414738.
91.
Murphy RL, Autran B, Katlama C, Brucker G, Debre P, Calvez V, Clotet B, Clumeck N,
Costagliola D, Deeks SG, Dorrell L, Gatell J, Haase A, Klein M, Lazzarin A, McMichael AJ,
Papagno L, Schacker TW, Wain-Hobson S, Walker BD, Youle M. A step ahead on the HIV
collaboratory. Science. 2009 Jun 5;324(5932):1264-5. PubMed PMID: 19498149.
92.
Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature. 2010 Mar
11;464(7286):224-31.PMID: 20220841.
Books, Monographs, and Text Books
1.
Aldovini A, Walker BD, editors. Techniques in HIV Research. New York: Stockton Press; 1990.
2.
Pantaleo G, Walker BD, editors. Retroviral Immunology: Immune Response and Restoration.
New Jersey: Humana Press; 2001.
3.
Autran B, Fridman H, Lotze M, Walker B, guest editors. Proceedings of the Therapeutic Vaccines
Against HIV and Cancers Meeting; 2002 June 24-26; Les Pensieres, Veyrier-du-Lac, Annecy,
France. In: Vaccine. 2002 Dec;20 Suppl 4.
4.
Kaufmann, SH, Walker BD, editors. AIDS and Tuberculosis: A Deadly Liaison.Weinheim: WilyVCH Verlag GmbH & Co; 2009
Professional educational materials or reports, in print or other media
AIDS: Evolution of an Epidemic. Howard Hughes Medical Institute, Holiday Lectures on Science, 2008.
DVD
Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings
2010
#452 Next-generation Sequencing for HLA Typing and MHC Sequence Interrogation for Host Genetics
of HIV Infection
#93 Plasma Levels of WFDC1/ps20, a Novel Viral Permissivity Factor in CD4 T Lymphocytes,
Correlates Directly with CD4 T Cell Count in Chronic HIV-1 Infection
#340 Identification of CTL Selection Pressures Associated with HIV-1 Fitness Defects Using a
Recombinant Virus Screening Approach
#353 DNA Damage and p16-mediated Growth Arrest in HIV-1-specific CD8+ T Cells
#454 The HLA Class II Allele DRB1*1303 is Associated With Reduced Viral Loads in Two Independent
Cohorts of Different Ethnicity and HIV Clades of Infection
72
#76 Factors Associated with Viral Rebound in HIV-Positive Subjects Receiving a Therapeutic HIV-1 gag
Vaccine
#343 Rules Defining the Production of HIV Antigenic Peptides
#354 HIV-1-specific CD4+ T Helper Signals Are Critical for the Maintenance of CD8+ T Cell Function
#466 Gag-Protease-Mediated Fitness is Associated with Viral Set Point in Individuals Acutely Infected
with HIV-1 Subtype C
#776 Development of a Novel MIG/IP-10 qPCR Assay for Sensitive Detection of Antigen-specific T cells
and Its Use in the Identification of Latent Mycobacterium Tuberculosis (MTB) Infection in a HIV-MTB
Co-infected Population
2009
#318 Role of CD4+ CD25+ Regulatory T Cells in Interleukin-10-mediated T Cell Impairment in Chronic
HIV Infection
#541 A Genome-wide Association Study in HIV-1 Controllers
#888 Longitudinal Analysis of a Pediatric Cohort Who Failed First-line HAART in an Antiretroviral
Roll-out Site in Kwa Zulu Natal, South Africa
#112 The First Emerging CD8 T Cell Responses Are a Major Determinant of Early Viral Set-Point
#549 Missing Duffy Antigen Receptor for Chemokines: No Influence on Disease Progression in
Treatment-naïve HIV-1 Clade C-infected South Africans
#495 Challenges and Opportunities of Identifying Acute HIV-1 Infections in Resource-poor Settings:
Experiences from the HIV Pathogenesis Programme's Acute Infection Study in Durban, South Africa
#93LB Accelerated HIV Disease Progression in African Infants Co-infected with Cytomegalovirus
#283 HIV-1 Subtype C Diversity in an Adult Cohort of Progressors and Non-progressors Using Single
Genome Amplification
#409 Immunogenetic and Clinical Biomarkers Discriminate Rates of CD4 Decline in Chronic Untreated
HIV-1 Subtype C Infection
#415 Compartmentalization of Drug Resistance, Immune Escape, and Co-receptor Tropism in Circulating
Plasma Viruses during Late-stage HIV Infection
#86LB Vaccine-induced Targeting of Epitopes Associated with Spontaneous Control of HIV Viral
Replication is Associated with Lower Set-point Viral Loads in HIV-Infected Participants from the STEP
Trial
#115 A Molecular Perspective of PD-1 Receptor Function
73
#344 Matrix Metalloprotease Inhibitors Restore Impaired Natural Killer Cell-mediated Antibodydependent Cellular Cytotoxicity in HIV-1 Infection
#444 Amino Acid Co-variation and Compensatory Dynamics in HIV-1 Gag Subtype C
2008
#235 Application of 2 Bioinformatic Methods to Assess HIV Evolution in Response to HLA Class-Imediated Selection Pressures Reveals Unprecedented Levels of HLA-associated Escape Mutations across
HIV nef
#23 Presence of HLA Class I-associated Cytotoxic T Lymphocyte Escape Mutations in Chronic Untreated
HIV Infection Is Significantly Correlated with Clinical Markers of More Severe Disease Progression
#295 An HIV-1 CTL Escape Mutation Leading to ILT4-mediated Functional Inhibition of Dendritic Cells
#123 Immunodomination by HLA-B27- and HLA-B57-restricted HIV-1-specific T-cell Responses
Results in Abrogation of other HLA-restricted Responses in Primary HIV-1 Infection
#324 A Comprehensive Study of the Complexity of Viral Populations in Acute and Chronic HIV-1
Infection
#401 An Assay Utilizing Short-term Culture of Peripheral Blood Mononuclear Cells to Assess CD8 Tcell-mediated Control of HIV-1 Replication in vitro
#26 Protective HLA Class I Alleles Select HIV-1 Mutants and Slow Disease Progression
#126LB Time to ART Resumption following Treatment Interruption Is Shorter for Individuals
Immunized with HIV-Recombinant Canarypox Vaccine (Vcp1452) Compared to Placebo: The Manon-02
Trial
#299 HLA Frequency and HIV-1 Divergence
#94 Prevalence of HIV-1 Drug Resistance after Virologic Failure of First HAART Regimen in South
Africa: Initial Results of the South Africa Resistance Cohort Study
#486 A Phase II, Randomized, Placebo-controlled Study to Evaluate the Immunogenicity of 2 Schedules
of an Homologous Prime-boost with the ALVAC-HIV vCP1452 in Chronically HIV-infected Patients
(MANON 02)
#176 Gross Viral Genetic Defects Unlikely to Explain Many Spontaneous HIV-1 Viremia Controllers
74
Narrative Report
Our laboratory focuses on the cellular immune response to chronic viral infections, including HIV and
hepatitis C virus. In 1987 we discovered that HIV infection induces a strong virus specific cytotoxic T
lymphocyte (CTL) response in infected individuals, and have subsequently shown that these cells are
extremely efficient at controlling virus replication in vitro. We have characterized the precise viral
proteins that are targeted by this response, and have been investigating the role of viral sequence variation
within CTL epitopes as a means for the virus to evade this arm of the host defense system. More recently,
we have been studying CD4 helper cell responses, which are the central orchestrator of immune function
against viral infections and had been thought to be absent in people who are HIV infected. We have
recently discovered that persons with long-term non-progressing infection and very low viral loads have
high levels of helper cell responses directed against HIV, and that these responses are associated with
control of viremia. Future efforts in the laboratory are designed to augment virus specific host defenses as
a means of controlling these viral infections, and to develop vaccines that induce cellular immune
responses. In addition to these efforts in Boston, we have collaborated with the Nelson Mandela School
of Medicine in KwaZulu Natal South Africa to build a fully functional biomedical research facility to
study the viruses fueling the extensive epidemic there, and to capacitate African researchers and clinicians
to become involved in the global fight against HIV.
75